

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
FORM PTO-1390 (REV 10-2000)		CU-2561 RJS	
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>09/857994</b>	
INTERNATIONAL APPLICATION NO. PCT/US99/30670	INTERNATIONAL FILING DATE 22 December 1999	PRIORITY DATE CLAIMED 23 December 1998	
TITLE OF INVENTION METHOD OF USING AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA			
APPLICANT(S) FOR DO/EO/US John P. McKEARN et al			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))        a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).        b. <input type="checkbox"/> has been communicated by the International Bureau.        c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))        a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).        b. <input type="checkbox"/> have been communicated by the International Bureau.        c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.        d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
Items 11 to 16 below concern document(s) or information included:			
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A <b>FIRST</b> preliminary amendment.  <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input type="checkbox"/> Other items or information:</p>			
Express Mail Label No.: EL698181221US			

17.  The following fees are submitted:

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5) ):**

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1000.00  
 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00  
 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00  
 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00  
 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

\$ 860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than  20  30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	85 - 20 =	65	X \$18.00	\$ 1170.00
Independent claims	2 - 3 =	0	X \$80.00	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$

**TOTAL OF ABOVE CALCULATIONS =**

\$ 2030.00

Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

\$

**SUBTOTAL =** \$ 2030.00

Processing fee of \$130.00 for furnishing the English translation later than  20  30 months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

**TOTAL NATIONAL FEE =** \$

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

\$

**TOTAL FEES ENCLOSED =** \$ 2030.00

Amount to be refunded: \$

charged: \$

a.  A check in the amount of \$ 2030.00 to cover the above fees is enclosed.

b.  Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.


c.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 12-0400. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Ladas & Parry  
 224 South Michigan Avenue  
 Suite 1200  
 Chicago, Illinois 60604  
 (312) 427-1300

June 13, 2001

  
 SIGNATURE.  
 Richard J. Streit

NAME

25765

REGISTRATION NUMBER

**METHOD OF USING AN INTEGRIN ANTAGONIST AND ONE OR MORE  
ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN  
THE TREATMENT OF NEOPLASIA**

5

**Field of the Invention**

The present invention relates to combinations and methods for treatment or prevention of neoplasia disorders in a mammal using two or more components with at least one component being an antiangiogenesis agent.

**Background of the Invention**

A neoplasm, or tumor, is an abnormal, unregulated, and disorganized proliferation of cell growth. A neoplasm is malignant, or cancerous, if it has properties of destructive growth, invasiveness and metastasis. Invasiveness refers to the local spread of a neoplasm by infiltration or destruction of surrounding tissue, typically breaking through the basal laminas that define the boundaries of the tissues, thereby often entering the body's circulatory system. Metastasis typically refers to the dissemination of tumor cells by lymphatics or blood vessels. Metastasis also refers to the migration of tumor cells by direct extension through serous cavities, or subarachnoid or other spaces. Through the process of metastasis, tumor cell migration to other areas of the body establishes neoplasms in areas away from the site of initial appearance.

Cancer is now the second leading cause of death in the United States and over 8,000,000 persons in the

United States have been diagnosed with cancer. In 1995, cancer accounted for 23.3% of all deaths in the United States. (See U.S. Dept. of Health and Human Services, National Center for Health Statistics, Health United States 1996-97 and Injury Chartbook 117 (1997)).

Cancer is not fully understood on the molecular level. It is known that exposure of a cell to a carcinogen such as certain viruses, certain chemicals, or radiation, leads to DNA alteration that inactivates a " suppressive" gene or activates an "oncogene".

Suppressive genes are growth regulatory genes, which upon mutation, can no longer control cell growth.

Oncogenes are initially normal genes (called prooncogenes) that by mutation or altered context of expression become transforming genes. The products of transforming genes cause inappropriate cell growth. More than twenty different normal cellular genes can become oncogenes by genetic alteration. Transformed cells differ from normal cells in many ways, including cell morphology, cell-to-cell interactions, membrane content, cytoskeletal structure, protein secretion, gene expression and mortality (transformed cells can grow indefinitely).

Cancer is now primarily treated with one or a combination of three types of therapies: surgery, radiation, and chemotherapy. Surgery involves the bulk removal of diseased tissue. While surgery is sometimes effective in removing tumors located at certain sites, for example, in the breast, colon, and skin, it cannot be used in the treatment of tumors located in other areas, such as the backbone, nor in the treatment of disseminated neoplastic conditions such as leukemia.

Chemotherapy involves the disruption of cell replication or cell metabolism. It is used most often in the treatment of breast, lung, and testicular cancer.

The adverse effects of systemic chemotherapy used  
5 in the treatment of neoplastic disease is most feared by patients undergoing treatment for cancer. Of these adverse effects nausea and vomiting are the most common and severe side effects. Other adverse side effects include cytopenia, infection, cachexia, mucositis in  
10 patients receiving high doses of chemotherapy with bone marrow rescue or radiation therapy; alopecia (hair loss ); cutaneous complications (see M.D. Abeloff, et al: Alopecia and Cutaneous Complications. P. 755-56. In Abeloff, M.D., Armitage, J.O., Lichter, A.S., and  
15 Niederhuber, J.E. (eds) Clinical Oncology. Churchill Livingston, New York, 1992, for cutaneous reactions to chemotherapy agents), such as pruritis, urticaria, and angioedema; neurological complications; pulmonary and cardiac complications in patients receiving radiation or  
20 chemotherapy; and reproductive and endocrine complications.

Chemotherapy-induced side effects significantly impact the quality of life of the patient and may dramatically influence patient compliance with  
25 treatment.

Additionally, adverse side effects associated with chemotherapeutic agents are generally the major dose-limiting toxicity (DLT) in the administration of these drugs. For example, mucositis, is one of the major dose  
30 limiting toxicity for several anticancer agents, including the antimetabolite cytotoxic agents 5-FU,

methotrexate, and antitumor antibiotics, such as doxorubicin. Many of these chemotherapy-induced side effects if severe, may lead to hospitalization, or require treatment with analgesics for the treatment of 5 pain.

The adverse side effects induced by chemotherapeutic agents and radiation therapy have become of major importance to the clinical management of cancer patients.

- 10 U.S. Patent No. 5,854,205 describes an isolated endostatin protein that is an inhibitor of endothelial cell proliferation and angiogenesis. U.S. Patent No. 5,843,925 describes a method for inhibiting angiogenesis and endothelial cell proliferation using a 15 7-[substituted amino]-9-[substituted glycylamido]-6-demethyl-6-deoxytetracycline. U.S. Patent No. 5,863,538 describes methods and compositions for targeting tumor vasculature of solid tumors using immunological and growth factor-based reagents in combination with 20 chemotherapy and radiation. U.S. Patent No. 5,837,682 describes the use of fragments of an endothelial cell proliferation inhibitor, angiostatin. U.S. Patent No. 5,861,372 describes the use of an aggregate endothelial inhibitor, angiostatin, and its use in inhibiting 25 angiogenesis. U.S. Patent No. 5,885,795 describes methods and compositions for treating diseases mediated by undesired and uncontrolled angiogenesis by administering purified angiostatin or angiostatin derivatives.
- 30 PCT/GB97/00650 describes the use of cinnoline derivatives for use in the production of an

antiangiogenic and/or vascular permeability reducing effect.

PCT/US97/09610 describes administration of an anti-endogin monoclonal antibody, or fragments thereof, which 5 is conjugated to at least one angiogenesis inhibitor or antitumor agent for use in treating tumor and angiogenesis-associated diseases.

PCT/IL96/00012 describes a fragment of the Thrombin B-chain for the treatment of cancer.

10 PCT/US95/16855 describes compositions and methods of killing selected tumor cells using recombinant viral vectors.

Ravaud, A. et al. describes the efficacy and tolerance of interleukin-2 (IL-2), interferon alpha-2a, 15 and fluorouracil in patients with metastatic renal cell carcinoma. J.Clin.Oncol. 16, No. 8, 2728-32, 1998.

Stadler, W.M. et al. describes the response rate and toxicity of oral 13-cis-retinoic acid added to an outpatient regimen of subcutaneous interleukin-2 and 20 interferon alpha in patients with metastatic renal cell carcinoma. J.Clin.Oncol. 16, No. 5, 1820-25, 1998.

Rosenbeg, S.A. et al. describes treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in 25 combination with interleukin-2 and interferon alpha-2b.

J.Clin.Oncol. 17, No. 3, 968-75, 1999. Tourani, J-M. et al describes treatment of renal cell carcinoma using interleukin-2, and interferon alpha-2a administered in combination with fluorouracil. J.Clin.Oncol. 16, No. 7,

30 2505-13, 1998. Majewski, S. describes the anticancer action of retinoids, vitamin D3 and cytokines

(interferons and interleukin-12) as related to the antiangiogenic and antiproliferative effects.

J.Invest.Dermatol. 108, No. 4, 571, 1997. Ryan, C.W. describes treatment of patients with metastatic renal

5 cell cancer with GM-CSF, Interleukin-2, and interferon-alpha plus oral cis-retinoic acid in patients with metastatic renal cell cancer. J.Invest.Med. 46, No. 7, 274A, 1998. Tai-Ping, D. describes potential anti-angiogenic therapies. Trends Pharmacol.Sci. 16, No. 2,

10 57-66, 1995. Brembeck, F.H. describes the use of 13-cis retinoic acid and interferon alpha to treat UICC stage III/IV pancreatic cancer. Gastroenterology 114, No. 4, Pt. 2, A569, 1998. Brembeck, F.H. describes the use of 13-cis retinoic acid and interferon alpha in

15 patients with advanced pancreatic carcinoma. Cancer 83, No. 11, 2317-23, 1998. Mackean, M.J. describes the use of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma. Br.J.Cancer 78, No. 12, 1620-23, 1998

20 Jayson, G.C. describes the use of interleukin 2 and interleukin -interferon alpha in advanced renal cancer. Br.J.Cancer 78, No. 3, 366-69, 1998. Abraham, J.M. describes the use of Interleukin-2, interferon alpha and 5-fluorouracil in patients with metastatic renal

25 carcinoma. Br.J.Cancer 78, Suppl. 2, 8, 1998. Soori, G.S. describes the use of chemo-biotherapy with chlorambucil and alpha interferon in patients with non-hodgkins lymphoma. Blood 92, No. 10, Pt. 2 Suppl. 1, 240b, 1998. Enschede, S.H. describes the use of

30 interferon alpha added to an anthracycline-based regimen in treating low grade and intermediate grade non-

hodgkin's lymphoma. Blood 92, No. 10, Pt. 1 Suppl. 1, 412a, 1998. Schachter, J. describes the use of a sequential multi-drug chemotherapy and biotherapy with interferon alpha, a four drug chemotherapy regimen and 5 GM-CSF. Cancer Biother.Radiopharm. 13, No. 3, 155-64, 1998. Mross, K. describes the use of retinoic acid, interferon alpha and tamoxifen in metastatic breast cancer patients. J.Cancer Res. Clin. Oncology. 124 Suppl. 1 R123, 1998. Muller, H. describes the use of 10 suramin and tamoxifen in the treatment of advanced and metastatic pancreatic carcinoma. Eur.J.Cancer 33, Suppl. 8, S50, 1997. Rodriguez, M.R. describes the use of taxol and cisplatin, and taxotere and vinorelbine in the treatment of metastatic breast cancer. Eur.J.Cancer 15 34, Suppl. 4, S17-S18, 1998. Formenti, C. describes concurrent paclitaxel and radiation therapy in locally advanced breast cancer patients. Eur.J.Cancer 34, Suppl. 5, S39, 1998. Durando, A. describes combination chemotherapy with paclitaxel (T) and epirubicin (E) for 20 metastatic breast cancer. Eur.J.Cancer 34, Suppl. 5, S41, 1998. Osaki, A. describes the use of a combination therapy with mitomycin-C, etoposide, doxifluridine and medroxyprogesterone acetate as second-line therapy for advanced breast cancer. Eur.J.Cancer 34, Suppl. 5, S59, 25 1998. Lode, H. et al. describes Synergy between an antiangiogenic integrin alpha v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastasis. Proc. Nat. Acad. Sci. USA. , 96 (4), 1591-1596, 1999. Giannis, A. et al describes Integrin 30 antagonists and other low molecular weight compounds as inhibitors of angiogenesis: new drugs in cancer therapy.

Angew. Chem. Int. Ed. Engl. 36(6), 588-590, 1997.

Takada, Y. et al describes the structures and functions of integrins. Jikken Igaku 14 (17), 2317-2322, 1996.

Varner, J. et al. Tumor angiogenesis and the role of  
5 vascular cell integrin alphavbeta3. Impt. Adv. Onc., 69-  
87 Ref:259. 1996.

WO 98/16,227 describes a method of using [Pyrozol-  
1-yl]benzenesulfonamides in the treatment of and  
prevention of neoplasia. WO 98/22,101 describes a  
10 method of using [Pyrozol-1-yl]benzenesulfonamides as  
anti-angiogenic agents.

#### Description of the Invention

15

Treatment or prevention of a neoplasia disorder in  
a mammal in need of such treatment or prevention is  
provided by methods and combinations using two or more  
components with at least one component being an integrin  
20 antagonist.

The method comprises treating a mammal with a  
therapeutically effective amount of a combination  
comprising two or more agents. The first agent is a  
integrin antagonist. The second agent or agents is an  
25 antineoplastic agent. Besides being useful for human  
treatment, the present invention is also useful for  
veterinary treatment of companion animals, exotic  
animals and farm animals, including mammals, rodents,  
and the like. More preferred animals include horses,  
30 dogs, and cats.

The methods and combinations of the present invention may be used for the treatment or prevention of neoplasia disorders including the group consisting of acral lentiginous melanoma, actinic keratoses,

5 adenocarcinoma, adenoid cycstic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, astrocytic tumors, bartholin gland carcinoma, basal cell carcinoma, bronchial gland carcinomas, capillary, carcinoids, carcinoma, carcinosarcoma, cavernous,

10 cholangiocarcinoma, chondrosarcoma, choriod plexus papilloma/carcinoma, clear cell carcinoma, cystadenoma, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ependymal, epitheloid, Ewing's sarcoma,

15 fibrolamellar, focal nodular hyperplasia, gastrinoma, germ cell tumors, glioblastoma, glucagonoma, hemangiblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatocellular carcinoma, insulinoma, intaepithelial neoplasia,

20 interepithelial squamous cell neoplasia, invasive squamous cell carcinoma, large cell carcinoma, leiomyosarcoma, lentigo maligna melanomas, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, melanoma, meningeal, mesothelial,

25 metastatic carcinoma, mucoepidermoid carcinoma, neuroblastoma, neuroepithelial adenocarcinoma nodular melanoma, oat cell carcinoma, oligodendroglial, osteosarcoma, pancreatic polypeptide, papillary serous adenocarcinoma, pineal cell, pituitary tumors,

30 plasmacytoma, pseudosarcoma, pulmonary blastoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma,

sarcoma, serous carcinoma, small cell carcinoma, soft tissue carcinomas, somatostatin-secreting tumor, squamous carcinoma, squamous cell carcinoma, submesothelial, superficial spreading melanoma, 5 undifferentiated carcinoma, uveal melanoma, verrucous carcinoma, vipoma, well differentiated carcinoma, and Wilm's tumor.

The methods and combinations of the present invention provide one or more benefits. Combinations of 10 integrin antagonists with the compounds, compositions, agents and therapies of the present invention are useful in treating and preventing neoplasia disorders. Preferably, the integrin antagonist and the compounds, compositions, agents and therapies of the present 15 invention are administered in combination at a low dose, that is, at a dose lower than has been conventionally used in clinical situations.

A benefit of lowering the dose of the compounds, compositions, agents and therapies of the present 20 invention administered to a mammal includes a decrease in the incidence of adverse effects associated with higher dosages. For example, by the lowering the dosage of a chemotherapeutic agent such as methotrexate, a reduction in the frequency and the severity of nausea 25 and vomiting will result when compared to that observed at higher dosages. Similar benefits are contemplated for the compounds, compositions, agents and therapies in combination with the integrin antagonists of the present invention.

30 By lowering the incidence of adverse effects, an improvement in the quality of life of a patient

undergoing treatment for cancer is contemplated. Further benefits of lowering the incidence of adverse effects include an improvement in patient compliance, a reduction in the number of hospitalizations needed for 5 the treatment of adverse effects, and a reduction in the administration of analgesic agents needed to treat pain associated with the adverse effects.

Alternatively, the methods and combination of the present invention can also maximize the therapeutic 10 effect at higher doses.

When administered as a combination, the therapeutic agents can be formulated as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition. 15

When used as a therapeutic the compounds described herein are preferably administered with a physiologically acceptable carrier. A physiologically acceptable carrier is a formulation to which the compound can be added to dissolve it or otherwise 20 facilitate its administration. Examples of physiologically acceptable carriers include, but are not limited to, water, saline, physiologically buffered saline. Additional examples are provided below.

The term "pharmaceutically acceptable" is used 25 adjectivally herein to mean that the modified noun is appropriate for use in a pharmaceutical product.

Pharmaceutically acceptable cations include metallic ions and organic ions. More preferred metallic ions include, but are not limited to appropriate alkali metal 30 salts, alkaline earth metal salts and other physiological acceptable metal ions. Exemplary ions

include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc in their usual valences. Preferred organic ions include protonated tertiary amines and quaternary ammonium cations, including in part, trimethylamine, diethylamine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Exemplary pharmaceutically acceptable acids include without limitation hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid, malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, glucuronic acid, pyruvic acid oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like.

A compound of the present invention can be formulated as a pharmaceutical composition. Such a composition can then be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration can also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical

Sciences, Mack Publishing Co., Easton, Pennsylvania; 1975. Another example of includes Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980.

- 5        Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile 10 injectable solution or suspension in a nontoxic parenterally acceptable dilutent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium 15 chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the 20 preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, polyethylene glycols can be used. Mixtures of solvents and wetting agents such as those discussed above are also useful.
- 25        Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter, synthetic mono- di- or triglycerides, fatty acids and polyethylene glycols that are sold at ordinary temperatures but 30 liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

Solid dosage forms for oral administration can include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, a contemplated aromatic sulfone hydroximate inhibitor compound can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.

Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.

For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. A contemplated aromatic sulfone hydroximate inhibitor compound can be dissolved in water, polyethylene glycol, propylene

glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

- Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water.
- 10 Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the mammalian host treated and the particular mode of administration.

15 The present invention further includes kits comprising and integrin antagonist and an antineoplastic agent.

20 The term "treatment" refers to any process, action, application, therapy, or the like, wherein a mammal, including a human being, is subject to medical aid with the object of improving the mammal's condition, directly or indirectly.

25 The term "inhibition," in the context of neoplasia, tumor growth or tumor cell growth, may be assessed by delayed appearance of primary or secondary tumors, slowed development of primary or secondary tumors, decreased occurrence of primary or secondary tumors,

30 slowed or decreased severity of secondary effects of disease, arrested tumor growth and regression of tumors,

among others. In the extreme, complete inhibition, is referred to herein as prevention or chemoprevention.

The term "prevention" includes either preventing the onset of clinically evident neoplasia altogether or preventing the onset of a preclinically evident stage of neoplasia in individuals at risk. Also intended to be encompassed by this definition is the prevention of initiation for malignant cells or to arrest or reverse the progression of premalignant cells to malignant cells. This includes prophylactic treatment of those at risk of developing the neoplasia.

The term "angiogenesis" refers to the process by which tumor cells trigger abnormal blood vessel growth to create their own blood supply, and is a major target of cancer research. Angiogenesis is believed to be the mechanism via which tumors get needed nutrients to grow and metastasize to other locations in the body.

Antiangiogenic agents interfere with these processes and destroy or control tumors.

Angiogenesis is an attractive therapeutic target because it is a multi-step process that occurs in a specific sequence, thus providing several possible targets for drug action. Examples of agents that interfere with several of these steps include thrombospondin-1, angiostatin, endostatin, interferon alpha and compounds such as matrix metalloproteinase (MMP) inhibitors that block the actions of enzymes that clear and create paths for newly forming blood vessels to follow; compounds, such as  $\alpha v \beta 3$  inhibitors, that interfere with molecules that blood vessel cells use to bridge between a parent blood vessel and a tumor;

agents, such as specific COX-2 inhibitors, that prevent the growth of cells that form new blood vessels; and protein-based compounds that simultaneously interfere with several of these targets.

5       Antiangiogenic therapy may offer several advantages over conventional chemotherapy for the treatment of cancer.

Antiangiogenic agents have low toxicity in preclinical trials and development of drug resistance has not been observed (Folkman, J., *Seminars in Medicine of the Beth Israel Hospital, Boston* 33(26): 1757-1763, 1995). As angiogenesis is a complex process, made up of many steps including invasion, proliferation and migration of endothelial cells, it can be anticipated that combination therapies will be most effective. Kumar and Armstrong describe anti-angiogenesis therapy used as an adjunct to chemotherapy, radiation therapy, or surgery. (Kumar, CC, and Armstrong, L., *Tumor-induced angiogenesis: a novel target for drug therapy?*, *Emerging Drugs* (1997), 2, 175-190).

The phrase "therapeutically-effective" is intended to qualify the amount of each agent that will achieve the goal of improvement in neoplastic disease severity and the frequency of neoplastic disease over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies.

A "therapeutic effect" or "therapeutic effective amount" is intended to qualify the amount of an anticancer agent required to relieve to some extent one or more of the symptoms of a neoplasia disorder, including, but is not limited to: 1) reduction in the

number of cancer cells; 2) reduction in tumor size; 3) inhibition (i.e., slowing to some extent, preferably stopping) of cancer cell infiltration into peripheral organs; 3) inhibition (i.e., slowing to some extent, preferably stopping) of tumor metastasis; 4) inhibition, to some extent, of tumor growth; 5) relieving or reducing to some extent one or more of the symptoms associated with the disorder; and/or 6) relieving or reducing the side effects associated with the administration of anticancer agents.

The phrase "combination therapy" (or "co-therapy") embraces the administration of an integrin antagonist and an antineoplastic agent as part of a specific treatment regimen intended to provide a beneficial effect from the co-action of these therapeutic agents. The beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents. Administration of these therapeutic agents in combination typically is carried out over a defined time period (usually minutes, hours, days or weeks depending upon the combination selected). "Combination therapy" generally is not intended to encompass the administration of two or more of these therapeutic agents as part of separate monotherapy regimens that incidentally and arbitrarily result in the combinations of the present invention. "Combination therapy" is intended to embrace administration of these therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents,

or at least two of the therapeutic agents, in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single capsule having a fixed ratio of each therapeutic agent or in multiple, single capsules for each of the therapeutic agents. Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally or all therapeutic agents may be administered by intravenous injection. The sequence in which the therapeutic agents are administered is not narrowly critical. "Combination therapy" also can embrace the administration of the therapeutic agents as described above in further combination with other biologically active ingredients (such as, but not limited to, a second and different antineoplastic agent) and non-drug therapies (such as, but not limited to, surgery or radiation treatment). Where the combination therapy further comprises radiation treatment, the radiation treatment may be conducted at any suitable

time so long as a beneficial effect from the co-action of the combination of the therapeutic agents and radiation treatment is achieved. For example, in appropriate cases, the beneficial effect is still 5 achieved when the radiation treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks.

The phrases "low dose" or "low dose amount", in 10 characterizing a therapeutically effective amount of the antiangiogenesis agent and the antineoplastic agent or therapy in the combination therapy, defines a quantity of such agent, or a range of quantity of such agent, that is capable of improving the neoplastic disease 15 severity while reducing or avoiding one or more antineoplastic-agent-induced side effects, such as myelosuppression, cardiac toxicity, alopecia, nausea or vomiting.

20 The phrase "adjunctive therapy" encompasses treatment of a subject with agents that reduce or avoid side effects associated with the combination therapy of the present invention, including, but not limited to, those agents, for example, that reduce the toxic effect 25 of anticancer drugs, e.g., bone resorption inhibitors, cardioprotective agents; prevent or reduce the incidence of nausea and vomiting associated with chemotherapy, radiotherapy or operation; or reduce the incidence of infection associated with the administration of 30 myelosuppressive anticancer drugs.

The phrase an "immunotherapeutic agent" refers to agents used to transfer the immunity of an immune donor, e.g., another person or an animal, to a host by inoculation. The term embraces the use of serum or 5 gamma globulin containing purified antibodies produced by another individual or an animal; nonspecific systemic stimulation; adjuvants; active specific immunotherapy; and adoptive immunotherapy. Adoptive immunotherapy refers to the treatment of a disease by therapy or 10 agents that include host inoculation of sensitized lymphocytes, transfer factor, immune RNA, or antibodies in serum or gamma globulin.

The phrase a "device" refers to any appliance, 15 usually mechanical or electrical, designed to perform a particular function.

The phrase a "vaccine" includes agents that induce the patient's immune system to mount an immune response 20 against the tumor by attacking cells that express tumor associated antigens (TAAs).

The phrase "multi-functional proteins" encompass a variety of pro-angiogenic factors that include basic and 25 acid fibroblast growth factors (bFGF and aFGF) and vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) ( Bikfalvi, A. et al., *Endocrine Reviews* 18: 26-45, 1997). Several endogenous antiangiogenic factors have also been characterized as 30 multi-functional proteins and include angiostatin (O'Reilly et al., *Cell (Cambridge, Mass)* 79(2): 315-328,

1994), endostatin (O'Reilly et al, *Cell* (Cambridge, Mass) 88(2): 277-285, 1997), interferon .alpha. (Ezekowitz et al, *N. Engl. J. Med.*, May 28, 326(22) 1456-1463, 1992), thrombospondin (Good et al, *Proc Natl Acad Sci USA* 87(17): 6624-6628, 1990; Tolsma et al, *J Cell Biol* 122(2): 497-511, 1993), and platelet factor 4 (PF4) (Maione et al, *Science* 247:(4938): 77-79, 1990).

The phrase an "analgesic agent" refers to an agent  
10 that relieves pain without producing anesthesia or loss  
of consciousness generally by altering the perception of  
nociceptive stimuli.

The phrase a "radiotherapeutic agent" refers to the  
15 use of electromagnetic or particulate radiation in the  
treatment of neoplasia.

The term "pBATT" embraces" or "Protein-Based Anti-Tumor Therapies," refers to protein-based therapeutics  
20 for solid tumors. The pBATTs include proteins that have demonstrated efficacy against tumors in animal models or in humans. The protein is then modified to increase its efficacy and toxicity profile by enhancing its bioavailability and targeting.

25 "Angiostatin" is a 38 kD protein comprising the first three or four kringle domains of plasminogen and was first described in 1994 (O'Reilly, M. S. et al., *Cell* (Cambridge, Mass.) 79(2): 315-328, 1994). Mice bearing  
30 primary (Lewis lung carcinoma-low metastatic) tumors did not respond to angiogenic stimuli such as bFGF in a

corneal micropocket assay and the growth of metastatic tumors in these mice was suppressed until the primary tumor was excised. The factor responsible for the inhibition of angiogenesis and tumor growth was 5 designated mouse angiostatin. Angiostatin was also shown to inhibit the growth of endothelial cells in vitro.

Human angiostatin can be prepared by digestion of plasminogen by porcine elastase (O'Reilly, et al., *Cell* 10 **79**(2): 315-328, 1994) or with human metalloelastase (Dong et al., *Cell* 88, 801-810, 1997). The angiostatin produced via porcine elastase digestion inhibited the growth of metastases and primary tumors in mice. O'Reilly et al., (*Cell* **79**(2): 315-328, 1994) 15 demonstrated that human angiostatin inhibited metastasis of Lewis lung carcinoma in SCID mice. The same group (O'Reilly, M. S. et al., *Nat. Med. (N. Y.)* **2**(6): 689-692, 1996) subsequently showed that human angiostatin inhibited the growth of the human tumors PC3 prostate 20 carcinoma, clone A colon carcinoma, and MDA-MB breast carcinoma in SCID mice. Human angiostatin also inhibited the growth of the mouse tumors Lewis lung carcinoma, T241 fibrosarcoma and M5076 reticulum cell carcinoma in C57Bl mice. Because these enzymatically-prepared angiostatins are not well characterized 25 biochemically, the precise composition of the molecules is not known.

Angiostatins of known composition can be prepared by means of recombinant DNA technology and expression in 30 heterologous cell systems. Recombinant human angiostatin comprising Kringle domains one through four

(K1-4) has been produced in the yeast *Pichia pastoris* (Sim et al., *Cancer Res* **57**: 1329-1334, 1997). The recombinant human protein inhibited growth of endothelial cells in vitro and inhibited metastasis of 5 Lewis lung carcinoma in C57Bl mice. Recombinant murine angiostatin (K1-4) has been produced in insect cells (Wu et al., *Biochem Biophys Res Comm* **236**: 651-654, 1997). The recombinant mouse protein inhibited endothelial cell growth in vitro and growth of primary Lewis lung 10 carcinoma *in vivo*. These experiments demonstrated that the first four kringle domains are sufficient for angiostatin activity but did not determine which kringle domains are necessary.

Cao et al. (*J. Biol. Chem.* **271**: 29461-29467, 1996), 15 produced fragments of human plasminogen by proteolysis and by expression of recombinant proteins in *E. coli*. These authors showed that kringle one and to a lesser extent kringle four of plasminogen were responsible for the inhibition of endothelial cell growth in vitro. 20 Specifically, kringles 1-4 and 1-3 inhibited at similar concentrations, while K1 alone inhibited endothelial cell growth at four-fold higher concentrations. Kringles two and three inhibited to a lesser extent. More recently Cao et al. (*J Biol Chem* **272**: 22924-22928, 25 1997), showed that recombinant mouse or human kringle five inhibited endothelial cell growth at lower concentrations than angiostatin (K1-4). These experiments demonstrated in vitro angiostatin-like activity but did not address *in vivo* action against 30 tumors and their metastases.

PCT publication WO 95/29242 discloses purification of a protein from blood and urine by HPLC that inhibits proliferation of endothelial cells. The protein has a molecular weight between 38 kilodaltons and 45  
5 kilodaltons and an amino acid sequence substantially similar to that of a murine plasminogen fragment beginning at amino acid number 79 of a murine plasminogen molecule. PCT publication WO 96/41194, discloses compounds and methods for the diagnosis and  
10 monitoring of angiogenesis-dependent diseases. PCT publication WO 96/35774 discloses the structure of protein fragments, generally corresponding to kringle structures occurring within angiostatin. It also discloses aggregate forms of angiostatin, which have  
15 endothelial cell inhibiting activity, and provides a means for inhibiting angiogenesis of tumors and for treating angiogenic-mediated diseases.

"Endostatin" is a 20-kDa (184 amino acid) carboxy fragment of collagen XVIII, is an angiogenesis inhibitor produced by a hemangioendothelioma (O'Reilly, M. S. et al., *Cell* (Cambridge, Mass.) 88(2): 277-285, 1997); and WO 97/15666). Endostatin specifically inhibits endothelial proliferation and inhibits angiogenesis and tumor growth. Primary tumors treated with non-refolded suspensions of *E. coli*-derived endostatin regressed to dormant microscopic lesions. Toxicity was not observed and immunohistochemical studies revealed a blockage of angiogenesis accompanied by high proliferation balanced  
25 by apoptosis in tumor cells.  
30

"Interferon .alpha." (IFN.alpha.) is a family of highly homologous, species-specific proteins that possess complex antiviral, antineoplastic and immunomodulating activities (Extensively reviewed in the 5 monograph "Antineoplastic agents, interferon alfa", American Society of Hospital Pharmacists, Inc., 1996). Interferon .alpha. also has anti-proliferative, and antiangiogenic properties, and has specific effects on cellular differentiation (Sreevalsan, in "Biologic 10 Therapy of Cancer", pp. 347-364, (eds. V.T. DeVita Jr., S. Hellman, and S.A. Rosenberg), J.B. Lippincott Co, Philadelphia, PA, 1995).

Interferon .alpha. is effective against a variety of cancers including hairy cell leukemia, chronic 15 myelogenous leukemia, malignant melanoma, and Kaposi's sarcoma. The precise mechanism by which IFN.alpha. exerts its anti-tumor activity is not entirely clear, and may differ based on the tumor type or stage of disease. The anti-proliferative properties of 20 IFN.alpha., which may result from the modulation of the expression of oncogenes and/or proto-oncogenes, have been demonstrated on both tumor cell lines and human tumors growing in nude mice (Gutterman, J. U., *Proc. Natl. Acad. Sci., USA* **91**: 1198-1205, 1994).

25 Interferon is also considered an anti-angiogenic factor, as demonstrated through the successful treatment of hemangiomas in infants (Ezekowitz et al, *N. Engl. J. Med.*, May 28, 326(22) 1456-1463, 1992) and the effectiveness of IFN.alpha. against Kaposi's sarcoma 30 (Krown, *Semin Oncol* 14(2 Suppl 3): 27-33, 1987). The mechanism underlying these anti-angiogenic effects is

not clear, and may be the result of IFN. $\alpha$ . action on the tumor (decreasing the secretion of pro-angiogenic factors) or on the neo-vasculature. IFN receptors have been identified on a variety of cell types (Navarro et al., *Modern Pathology* 9(2): 150-156, 1996).

United States Patent 4,530,901, by Weissmann, describes the cloning and expression of IFN-. $\alpha$ -type molecules in transformed host strains. United States Patent 4,503,035, Pestka, describes an improved processes for purifying 10 species of human leukocyte interferon using preparative high performance liquid chromatography. United States Patent 5,231,176, Goeddel, describes the cloning of a novel distinct family of human leukocyte interferons containing in their mature form greater than 166 and no more than 172 amino acids.

United States Patent 5,541,293, by Stabinsky, describes the synthesis, cloning, and expression of consensus human interferons. These are non-naturally occurring analogues of human (leukocyte) interferon-. $\alpha$ . assembled from synthetic oligonucleotides. The sequence of the consensus interferon was determined by comparing the sequences of 13 members of the IFN-. $\alpha$ . family of interferons and selecting the preferred amino acid at each position. These variants differ from naturally occurring forms in terms of the identity and/or location of one or more amino acids, and one or more biological and pharmacological properties (e.g., antibody reactivity, potency, or duration effect) but retain other such properties.

"Thrombospondin-1" (TSP-1) is a trimer containing three copies of a 180 kDa polypeptide. TSP-1 is produced by many cell types including platelets, fibroblasts, and endothelial cells (see Frazier, *Curr Opin Cell Biol* 3(5): 792-799, 1991) and the cDNA encoding the subunit has been cloned (Hennessy, et al., 1989, *J Cell Biol* 108(2): 729-736; Lawler and Hynes, *J Cell Biol* 103(5): 1635-1648, 1986). Native TSP-1 has been shown to block endothelial cell migration *in vitro* and neovascularization *in vivo* (Good et al, *Proc Natl Acad Sci USA* 87(17): 6624-6628, 1990). Expression of TSP-1 in tumor cells also suppresses tumorigenesis and tumor-induced angiogenesis (Sheibani and Frazier, *Proc Natl Acad Sci USA* 92(15): 6788-6792, 1995; Weinstat-Saslow et al., *Cancer Res* 54(24):6504-6511, 1994). The antiangiogenic activity of TSP-1 has been shown to reside in two distinct domains of this protein (Tolsma et al, *J Cell Biol* 122(2): 497-511, 1993). One of these domains consists of residues 303 to 309 of native TSP-1 and the other consists of residues 481 to 499 of TSP-1. Another important domain consists of the sequence CSVTCG which appears to mediate the binding of TSP-1 to some tumor cell types (Tuszynski and Nicosia, *Bioessays* 18(1): 71-76, 1996). These results suggest that CSVTCG, or related sequences, can be used to target other moieties to tumor cells. Taken together, the available data indicate that TSP-1 plays a role in the growth and vascularization of tumors. Subfragments of TSP-1, then, may be useful as antiangiogenic components of chimeras and/or in targeting other proteins to specific tumor cells. Subfragments may be generated by standard

procedures (such as proteolytic fragmentation, or by DNA amplification, cloning, expression, and purification of specific TSP-1 domains or subdomains) and tested for antiangiogenic or anti-tumor activities by methods known 5 in the art (Tolsma et al, *J Cell Biol* 122(2): 497-511, 1993; Tuszyński and Nicosia, *Bioessays* 18(1): 71-76, 1996).

The phrase "cyclooxygenase-2 inhibitor" or "COX-2 inhibitor" or "cyclooxygenase-II inhibitor" includes 10 agents that specifically inhibit a class of enzymes, cyclooxygenase-2, without significant inhibition of cyclooxygenase-1. Preferably, it includes compounds which have a cyclooxygenase-2 IC<sub>50</sub> of less than about 0.2 μM, and also have a selectivity ratio of 15 cyclooxygenase-2 inhibition over cyclooxygenase-1 inhibition of at least 50, and more preferably of at least 100. Even more preferably, the compounds have a cyclooxygenase-1 IC<sub>50</sub> of greater than about 1 μM, and more preferably of greater than 10 μM.

Studies indicate that prostaglandins synthesized by cyclooxygenases play a critical role in the initiation and promotion of cancer. Moreover, COX-2 is overexpressed in neoplastic lesions of the colon, breast, lung, prostate, esophagus, pancreas, intestine, 25 cervix, ovaries, urinary bladder, and head & neck. In several in vitro and animal models, COX-2 inhibitors have inhibited tumor growth and metastasis. Non-limiting examples of Cox-2 inhibitors include rofecoxib and JTE-522.

30 The phrase "matrix metalloproteinase inhibitor" or "MMP inhibitor" includes agents that specifically

inhibit a class of enzymes, the zinc metalloproteinases (metalloproteases). The zinc metalloproteinases are involved in the degradation of connective tissue or connective tissue components. These enzymes are 5 released from resident tissue cells and/or invading inflammatory or tumor cells. Blocking the action of zinc metalloproteinases interferes with the creation of paths for newly forming blood vessels to follow.

Examples of MMP inhibitors are described in Golub, LM, 10 Inhibition of Matrix Metalloproteinases: Therapeutic Applications (Annals of the New York Academy of Science, vol 878). Robert A. Greenwald and Stanley Zucker (Eds.), June 1999), and is hereby incorporated by reference.

The phrase "integrin antagonist" includes agents 15 that impair endothelial cell adhesion via the various integrins. Integrin antagonists induce improperly proliferating endothelial cells to die, by interfering with molecules that blood vessel cells use to bridge between a parent blood vessel and a tumor.

Adhesion forces are critical for many normal 20 physiological functions. Disruptions in these forces, through alterations in cell adhesion factors, are implicated in a variety of disorders, including cancer, stroke, osteoporosis, restenosis, and rheumatoid 25 arthritis (A. F. Horwitz, *Scientific American*, 276:(5): 68-75, 1997).

Integrins are a large family of cell surface 30 glycoproteins which mediate cell adhesion and play central roles in many adhesion phenomena. Integrins are heterodimers composed of noncovalently linked alpha and beta polypeptide subunits. Currently eleven different

alpha subunits have been identified and six different beta subunits have been identified. The various alpha subunits can combine with various beta subunits to form distinct integrins.

- 5 One integrin known as  $\alpha_v\beta_3$  (or the vitronectin receptor) is normally associated with endothelial cells and smooth muscle cells.  $\alpha_v\beta_3$  integrins can promote the formation of blood vessels (angiogenesis) in tumors.

-32-

These vessels nourish the tumors and provide access routes into the bloodstream for metastatic cells.

The phrase "integrin antagonist" includes agents that impair endothelial cell adhesion via the various 5 integrins. Integrin antagonists induce improperly proliferating endothelial cells to die, by interfering with molecules that blood vessel cells use to bridge between a parent blood vessel and a tumor.

Adhesion forces are critical for many normal 10 physiological functions. Disruptions in these forces, through alterations in cell adhesion factors, are implicated in a variety of disorders, including cancer, stroke, osteoporosis, restenosis, and rheumatoid 15 arthritis (A. F. Horwitz, *Scientific American*, 276:(5): 68-75, 1997).

Integrins are a large family of cell surface glycoproteins which mediate cell adhesion and play central roles in many adhesion phenomena. Integrins are 20 heterodimers composed of noncovalently linked alpha and beta polypeptide subunits. Currently eleven different alpha subunits have been identified and six different beta subunits have been identified. The various alpha subunits can combine with various beta subunits to form distinct integrins.

25 One integrin known as  $\alpha_v\beta_3$  (or the vitronectin receptor) is normally associated with endothelial cells and smooth muscle cells.  $\alpha_v\beta_3$  integrins can promote the formation of blood vessels (angiogenesis) in tumors. These vessels nourish the tumors and provide access 30 routes into the bloodstream for metastatic cells.

The  $\alpha_v\beta_3$  integrin is also known to play a role in various other disease states or conditions including tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, angiogenesis, including tumor angiogenesis, retinopathy, arthritis, including rheumatoid arthritis, periodontal disease, psoriasis, and smooth muscle cell migration (e.g. restenosis).

Tumor cell invasion occurs by a three step process:

10 1) tumor cell attachment to extracellular matrix; 2) proteolytic dissolution of the matrix; and 3) movement of the cells through the dissolved barrier. This process can occur repeatedly and can result in metastases at sites distant from the original tumor.

15 The  $\alpha_v\beta_3$  integrin and a variety of other  $\alpha_v$ -containing integrins bind to a number of Arg-Gly-Asp (RGD) containing matrix macromolecules. Compounds containing the RGD sequence mimic extracellular matrix ligands and bind to cell surface receptors. Fibronectin and vitronectin are among the major binding partners of  $\alpha_v\beta_3$  integrin. Other proteins and peptides also bind the  $\alpha_v\beta_3$  ligand. These include the disintegrins (M. Pfaff et al., *Cell Adhes. Commun.* 2(6): 491-501, 1994), peptides derived from phage display libraries (Healy, J.M. et al., *Protein Pept. Lett.* 3(1): 23-30, 1996; Hart, S.L. et al., *J. Biol. Chem.* 269(17): 12468-12474, 1994) and small cyclic RGD peptides (M. Pfaff et al., *J. Biol. Chem.*, 269(32): 20233-20238, 1994). The monoclonal antibody LM609 is also an  $\alpha_v\beta_3$  integrin

-34-

antagonist (D.A. Cheresh et al., *J. Biol. Chem.*, 262(36): 17703-17711, 1987).

$\alpha_v\beta_3$  inhibitors are being developed as potential anti-cancer agents. Compounds that impair endothelial 5 cell adhesion via the  $\alpha_v\beta_3$  integrin induce improperly proliferating endothelial cells to die.

The  $\alpha_v\beta_3$  integrin has been shown to play a role in melanoma cell invasion (Seftor et al., *Proc. Natl. Acad. Sci. USA*, 89: 1557-1561, 1992). The  $\alpha_v\beta_3$  integrin 10 expressed on human melanoma cells has also been shown to promote a survival signal, protecting the cells from apoptosis (Montgomery et al., *Proc. Natl. Acad. Sci. USA*, 91: 8856-8860, 1994).

Mediation of the tumor cell metastatic pathway by 15 interference with the  $\alpha_v\beta_3$  integrin cell adhesion receptor to impede tumor metastasis would be beneficial. Antagonists of  $\alpha_v\beta_3$  have been shown to provide a therapeutic approach for the treatment of neoplasia (inhibition of solid tumor growth) because systemic 20 administration of  $\alpha_v\beta_3$  antagonists causes dramatic regression of various histologically distinct human tumors (Brooks et al., *Cell*, 79: 1157-1164, 1994).

The adhesion receptor identified as integrin  $\alpha_v\beta_3$  25 is a marker of angiogenic blood vessels in chick and man. This receptor plays a critical role in angiogenesis or neovascularization. Angiogenesis is characterized by the invasion, migration and proliferation of smooth muscle and endothelial cells by

new blood vessels. Antagonists of  $\alpha_v\beta_3$  inhibit this process by selectively promoting apoptosis of cells in the neovasculature. The growth of new blood vessels, also contributes to pathological conditions such as 5 diabetic retinopathy (Adonis et al., *Amer. J. Ophthalm.*, 118: 445-450, 1994) and rheumatoid arthritis (Peacock et al., *J. Exp. Med.*, 175:, 1135-1138, 1992). Therefore,  $\alpha_v\beta_3$  antagonists can be useful therapeutic targets for treating such conditions associated with 10 neovascularization (Brooks et al., *Science*, 264: 569-571, 1994).

The  $\alpha_v\beta_3$  cell surface receptor is also the major integrin on osteoclasts responsible for the attachment to the matrix of bone. Osteoclasts cause bone 15 resorption and when such bone resorbing activity exceeds bone forming activity, osteoporosis (a loss of bone) results, which leads to an increased number of bone fractures, incapacitation and increased mortality.

Antagonists of  $\alpha_v\beta_3$  have been shown to be potent 20 inhibitors of osteoclastic activity both *in vitro* (Sato et al., *J. Cell. Biol.*, 111: 1713-1723, 1990) and *in vivo* (Fisher et al., *Endocrinology*, 132: 1411-1413, 1993). Antagonism of  $\alpha_v\beta_3$  leads to decreased bone 25 resorption and therefore assists in restoring a normal balance of bone forming and resorbing activity. Thus it would be beneficial to provide antagonists of osteoclast  $\alpha_v\beta_3$  which are effective inhibitors of bone resorption

-36-

and therefore are useful in the treatment or prevention of osteoporosis.

PCT Int. Appl. WO 97/08145 by Sikorski et al., discloses meta-guanidine, urea, thiourea or azacyclic 5 amino benzoic acid derivatives as highly specific  $\alpha_v\beta_3$  integrin antagonists.

PCT Int. Appl. WO 96/00574 A1 960111 by Cousins, R.D. et. al., describe preparation of 3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine and -2-benzazepine 10 derivatives and analogs as vitronectin receptor antagonists.

PCT Int. Appl. WO 97/23480 A1 970703 by Jadhav, P.K. et. al. describe annelated pyrazoles as novel integrin receptor antagonists. Novel heterocycles 15 including 3-[1-[3-(imidazolin-2-ylamino)propyl]indazol-5-ylcarbonylamino]-2-(benzyl oxycarbonylamino)propionic acid, which are useful as antagonists of the avb3 integrin and related cell surface adhesive protein receptors.

20 PCT Int. Appl. WO 97/26250 A1 970724 by Hartman, G.D. et al., describe the preparation of arginine dipeptide mimics as integrin receptor antagonists. Selected compounds were shown to bind to human integrin  $\alpha_v\beta_3$  with EIB <1000 nM and claimed as compounds, useful 25 for inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.

PCT Int. Appl. WO 97/23451 by Diefenbach, B. et. al. describe a series of tyrosine-derivatives used as 30 alpha v-integrin inhibitors for treating tumors,

osteoporosis, osteolytic disorder and for suppressing angiogenesis.

PCT Int. Appl. WO 96/16983 A1 960606. by Vuori, K. and Ruoslahti, E. describe cooperative combinations of  
5  $\alpha_v\beta_3$  integrin ligand and second ligand contained within a matrix, and use in wound healing and tissue regeneration. The compounds contain a ligand for the  $\alpha_v\beta_3$  integrin and a ligand for the insulin receptor, the PDGF receptor, the IL-4 receptor, or the IGF receptor,  
10 combined in a biodegradable polymeric (e.g. hyaluronic acid) matrix.

PCT Int. Appl. WO 97/10507 A1 970320 by Ruoslahti, E; and Pasqualini, R. describe peptides that home to a selected organ or tissue *in vivo*, and methods of  
15 identifying them. A brain-homing peptide, nine amino acid residues long, for example, directs red blood cells to the brain. Also described is use of *in vivo* panning to identify peptides homing to a breast tumor or a melanoma.

20 PCT Int. Appl. WO 96/01653 A1 960125 by Thorpe, Philip E.; Edgington, Thomas S. describes bifunctional ligands for specific tumor inhibition by blood coagulation in tumor vasculature. The disclosed bispecific binding ligands bind through a first binding  
25 region to a disease-related target cell, e.g. a tumor cell or tumor vasculature; the second region has coagulation-promoting activity or is a binding region for a coagulation factor. The disclosed bispecific binding ligand may be a bispecific (monoclonal)  
30 antibody, or the two ligands may be connected by a

(selectively cleavable) covalent bond, a chemical linking agent, an avidin-biotin linkage, and the like. The target of the first binding region can be a cytokine-inducible component, and the cytokine can be 5 released in response to a leukocyte-activating antibody; this may be a bispecific antibody which crosslinks activated leukocytes with tumor cells.

Nonlimiting examples of integrin antagonists that may be used in the present invention are identified in 10 Table 1, below.

Table No. 1. Examples of Integrin antagonists

Compound	Trade/ Research Name	Mode of Action	Reference	Dosage
2(S)- Benzenesulfonamido)-3-[4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzamido]propionic acid	L-748415	Vitronectin antagonist		
	Merk KGaA Compound I25			
Ethyl beta-[[2-[[[3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]phenyl]carbonyl]amino]acetyl]-amino]pyridine-3-propanoic acid		Vitronectin antagonist	WO 97/08145	
O-[9,10-dimethoxy-		Vitronectin antagonist	WO 97/34865	

Compound	Trade/ Research Name	Mode of Action	Reference	Dosage
1,2,3,4,5,6-hexahydro-4-[ (1,4,5,6-tetrahydro-2-pyrimidinyl)hydrazono]-8-benz(e)azulenyl] -N-[ (phenylmethoxy)carbonyl]-DL-homoserine 2,3-dihydroxypropyl ester				
(2S)-Benzoylcarbonyl amino-3-[2-((4S)-(3-(4,5-dihydro-1H-imidazol-2-ylamino)-propyl)-2,5-dioxo-imidazolidin-1-yl)-acetylamino]-propionate		Vitronectin antagonist	EP 796855	
	S-836	Vitronectin antagonist; Angiogenesis inhibitor; solid tumors		
(S)-2-[7-[N-(Benzimidazol-2-ylmethyl)-N-methylcarbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-yl]acetic	SB-223245	Vitronectin antagonist; Angiogenesis inhibitor		

Compound	Trade/ Research Name	Mode of Action	Reference	Dosage
acid				
	SD-983	Vitronectin antagonist; Angiogenesis inhibitor		
Isoxaoline derivatives		Vitronectin receptor antagonist	WO 96/37492	0.001-10 mg/kg/day; 0.01-0.5 (pref. 0.01-0.1) mg/kg/ day intra-nasally
(2S)- Benzoylcarbonyl amino-3-[2- ((4S)-(3-(4,5- dihydro-1H- imidazol-2- ylamino)- propyl)-2,5- dioxo- imidazolidin- 1-yl)- acetyl amino]- propionate		Vitronectin antagonist	EP 796855	
Benzazulene derivatives; O-[9,10- dimethoxy- 1,2,3,4,5,6- hexahydro-4- [(1,4,5,6- tetrahydro-2- pyrimidinyl) hydrazone]-8- benz(e)azzulenyl 1]-N- [(phenylmethoxy) carbonyl]-DL- homoserine 2,3- dihydroxypropyl		Vitronectin antagonist	WO 97/34865	

Compound	Trade/ Research Name	Mode of Action	Reference	Dosage
ester				
Immunoglobulin G, (human-mouse monoclonal c7E3 clone p7E3VHhC gamma 4 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human -mouse monoclonal c7E3 clone p7E3VkhCk light chain-	abcix-imab; ReoPro	GPIIb IIIa receptor antagonist; Vitronectin antagonist		Recomended dosage: Intra-venous bolus of 0.25 mg/kg, followed by 10 µg/min for 12 hrs.
Arg-Gly-Asp-D-phe-Val	cRGDFV penta-peptide	Apoptosis agonist; Vitronectin antagonist		
	vitronectin antagonist	Vitronectin antagonist		Orally active

Further examples of integrin antagonists can be found in the following documents:

WO 98/07432	WO 98/16227	WO 97/36862	WO 97/36861
WO 97/36860	WO 9736859	WO 97/36858	US 5639765
WO 97/08145	US 5639765	WO 98/22500	WO 98/20897
WO 98/18764	WO 98/14192	WO 98/08840	WO 98/04913
WO 97/48395	WO 9744333	WO 98/00395	WO 97/41102
WO 97/34865	WO 97/39028	WO 97/37655	WO 97/33887
EP 796855	WO 97/26250	WO 97/24124	WO 97/24122
WO 97/24336	WO 97/24119	WO 97/23480	WO 97/23451
EP 765660	WO 97/14716	EP 77/1818	WO 97/01540

-42-

WO 96/37492	EP 741133	US 5565449	WO 96/26190
EP 727425	US 5627197	DE 4439846	EP 711770
EP 710657	WO 96/06087	WO 96/00730	WO 96/00574
WO 95/23811	US 5464855	WO 95/28426	JP 07242645
JP 07206860	EP 645376	WO 95/07712	WO 95/00544
AU 9464771	EP 614664	WO 94/21607	WO 94/15936
JP 06128289	WO 9411739	WO 93/08174	EP 537654
EP 529858	US 5229366	WO 92/07870	WO 92/00995
EP 381033	WO 98/08518	US 5721210	EP 820991
EP 820988	WO 97/48444	WO 97/41844	WO 97/45447
WO 97/45137	US 5686570	US 5686568	US 5686571
US 5686569	US 5686567	US 5686566	WO 97/41149
DE 19613933	WO 97/35615	WO 97/25031	US 5639726
WO 97/18838	WO 97/11718	US 5612311	EP 77/0622
WO 97/08203	WO 97/06791	WO 97/03094	WO 96/40781
WO 96/40250	US 5536814	US 5510332	WO 96/07734
WO 96/05304	WO 96/00581	WO 95/34641	WO 95/30438
DE 4415310	EP 668278	EP 656348	DE 4336758
EP 623615	DE 4310643	AU 9459185	WO 94/01152
CA 2120303	EP 632053	EP 618225	WO 94/18981
WO 94/13310	JP 06116289	WO 94/05310	EP 58/9181
EP 589181	US 5491129	WO 93/25218	WO 93/20229
US 5225531	EP 570352	EP 570352	WO 92/09200
WO 91/15515	EP 445796	WO 91/07977	EP 410767
US 5061693	EP 384362	US 5663297	EP 372486
US 5039805	WO 9003983	WO 89/05155	DE 19548798
DE 19626701	DE 19653645	DE 9653646	DE 19653647
DE 19654483	DE 4439846	EP 683173	EP 537654
EP 645376	EP 0710657	EP 727425	EP 741133
EP 771565	EP 0846702	EP 853084	JP 07285992

-43-

JP 08337523	JP 09169742	JP 9235239	JP 09316000
JP 10045587	JP 08183752	JP 183788	US 5574026
WO 95/14714	WO 9525543	WO 95/28426	WO 95/32710
WP 96/06087	WO 96/26190	WO 96/32945	WO 97/12625
WO 97/15666	WO 97/16197	WO 97/21726	WO 97/22596
WO 97/23625	WO 97/24336	WO 98/25892	WO 98/25601
WO 97/26258	WO 97/33576	WO 98/00144	WO 98/00395
WO 98/03573	WO 98/08518	WO 98/08840	WO 98/10795
WO 98/11089	WO 98/11223	WO 98/12226	WO 98/13071
WO 98/13350	WO 98/13354	WO 98/14192	WO 98/15278
WO 98/15574	WO 98/18460	WO 98/18461	WO 98/18764
WO 98/21230	WO 98/23608	WO 98/23613	

The following individual references each hereby incorporated by reference herein, describe various integrin antagonists suitable for use in the invention  
 5 described herein, and processes for their manufacture:

WO 98/07432	WO 98/16227	WO 97/36862	WO 97/36861
WO 97/36860	WO 97/36859	WO 97/36858	US 5639765
WO 97/08145	US 5639765	WO 98/22500	WO 98/20897
WO 98/18764	WO 98/14192	WO 98/08840	WO 98/04913
WO 97/48395	WO 97/44333	WO 98/00395	WO 97/41102
WO 97/34865	WO 97/39028	WO 97/37655	WO 97/33887
EP 79/6855	WO 97/26250	WO 97/24124	WO 97/24122
WO 97/24336	WO 97/24119	WO 97/23480	WO 97/23451
EP 76/5660	WO 97/14716	EP 771818	WO 97/01540
WO 96/37492	EP 74/1133	US 5565449	WO 96/26190
EP 72/7425	US 5627197	DE 4439846	EP 711770
EP 71/0657	WO 96/06087	WO 96/00730	WO 96/00574
WO 95/23811	US 5464855	WO 95/28426	JP 07242645

-44-

JP 07/206860	EP 64/5376	WO 95/07712	WO 95/00544
AU 94/64771	EP 61/4664	WO 94/21607	WO 94/15936
JP 06/128289	WO 94/11739	WO 93/08174	EP 537654
EP 52/9858	US 52/29366	WO 92/07870	WO 92/00995
EP 38/1033	WO 98/08518	US 572,210	EP 820991
EP 82/0988	WO 97/48444	WO 97/41844	WO 97/45447
WO 97/45137	US 5686570	US 5686568	US 5686571
US 5686569	US 5686567	US 5686566	WO 97/41149
DE 19/613933	WO 97/35615	WO 97/25031	US 5639726
WO 97/18838	WO 97/11718	US 5612311	EP 770622
WO 97/08203	WO 97/06791	WO 97/03094	WO 96/40781
WO 96/40250	US 5536814	US 5510332	WO 96/07734
WO 96/05304	WO 96/00581	WO 95/34641	WO 95/30438
DE 44/15310	EP 66/8278	EP 656348	DE 4336758
EP 62/3615	DE 43/10643	AU 94/59185	NO 94/01152
CA 21/20303	EP 63/2053	EP 618225	WO 94/18981
WO 94/13310	JP 06/116289	WO 94/05310	EP 58/9181
EP 58/9181	US 5491129	WO 93/25218	WO 93/20229
U.S. 5225531	EP 570352	EP 57/0352	WO 92/09200
WO 91/15515	EP 445796	WO 91/07977	EP 410767
US 5061693	EP 384362	US 5,63297	EP 37/2486
US 5039805	WO 90/03983	WO 89/05155	DE 19548798
DE 19/626701	DE 19653645	DE 19653646	DE 19653647
DE 19/654483	DE 4439846	EP 683173	EP 537654
EP 0/645376	EP 0710657	EP 727425	EP 741133
EP 0/771565	EP 0846702	EP 853084	JP 07285992
JP 08/337523	JP 09169742	JP 09235239	JP 09316000
JP 10/045587	JP 08183752	JP 08183788	US 5574026
WO 95/14714	WO 95/25543	WO 95/28426	WO 95/32710
WP 96/06087	WO 96/26190	WO 96/32945	WO 97/12625

-45-

WO 97/15666	WO 97/16197	WO 97/21726	WO 97/22596
WO 97/23625	WO 97/24336	WO 98/25892	WO 98/25601
WO 97/26258	WO 97/33576	WO 98/00144	WO 98/00395
WO 98/03573	WO 98/08518	WO 98/08840	WO 98/10795
WO 98/11089	WO 98/11223	WO 98/12226	WO 98/13071
WO 98/13350	WO 98/13354	WO 98/14192	WO 98/15278
WO 98/15574	WO 98/18460	WO 98/18461	WO 98/18764
WO 98/21230	WO 98/23608	WO 98/23613	

The following individual references each hereby  
incorporated by reference herein, describe additional  
5 integrin antagonists suitable for use in the invention  
described herein, and processes for their manufacture:

WO 99/50249	WO 99/45927	WO 99/44994	US 5955572
US 59552341	WO 99/38849	WO 99/37683	WO 99/37621
WO 99/33798	EP 928793	US 5925655	US 5919792
WO 99/32457	WO 99/31099	US 5912234	WO 99/31061
WO 99/31061	WO 99/30713	WO 99/30709	WO 99/26945
WO 99/15508	WO 99/15507	WO 99/15506	WO 99/15178
WO 99/15170	WO 99/11626	WO 99/06049	WO 99/05107
US 5852210	US 5843906	WO 98/54217	US 5840961
WO 98/43962	US 5773646	US 5773644	WO 98/33919
WO 98/31359	WO 98/30542	EP 854145	EP 854140
EP 853084	US 5773412	US 5766591	US 5760028
US 5759996	WO 98/15278	US 5741796	WO 98/10795
WO 97/08145			


-46-

The Vitaxin used in the therapeutic combinations of the present invention can be prepared in the manner set forth in WO 98/33,919.

Some Preferred integrin antagonists that may be  
5 used in the present invention are listed in the  
following references hereby each individually  
incorporated by reference, herein:  
U.S. Patent No. 5,773,644; U.S. Patent No. 5,773,646;  
10 Patent Application Serial No. U.S. 092/89,140; U.S.  
Patent No. 5,852,210; U.S. Patent No. 5,843,906; U.S.  
Patent Application Serial No. 091/41,547; U.S. Patent  
No. 5,952,381; U.S. Patent Application No. 092/88,742;  
Patent Application Serial No. U.S. 600/03,277; Patent  
Application Serial No. U.S. 087/13,555; Patent  
15 Application Serial No. U.S.092/15,229; Patent  
Application Serial No. U.S.090/34,758; Patent  
Application Serial No. U.S.092/61,822; WO 98/33919.

More preferred integrin antagonists that may be  
20 used in the present invention include, but are not  
limited to


II)



25 (3R)-N-[(5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl)glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine;

-47-

I2)




5

(3R)-N-[1,6-dihydro-6-oxo-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine;

10


I3)



(3R)-N-[3-amino-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine;

15

I4)




20

(3R)-N-[3-[(hydroxyamino)carbonyl]-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine;

-48-

pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)- $\beta$ -alanine;

I5)




5

(3R)-N-[3-[(4-, 5-dihydro-1H-imidazol-2-yl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)- $\beta$ -alanine;

10


I6)



(3R)-N-[3-[(aminoiminomethyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)- $\beta$ -alanine;

15

I7)




20

(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)- $\beta$ -alanine;

-49-


I8)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-D-alanine;

5

I9)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(5-bromo-3-chloro-2-hydroxyphenyl)-D-alanine;

10


I10)



15


(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine;

I11)



5 b-[3-[[[3-[[4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]sulfonyl]amino]phenyl]-3,5-difluorobenzenepropanoic acid;


I12)



10 3,5-difluoro-b-[3-[[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]amino]methyl]phenyl]benzenepropanoic acid;


15

I13)



;


I14)



(2E)-3-[3-ethyl-4-[(3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl)amino]phenyl]-2-propenoic acid;

5

I15)




10

(2E)-3-[3-[2-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]-2-oxoethoxy]phenyl]-2-propenoic acid;

15

I16)




20

(10S)-10,11-dihydro-3-[3-(2-pyridinylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid;

-52-


I17)



(2S)-7-[[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid;

5

I18)




10

(2S)-2,3,4,5-tetrahydro-4-methyl-7-[[(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-benzodiazepine-2-acetic acid;

15

I19)




20


(bR)-b-[[[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl]acetyl]amino]-1H-indole-3-pentanoic acid;

-53-

I20)




I21)




5

I22)



I23)

10




I24) Vitaxin antibody(IxsyS);

15

I25) Merck KGaA EMD-121974, cyclo[RGDF-N(Me)V-];


-54-

I26)




;

I27)




5

I28)



;


I29)



;


10

I30)




;

I31)




5

I32)




I33)




10

I34)




-56-

I35)




5


I36)



I37)




I38)



10


-57-

I39)



;


I40)



5

;


I41)




;

10

I42)



I43)




;

Still more preferred integrin antagonists include  
but are not limited to

5


I16)



10

(10S)-10,11-dihydro-3-[3-(2-pyridinylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid;

I17)




15

(2S)-7-[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid;


I18)

20



(2S)-2,3,4,5-tetrahydro-4-methyl-7-[(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-benzodiazepine-2-acetic acid;


I19)



(bR)-b-[[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-  
1,8-naphthyridin-2-yl)ethyl]-1-  
pyrrolidinyl]acetyl]amino]-1H-indole-3-  
pentanoic acid;

5

I23)




10

I24) Vitaxin antibody(Ixsys);

15


I25) Merck KGaA EMD-121974, cyclo[RGDF-N(Me)V-];

I27)




-60-

I34)




I35)

5



I36)



- 10        The phrase "antineoplastic agents" includes agents that exert antineoplastic effects, i.e., prevent the development, maturation, or spread of neoplastic cells, directly on the tumor cell, e.g., by cytostatic or cytocidal effects, and not indirectly through mechanisms  
15        such as biological response modification. There are large numbers of antineoplastic agents available in commercial use, in clinical evaluation and in pre-clinical development, which could be included in the present invention for treatment of neoplasia by  
20        combination drug chemotherapy. For convenience of

- discussion, antineoplastic agents are classified into the following classes, subtypes and species:
- ACE inhibitors,  
alkylating agents,  
5 angiogenesis inhibitors,  
angiostatin,  
anthracyclines/DNA intercalators,  
anti-cancer antibiotics or antibiotic-type agents,  
antimetabolites,  
10 antimetastatic compounds,  
asparaginases,  
bisphosphonates,  
cGMP phosphodiesterase inhibitors,  
calcium carbonate,  
15 cyclooxygenase-2 inhibitors  
DHA derivatives,  
DNA topoisomerase,  
endostatin,  
epipodophylotoxins,  
20 genistein,  
hormonal anticancer agents,  
hydrophilic bile acids (URSO),  
immunomodulators or immunological agents,  
integrin antagonists  
25 interferon antagonists or agents,  
MMP inhibitors,  
miscellaneous antineoplastic agents,  
monoclonal antibodies,  
nitrosoureas,  
30 NSAIDs,  
ornithine decarboxylase inhibitors,

pBATTs,  
radio/chemo sensitizers/protectors,  
retinoids  
selective inhibitors of proliferation and migration  
5 of endothelial cells,  
selenium,  
stromelysin inhibitors,  
taxanes,  
vaccines, and  
10 vinca alkaloids.

The major categories that some preferred antineoplastic agents fall into include antimetabolite agents, alkylating agents, antibiotic-type agents, hormonal anticancer agents, immunological agents, 15 interferon-type agents, and a category of miscellaneous antineoplastic agents. Some antineoplastic agents operate through multiple or unknown mechanisms and can thus be classified into more than one category.

A first family of antineoplastic agents which may 20 be used in combination with the present invention consists of antimetabolite-type antineoplastic agents. Antimetabolites are typically reversible or irreversible enzyme inhibitors, or compounds that otherwise interfere with the replication, translation or transcription of 25 nucleic acids. Suitable antimetabolite antineoplastic agents that may be used in the present invention include, but are not limited to acanthifolic acid, aminothiadiazole, anastrozole, bicalutamide, brequinar sodium, capecitabine, carmofur, Ciba-Geigy CGP-30694, 30 cladribine, cyclopentyl cytosine, cytarabine phosphate stearate, cytarabine conjugates, cytarabine ocfosfate,

Lilly DATHF, Merrel Dow DDFC, dezaguanine,  
 dideoxycytidine, dideoxyguanosine, didox, Yoshitomi  
 DMDC, doxifluridine, Wellcome EHNA, Merck & Co. EX-015,  
 fazarabine, finasteride, floxuridine, fludarabine  
 5 phosphate, N-(2'-furanidyl)-5-fluorouracil, Daiichi  
 Seiyaku FO-152, fluorouracil (5-FU), 5-FU-fibrinogen,  
 isopropyl pyrrolizine, Lilly LY-188011, Lilly LY-264618,  
 methobenzaprim, methotrexate, Wellcome MZPES, nafarelin,  
 norspermidine, nolvadex, NCI NSC-127716, NCI NSC-264880,  
 10 NCI NSC-39661, NCI NSC-612567, Warner-Lambert PALA,  
 pentostatin, piritrexim, plicamycin, Asahi Chemical PL-  
 AC, stearate; Takeda TAC-788, thioguanine, tiazofurin,  
 Erbamont TIF, trimetrexate, tyrosine kinase inhibitors,  
 tyrosine protein kinase inhibitors, Taiho UFT,  
 15 toremifene, and uricytin.

Preferred antimetabolite agents that may be used in  
 the present invention include, but are not limited to,  
 those identified in Table No. 1, below.

20 Table No. 1. Antimetabolite agents

Compound	Common Name/ Trade Name	Company	Reference	Dosage
1,3-Benzenediaceto nitrile, alpha, alpha, alpha', a lpha'- tetramethyl-5- (1H-1,2,4-triazol-1-ylmethy1)-	anastrozole ; ARIMIDEX®	Zeneca	EP 296749	1-mg/day
Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-	bicalutamide; CASODEX®	Zeneca	EP 100172	50 mg once daily

Compound	Common Name/ Trade Name	Company	Reference	Dosage
[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, (+/-)-				
	capecitabine	Roche	US 5472949	
Adenosine, 2-chloro-2'-deoxy-, 2-chloro-2'-deoxy-(beta)-D-adenosine)	cladribine; 2-CdA; LEUSTAT; LEUSTA-TIN®; LEUSTA-TIN® injection; LEUSTATINE® ; RWJ-26251;	Johnson & Johnson	EP 173059	0.09 mg/kg/day for 7 days.
2 (1H)-Pyrimidinone, 4-amino-1-[5-O-[hydroxy(octadecyloxy)phosphoryl]-beta-D-arabinofuranosyl]-, monosodium salt	cytarabine ocfosfate; ara CMP stearyl ester; C-18-PCA; cytarabine phosphate stearate; Starasid; YNK-01; CYTOSAR-U®	Yamasa Corp	EP 239015	100 - 300 mg/day for 2 weeks
4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)-	finasteride ; PROPECIA®	Merck & Co	EP 155096	
	fluorouracil (5-FU)		US 4336381	
Fludarabine phosphate. 9H-Purin-6-	fludarabine phosphate; 2-F-araAMP;	Southern Research Institute	US 4357324	25 mg/m <sup>2</sup> /d IV over a period of

Compound	Common Name/ Trade Name	Company	Reference	Dosage
amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)	Fludara; Fludara iv; Fludara Oral; NSC-312887; SH-573; SH-584; SH-586;	; Berlex		approximately 30 minutes daily for 5 consecutive days, commenced every 28 days.
	gemcitabine	Eli Lilly	US 4526988	
N-(4-(((2,4-diamino-6-pteridinyl)methyl)methoxy)benzoyl)-L-glutamic acid	methotrexate iv, Hyal; HA + methotrexate, Hyal; methotrexate iv, HIT Technolog;	Hyal Pharmaceutical; American Home Products; Lederle	US 2512572	trophoblastic diseases: 15 to 30 mg/d orally or intramuscularly in a five-day course (repeated 3 to 5 times as needed)
Luteinizing hormone-releasing factor (pig), 6-[3-(2-naphthalenyl)-D-alanine]-	nafarelin	Roche	EP 21234	
	pentostatin ; CI-825; DCF; deoxycoformycin; Nipent; NSC-218321; Oncopent;	Warner-Lambert	US 3923785	
Ethanamine, 2-[4-(4-chloro-	toremifene; FARESTON®	Orion Pharma	EP 95875	60 mg/d

Compound	Common Name/ Trade Name	Company	Reference	Dosage
1,2-diphenyl- 1- butenyl)phenoxy]-N,N- dimethyl-, (Z)-				

A second family of antineoplastic agents which may be used in combination with the present invention consists of alkylating-type antineoplastic agents. The 5 alkylating agents are believed to act by alkylating and cross-linking guanine and possibly other bases in DNA, arresting cell division. Typical alkylating agents include nitrogen mustards, ethyleneimine compounds, alkyl sulfates, cisplatin, and various nitrosoureas. A 10 disadvantage with these compounds is that they not only attack malignant cells, but also other cells which are naturally dividing, such as those of bone marrow, skin, gastro-intestinal mucosa, and fetal tissue. Suitable alkylating-type antineoplastic agents that may be used 15 in the present invention include, but are not limited to, Shionogi 254-S, aldo-phosphamide analogues, altretamine, anaxirone, Boehringer Mannheim BBR-2207, bestrabucil, budotitane, Wakunaga CA-102, carboplatin, carmustine (BiCNU), Chinoim-139, Chinoim-153, 20 chlorambucil, cisplatin, cyclophosphamide, American Cyanamid CL-286558, Sanofi CY-233, cyplatate, dacarbazine, Degussa D-19-384, Sumimoto DACHP(Myr)2, diphenylspiromustine, diplatinum cytostatic, Erba distamycin derivatives, Chugai DWA-2114R, ITI E09, 25 elmustine, Erbamont FCE-24517, estramustine phosphate

sodium, etoposide phosphate, fotemustine, Unimed G-6-M, Chinoin GYKI-17230, hepsul-fam, ifosfamide, iproplatin, iomustine, mafosfamide, mitolactol, mycophenolate, Nippon Kayaku NK-121, NCI NSC-264395, NCI NSC-342215,  
 5 oxaliplatin, Upjohn PCNU, prednimustine, Proter PTT-119, ranimustine, semustine, SmithKline SK&F-101772, thiotepe, Yakult Honsha SN-22, spiromus-tine, Tanabe Seiyaku TA-077, tauromustine, temozolomide, teroxirone, tetraplatin and trimelamol.

10 Preferred alkylating agents that may be used in the present invention include, but are not limited to, those identified in Table No. 2, below.

Table No. 2. Alkylating agents

Compound	Common Name/ Trade Name	Company	Reference	Dosage
Platinum, diammine[1,1'-cyclobutanedicarboxylato(2-)]-, (SP-4-2)-	carboplatin; PARAPLATIN ®	Johnson Matthey	US 4657927. US 4140707.	360 mg/m <sup>2</sup> squared) I.V. on day 1 every 4 weeks.
Carmustine, 1,3-bis (2-chloroethyl)-1-nitro-sourea	BiCNU®	Ben Venue Laboratories, Inc.	JAMA 1985; 253 (11): 1590-1592.	Preferred: 150 to 200 mg/ m <sup>2</sup> every 6 wks.
	etoposide phosphate	Bristol-Myers Squibb	US 4564675	
	thiotepe			
Platinum, diamminedi-chloro-, (SP-4-2)-	cisplatin; PLATINOL-AQ	Bristol-Myers Squibb	US 4177263	
dacarbazine	DTIC Dome	Bayer		2 to 4.5mg/kg/day for 10

Compound	Common Name/ Trade Name	Company	Reference	Dosage
				days; 250mg/ square meter body surface/ day I.V. for 5 days every 3 weeks
ifosfamide	IFEX	Bristol- Meyers Squibb		4-5 g/m (square) single bolus dose, or 1.2-2 g/m (square) I.V. over 5 days.
	cyclophosphamide		US 4537883	
cis- diaminedichloroplatinum	Platinol Cisplatin	Bristol- Myers Squibb		20 mg/M <sup>2</sup> IV daily for a 5 day cycle.

A third family of antineoplastic agents which may be used in combination with the present invention consists of antibiotic-type antineoplastic agents.

- 5 Suitable antibiotic-type antineoplastic agents that may be used in the present invention include, but are not limited to Taiho 4181-A, aclarubicin, actinomycin D, actinoplanone, Erbamont ADR-456, aeroplysinin derivative, Ajinomoto AN-201-II, Ajinomoto AN-3, Nippon Soda anisomycins, anthracycline, azino-mycin-A, bisucaberin, Bristol-Myers BL-6859, Bristol-Myers BMY-25067, Bristol-Myers BMY-25551, Bristol-Myers BMY-26605, Bristol-Myers BMY-27557, Bristol-Myers BMY-28438,

bleomycin sulfate, bryostatin-1, Taiho C-1027,  
calichemycin, chromoximycin, dactinomycin, daunorubicin,  
Kyowa Hakko DC-102, Kyowa Hakko DC-79, Kyowa Hakko DC-  
88A, Kyowa Hakko DC89-A1, Kyowa Hakko DC92-B,  
5 ditrisarubicin B, Shionogi DOB-41, doxorubicin,  
doxorubicin-fibrinogen, elsamicin-A, epirubicin,  
erbstatin, esorubicin, esperamicin-A1, esperamicin-Alb,  
Erbamont FCE-21954, Fujisawa FK-973, fostriecin,  
Fujisawa FR-900482, glidobactin, gregatin-A,  
10 grincamycin, herbimycin, idarubicin, illudins,  
kazusamycin, kesarirhodins, Kyowa Hakko KM-5539, Kirin  
Brewery KRN-8602, Kyowa Hakko KT-5432, Kyowa Hakko KT-  
5594, Kyowa Hakko KT-6149, American Cyanamid LL-D49194,  
Meiji Seika ME 2303, menogaril, mitomycin, mitoxantrone,  
15 SmithKline M-TAG, neoenactin, Nippon Kayaku NK-313,  
Nippon Kayaku NKT-01, SRI International NSC-357704,  
oxalysine, oxaunomycin, peplomycin, pilatin,  
pirarubicin, porothramycin, pyrindamycin A, Tobishi RA-  
I, rapamycin, rhizoxin, rodorubicin, sibanomicin,  
20 siwenmycin, Sumitomo SM-5887, Snow Brand SN-706, Snow  
Brand SN-07, sorangicin-A, sparsomycin, SS  
Pharmaceutical SS-21020, SS Pharmaceutical SS-7313B, SS  
Pharmaceutical SS-9816B, steffimycin B, Taiho 4181-2,  
talisomycin, Takeda TAN-868A, terpentecin, thrazine,  
25 tricrozarin A, Upjohn U-73975, Kyowa Hakko UCN-10028A,  
Fujisawa WF-3405, Yoshitomi Y-25024 and zorubicin.

Preferred antibiotic anticancer agents that may be used in the present invention include, but are not limited to, those agents identified in Table No. 3, 30 below.

Table No. 3. Antibiotic anticancer agents

Compound	Common Name/ Trade Name	Company	Reference	Dosage
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (E)-	mycophenolate mofetil	Roche	WO 91/19498	1 to 3 gm/d
	mitoxantrone		US 4310666	
	doxorubicin		US 3590028	
Mitomycin and/or mitomycin-C	Mutamycin	Bristol-Myers Squibb Oncology/Immunology		After full hemato-logical recovery from any previous chemo-therapy: 20 <sup>2</sup> mg/m <sup>2</sup> intra-venously as a single dose via a functioning intra-venous catheter.

A fourth family of antineoplastic agents which may be used in combination with the present invention

5 consists of synthetic nucleosides. Several synthetic nucleosides have been identified that exhibit anticancer activity. A well known nucleoside derivative with strong anticancer activity is 5-fluorouracil (5-FU). 5-Fluorouracil has been used clinically in the treatment

of malignant tumors, including, for example, carcinomas, sarcomas, skin cancer, cancer of the digestive organs, and breast cancer. 5-Fluorouracil, however, causes serious adverse reactions such as nausea, alopecia, 5 diarrhea, stomatitis, leukocytic thrombocytopenia, anorexia, pigmentation, and edema. Derivatives of 5-fluorouracil with anti-cancer activity have been described in U.S. Pat. No. 4,336,381. Further 5-FU derivatives have been described in the following patents 10 listed in Table No. 4, hereby individually incorporated by reference herein.

Table No. 4. 5-Fu derivatives

JP 50-50383	JP 50-50384	JP 50-64281
JP 51-146482	JP 53-84981	

15 U.S. Pat. No. 4,000,137 discloses that the peroxidate oxidation product of inosine, adenine, or cytidine with methanol or ethanol has activity against lymphocytic leukemia. Cytosine arabinoside (also referred to as Cytarabin, araC, and Cytosar) is a 20 nucleoside analog of deoxycytidine that was first synthesized in 1950 and introduced into clinical medicine in 1963. It is currently an important drug in the treatment of acute myeloid leukemia. It is also active against acute lymphocytic leukemia, and to a 25 lesser extent, is useful in chronic myelocytic leukemia and non-Hodgkin's lymphoma. The primary action of araC is inhibition of nuclear DNA synthesis. Handschumacher, R. and Cheng, Y., "Purine and Pyrimidine Antimetabolites", Cancer Medicine, Chapter XV-1, 3rd

Edition, Edited by J. Holland, et al., Lea and Febigol, publishers.

5-Azacytidine is a cytidine analog that is primarily used in the treatment of acute myelocytic leukemia and  
5 myelodysplastic syndrome.

2-Fluoroadenosine-5'-phosphate (Fludara, also referred to as FaraA) is one of the most active agents in the treatment of chronic lymphocytic leukemia. The compound acts by inhibiting DNA synthesis. Treatment of  
10 cells with F-araA is associated with the accumulation of cells at the G1/S phase boundary and in S phase; thus, it is a cell cycle S phase-specific drug. InCorp of the active metabolite, F-araATP, retards DNA chain elongation. F-araA is also a potent inhibitor of  
15 ribonucleotide reductase, the key enzyme responsible for the formation of dATP. 2-Chlorodeoxyadenosine is useful in the treatment of low grade B-cell neoplasms such as chronic lymphocytic leukemia, non-Hodgkins' lymphoma, and hairy-cell leukemia. The spectrum of activity is  
20 similar to that of Fludara. The compound inhibits DNA synthesis in growing cells and inhibits DNA repair in resting cells.

A fifth family of antineoplastic agents which may be used in combination with the present invention  
25 consists of hormonal agents. Suitable hormonal-type antineoplastic agents that may be used in the present invention include, but are not limited to Abarelix; Abbott A-84861; Abiraterone acetate; Aminoglutethimide; anastrozole; Asta Medica AN-207; Antide; Chugai AG-041R;  
30 Avorelin; aseranox; Sensus B2036-PEG; Bicalutamide; buserelin; BTG CB-7598; BTG CB-7630; Casodex; cetrolix;

clastroban; clodronate disodium; Cosudex; Rotta Research CR-1505; cytadren; crinone; deslorelin; droloxifene; dutasteride; Elimina; Laval University EM-800; Laval University EM-652; epitostanol; epristeride; Mediolanum 5 EP-23904; EntreMed 2-ME; exemestane; fadrozole; finasteride; flutamide; formestane; Pharmacia & Upjohn FCE-24304; ganirelix; goserelin; Shire gonadorelin agonist; Glaxo Wellcome GW-5638; Hoechst Marion Roussel Hoe-766; NCI hCG; idoxifene; isocordoin; Zeneca ICI-10 182780; Zeneca ICI-118630; Tulane University J015X; Schering Ag J96; ketanserin; lanreotide; Milkhaus LDI-200; letrozol; leuprolide; leuprorelin; liarozole; lisuride hydrogen maleate; loxiglumide; mepitiostane; Leuprorelin; Ligand Pharmaceuticals LG-1127; LG-1447; LG-2293; LG-2527; LG-15 2716; Bone Care International LR-103; Lilly LY-326315; Lilly LY-353381-HCl; Lilly LY-326391; Lilly LY-353381; Lilly LY-357489; miproxifene phosphate; Orion Pharma MPV-2213ad; Tulane University MZ-4-71; nafarelin; nilutamide; Snow Brand NKS01; octreotide; Azko Nobel ORG-20 31710; Azko Nobel ORG-31806; orimeten; orimetene; orimetine; ormeloxifene; osaterone; Smithkline Beecham SKB-105657; Tokyo University OSW-1; Peptech PTL-03001; Pharmacia & Upjohn PNU-156765; quinagolide; ramorelix; Raloxifene; statin; sandostatin LAR; Shionogi S-10364; Novartis SMT-25 487; somavert; somatostatin; tamoxifen; tamoxifен methiodide; teverelix; toremifene; triptorelin; TT-232; vapreotide; vorozole; Yamanouchi YM-116; Yamanouchi YM-511; Yamanouchi YM-55208; Yamanouchi YM-53789; Schering AG ZK-1911703; Schering AG ZK-230211; and Zeneca ZD-30 182780.

Preferred hormonal agents that may be used in the present invention include, but are not limited to, those identified in Table No. 5, below.

5 Table No. 5. Hormonal agents

Compound	Common Name/ Trade Name	Company	Reference	Dosage
2-methoxyestradiol	EntreMed; 2-ME	EntreMed		
N-(S)-tetrahydrofuroyl-Gly-D2Nal-D4ClPhe-D3Pal-Ser-NMeTyr-DLys(Nic)-Leu-Lys(Isp)-Pro-DAla-NH2	A-84861	Abbott		
	raloxifene			
[3R-1-(2,2-Dimethoxyethyl)-3-((4-methylphenyl)aminoacarbonylmethyl)-3-(N'-(4-methylphenyl)ureido)-indoline-2-one]	AG-041R	Chugai	WO 94/19322	
	AN-207	Asta Medica	WO 97/19954	
Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-	toremifene; FARESTON®	Orion Pharma	EP 95875	60 mg/d
Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-,	tamoxifen NOLVADEX(R)	Zeneca	US 453,6516	For patients with breast cancer, the recommended

Compound	Common Name/ Trade Name	Company	Reference	Dosage
(Z)-				daily dose is 20-40 mg. Dosages greater than 20 mg per day should be divided (morning and evening).
D-Alaninamide N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N6-(3-pyridinylcarbonyl)-L-lysyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-	Antide; ORF-23541	Ares-Serono	WO 89/01944	25 or 50microg/kg sc
	B2036-PEG; Somaver; Trovert	Sensus		
4-Methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-7-(pivaloyloxy)-3-[4-(pivaloyloxy)phenyl]-2H-1-benzopyran	EM-800; EM-652	Laval University		
	letrozol		US 4749346	
	goserelin		US 4100274	
3-[4-[1,2-	GW-5638	Glaxo		

Compound	Common Name/ Trade Name	Company	Reference	Dosage
Diphenyl-1(Z)-butenylphenyl]-2(E)-propenoic acid		Wellcome		
Estra-1,3,5(10)-triene-3,17-diol, 7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]-nonyl]-, (7alpha,17beta)-	ICI-182780; Faslodex; ZD-182780	Zeneca	EP 34/6014	250mg/mth
	J015X	Tulane University		
	LG-1127; LG-1447	Ligand Pharmaceuticals		
	LG-2293	Ligand Pharmaceuticals		
	LG-2527; LG-2716	Ligand Pharmaceuticals		
	buserelin, Peptech; deslorelin, Peptech; PTL-03001; triptorelin, Peptech	Peptech		
	LR-103	Bone Care International		
[2-(4-Hydroxyphenyl)-	LY-326315	Lilly	WO 9609039	

Compound	Common Name/ Trade Name	Company	Reference	Dosage
6-hydroxynaphthalen-1-yl [4-[2-(1-piperdinyl)ethoxy]phenyl]methane hydrochloride				
	LY-353381-HCl	Lilly		
	LY-326391	Lilly		
	LY-353381	Lilly		
	LY-357489	Lilly		
	MPV-2213ad	Orion Pharma	EP 476944	0.3-300 mg
Isobutyryl-Tyr-D-Arg-Asp-Ala-Ile-(4-Cl)-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-(2-aminobutyryl)-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-Ser 4-guanidinobutyramide	MZ-4-71	Tulane University		
Androst-4-ene-3,6,17-trione, 14-hydroxy-	NKS01; 14alpha-OHAT; 14OHAT	Snow Brand	EP 300062	
3beta,16beta,17a-lpha-trihydroxycholest-5-en-22-one-16-O-(2-O-4-methoxybenzoyl-beta-D-xylopyranosyl)-(1-3)(2-O-acetyl-	OSW-1			

Compound	Common Name/ Trade Name	Company	Reference	Dosage
alpha-L-arabinopyranoside)				
Spiro[estra-4,9-diene-17,2'(3'H)-furan]-3-one, 11-[4-(dimethylamino)phenyl]-4',5'-dihydro-6-methyl-, (6beta,11beta,17beta)-	Org-31710; Org-31806	Akzo Nobel	EP 289073	
(22RS)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide	PNU-156765; FCE-28260	Pharmacia & Upjohn		
1-[ (benzofuran-2yl)-4-chlorophenylmethyl] imidazole		Menarini		
Tryptamine derivatives		Rhone-Poulenc Rorer	WO 96/35686	
Permanently ionic derivatives of steroid hormones and their antagonists		Pharmos	WO 95/26720	
Novel tetrahydronaphthofuranone derivatives		Meiji Seika	WO 97/30040	
	SMT-487;	Novartis		

Compound	Common Name/ Trade Name	Company	Reference	Dosage
	90Y-octreotide			
D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH <sub>2</sub>	TT-232			
2-(1H-imidazol-4-ylmethyl)-9H-carbazole monohydrochloride monohydrate	YM-116	Yamanouchi		
4-[N-(4-bromobenzyl)-N-(4-cyanophenyl)amino]-4H-1,2,4-triazole	YM-511	Yamanouchi		
2-(1H-imidazol-4-ylmethyl)-9H-carbazole monohydrochloride monohydrate	YM-55208; YM-53789	Yamanouchi		
	ZK-1911703	Schering AG		
	ZK-230211	Schering AG		
	abarelix	Praecis Pharmaceuticals		
Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3 $\beta$ )-	abiraterone acetate; CB-7598; CB-7630	BTG		
2,6-Piperidinedione, 3-(4-aminophenyl)-3-ethyl-	aminoglutethimide; Ciba-16038; Cytadren; Elimina; Orimeten; Orimet-	Novartis	US 3944671	

Compound	Common Name/ Trade Name	Company	Reference	Dosage
	ene; Orimetine			
1,3-Benzenediacetonitrile, alpha, alpha', alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-	anastrozole; Arimidex; ICI-D1033; ZD-1033	Zeneca	EP 296749	1mg/day
5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-2-methyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide	avorelin; Meterelin	Mediolanum	EP 23904	
Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, (+/-)-	bicalutamide; Casodex; Cosudex; ICI-176334	Zeneca	EP 100172	
Luteinizing hormone-releasing factor (pig), 6-[O-(1,1-dimethylethyl)-D-serine] -9-(N-ethyl-L-prolinamide)-10-deglycinamide-	buserelin; Hoe-766; Profact; Receptal; S-746766; Suprecor; Suprecur; Suprefact; Suprefakt	Hoechst Marion Roussel	GB 15/23623	200-600 microg/day
D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-	cetro-relix; SB-075; SB-75	Asta Medica	EP 29/9402	

Compound	Common Name/ Trade Name	Company	Reference	Dosage
3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ol-L-leucyl-L-arginyl-L-prolyl-				
Phosphonic acid, (dichloromethylene)bis-, disodium salt-	clodronate disodium, Leiras; Bonefos; Clastoban; KCO-692	Schering AG		
Luteinizing hormone-releasing factor (pig), 6-D-tryptophan-9-(N-ethyl-L-prolinamide)-10-deglycinamide-	deslorelin; gonadorelin analogue, Roberts; LHRH analogue, Roberts; Somagard	Roberts	US 4034082	
Phenol, 3-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]-, (E)-[CA S]	droloxi-fene; FK-435; K-060; K-21060E; RP 60850	Klinge	EP 54168	
4-Azaandrost-1-ene-17-carboxamide, N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-, (5alpha,17beta)-	dutasteride; GG-745; GI-198745	Glaxo Wellcome		
Androstan-17-ol, 2,3-epithio-,	epitio-stanol;	Shionogi	US 3230215	

Compound	Common Name/ Trade Name	Company	Reference	Dosage
(2alpha,3alpha,5alpha,17beta)-	10275-S; epithioan- drostan- ol; S- 10275; Thiobres- tin; Thiodrol			
Androsta-3,5-diene-3-carboxylic acid, 17-(((1,1-dimethylethyl)amino)carbonyl)-(17beta)-	epriste- ride; ONO-9302; SK&F- 105657; SKB- 105657	Smith- Kline Beecham	EP 289327	0.4- 160mg/day
estrone 3-O-sulfamate	estrone 3-O- sulfamate			
19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-(2-propanesulfonate), (17alpha)-	ethinyl estradiol sulfon- ate; J96; Turister- on	Schering AG	DE 1949095	
Androsta-1,4-diene-3,17-dione, 6-methylene-	exemes- tane; FCE-24304	Pharmaci a & Upjohn	DE 3622841	5mg/kg
Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)-, monohydrochloride	fadrozo- le; Afema; Arensin; CGS- 16949; CGS- 16949A; CGS- 20287; fadrozole monohydro chloride	Novartis	EP 165904	1 mg po bid
4-Azaandrost-1-	finaster-	Merck &	EP 155096	5mg/day

Compound	Common Name/ Trade Name	Company	Reference	Dosage
ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)-	ide; Andozac; ChibroPro scar; Finastid; MK-0906; MK-906; Procure; Prodel; Propecia; Proscar; Proskar; Prostide; YM-152	Co		
Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-	flutamide ; Drogenil; Euflex; Eulexin; Eulexine; Flucinom; Flutamida ; Fugerel; NK-601; Odyne; Prostogen at; Sch-13521	Schering Plough	US 4329364	
Androst-4-ene-3,17-dione, 4-hydroxy-	formestane; 4-HAD; 4-OHA; CGP-32349; CRC-82/01; Depot; Lentaron	Novartis	EP 346953	250 or 600mg/day po
[N-Ac-D-Nal,D-pCl-Phe,D-Pal,D-hArg(Et)2,hArg(Et)2,D-Ala]GnRH-	ganirelix; Org-37462; RS-26306	Roche	EP 312052	
	gonadore-	Shire		

Compound	Common Name/ Trade Name	Company	Reference	Dosage
	lin agonist, Shire			
Luteinizing hormone- releasing factor (pig), 6-[O- (1,1- dimethylethyl)- D-serine] -10- deglycinamide-, 2- (aminocarbonyl)h ydrazide	goserelin; ICI- 118630; Zoladex; Zoladex LA	Zeneca	US 4100274	
	hCG; gonadotro phin; LDI-200	Milkhaus		
	human chorionic gonadotro phin; hCG	NIH		
Pyrrolidine, 1- [2-[4-[1-(4- iodophenyl)-2- phenyl-1- butenyl]phenoxy] et hyl]-, (E)-	idoxifene ; CB- 7386; CB- 7432; SB- 223030	BTG	EP 260066	
	isocord- oin	Indena		
2,4(1H,3H)- Quinazolinedione , 3-[2-[4-(4- fluorobenzoyl)- 1- piperidinyl]ethy l]-	ketanse- rin; Aseranox; Ketensin; KJK-945; ketanse- rine; Perketan; R-41468; Serefrex; Serepr- ess;	Johnson & Johnson	EP 13612	

Compound	Common Name/ Trade Name	Company	Reference	Dosage
	Sufrexal; Taseron			
L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide	lanreotide; Angiopeptin; BIM-23014; Dermopeptin; Ipstyl; Somatuline; Somatuline LP	Beaufour-Ipsen	EP 215171	
Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-	letrozole; CGS-20267; Femara	Novartis	EP 236940	2.5mg/day
Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglicinamide-	leuprolide, Atrigel; leuprolide, Atrix	Atrix		
Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglicinamide-	leuprolerelin; Abbott-43818; Carcinil; Enantone; Leuplin; Lucrin; Lupron; Lupron Depot; leuprolide, Abbott; leuprolide,	Abbott	US 4005063	3.75microg sc q 28 days

Compound	Common Name/ Trade Name	Company	Reference	Dosage
	Takeda; leupror- elin, Takeda; Procren Depot; Procrin; Prostap; Prostap SR; TAP- 144-SR			
Luteinizing hormone- releasing factor (pig), 6-D- leucine-9-(N- ethyl-L- prolinamid e)- 10- deglycinamide-	leupror- elin, DUROS; leuprolid e, DUROS; leupror- elin	Alza		
1H- Benzimidazole, 5-[(3- chlorophenyl)- 1H-imidazol-1- ylmethyl]-	liaro- zole; Liazal; Liazol; liaro- zole fumarate; R-75251; R-85246; Ro-85264	Johnson & Johnson	EP 260744	300mg bid
Urea, N'- [(8alpha)-9,10- didehydro-6- methylergolin-8- yl]-N,N-diethyl- , (Z)-2- butenedioate (1:1)	lisuride hydrogen maleate; Cuvalit; Dopergin; Dopergine ; Eunal; Lysenyl; Lysenyl Forte; Revanil	VUFB		
Pentanoic acid, 4-[(3,4-	loxiglumi de; CR-	Rotta Research	WO 87/03869	

Compound	Common Name/ Trade Name	Company	Reference	Dosage
dichlorobenzoyl) amino]-5-[ (3-methoxypropyl) pentylamino]-5-oxo-, (+/-)-	1505			
Androstane, 2,3-epithio-17-[(1-methoxycyclopentyl)oxy]-, (2alpha,3alpha,5alpha,17beta) -	mepitiostane; S-10364; Thioderon	Shionogi	US 3567713	
Phenol, 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-[4-(1-methylethyl)phenyl]-1-butenyl]-, dihydrogen phosphate (ester), (E) -	miproxifene phosphate ; DP-TAT-59; TAT-59	Taiho	WO 87/07609	20mg/day
Luteinizing hormone-releasing factor (pig), 6-[3-(2-naphthalenyl)-D-alanine]-	nafarelin ; NAG, Syntex; Nasanyl; RS-94991; RS-94991-298; Synarel; Synarela; Synrelina	Roche	EP 21/234	
2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-	nilutamide; Anandron; Nilandron; Notostran; RU-23908	Hoechst Marion Roussel	US 4472382	
	obesity gene; diabetes	Lilly	WO 96/24670	

Compound	Common Name/ Trade Name	Company	Reference	Dosage
	gene; leptin			
L-Cysteinamide, D-phenylalanyl-L- L-cysteinyl-L- phenylalanyl-D- tryptophyl-L- lysyl-L- threonyl-N-[2- hydroxy-1- (hydroxymethyl)pro- pyl]-, cyclic (2-7)- disulfide, [R- (R*,R*)]-	octreot- ide; Longast- atina; octreot- ide pamoate; Sandost- atin; Sandostat- in LAR; Sandost- atina; Sandost- atine; SMS-201- 995	Novartis	EP 29/579	
Pyrrolidine, 1-[2-(p-(7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl]-, trans-	ormelox- ifene; 6720- CDRI; Centron; Choice-7; centchrom- an; Saheli	Central Drug Research Inst.	DE 2329201	
2-Oxapregna-4,6-diene-3,20-dione, 17-(acetoxy)-6-chloro-	osaterone acetate; Hipros; TZP-4238	Teikoku Hormone	EP 193871	
Pregn-4-ene-3,20-dione	progester- one; Crinone	Columbia Laborato- ries		
Sulfamide, N,N-diethyl-N'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo[g]quinolin-3-yl)-,	quinagol- ide; CV- 205-502; Nor- prolac; SDZ-205- 502	Novartis	EP 77754	

Compound	Common Name/ Trade Name	Company	Reference	Dosage
(3alpha,4aalpha, 10abeta)- (+/-)-				
L-Proline, 1- (N2-(N-(N-(N-(N- (N-(N-(N-acetyl- 3-(2- naphthalenyl)-D- alanyl)-4-chl oro-D- phenylalanyl)-D- tryptophyl)-L- seryl)-L- tyrosyl)-O-(6- deoxy-alpha-L- mannopyra nosyl)-D-seryl)- L-leucyl)-L- arginyl)-, 2- (aminocarbonyl)h ydrazide-	ramore- lix; Hoe- 013; Hoe- 013C; Hoe-2013	Hoechst Marion Roussel	EP 451791	
	somatosta tin analogues	Tulane Universi ty		
Ethanamine, 2- [4-(1,2- diphenyl-1- butenyl)phenoxy] -N,N-dimethyl-, (Z)-	tamoxi- fen; Ceadan; ICI- 46474; Kessar; Nolgen; Nolvadex; Tafoxen; Tamofen; Tamoplex; Tamoxas- ta; Tamoxen; Tomaxen	Zeneca	US 4536516	
	tamoxifen methiod- ide	Pharmos		
Ethanamine, 2- [4-(1,2-	tamoxifen	Douglas		

Compound	Common Name/ Trade Name	Company	Reference	Dosage
diphenyl-1- butenyl)phenoxy] -N,N-dimethyl-, (z)-				
D-Alaninamide, N-acetyl-3-(2- naphthalenyl)-D- alanyl-4-chloro- D-phenyl alanyl- 3-(3-pyridinyl)- D-alanyl-L- seryl-L-tyrosyl- N6- (aminocarbonyl)- D-lysyl-L - leucyl-N6-(1- methylethyl)-L- lysyl-L-prolyl-	tevere- lix; Antarelix	Asta Medica		
Ethanamine, 2- [4-(4-chloro- 1,2-diphenyl-1- butenyl)phenoxy] -N,N-dimethyl-, (Z)-	toremif- ene; Estrimex; Fareston; FC-1157; FC-1157a; NK-622	Orion Pharma	EP 95875	60mg po
Luteinizing hormone- releasing factor (pig), 6-D- tryptophan-	tripto- relin; ARVEKAP; AY-25650; BIM- 21003; BN-52104; Decap- eptyl; WY-42422	Debio- pharm	US 4010125	
L- Tryptophanamide, D-phenylalanyl- L-cysteinyl-L- tyrosyl-D- tryptophyl-L- lysyl- L-valyl- L-cysteinyl-,	vapreot- ide; BMY- 41606; Octasta- tin; RC- 160	Debio- pharm	EP 203031	500microg sc tid

Compound	Common Name/ Trade Name	Company	Reference	Dosage
cyclic (2-7)-disulfide-				
1H-Benzotriazole, 6-[(4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl]-1-methyl-	vorozole; R-76713; R-83842; Rivizor	Johnson & Johnson	EP 293978	2.5mg/day

A sixth family of antineoplastic agents which may be used in combination with the present invention consists of a miscellaneous family of antineoplastic agents including, but not limited to alpha-carotene, 5 alpha-difluoromethyl-arginine, acitretin, Biotec AD-5, Kyorin AHC-52, alstonine, amonafide, amphethinile, amsacrine, Angiostat, ankinomycin, anti-neoplaston A10, antineoplaston A2, antineoplaston A3, antineoplaston A5, antineoplaston AS2-1, Henkel APD, aphidicolin glycinate, 10 asparaginase, Avarol, baccharin, batracylin, benfluron, benzotript, Ipsen-Beaufour BIM-23015, bisantrene, Bristol-Myers BMY-40481, Vestar boron-10, bromofosfamide, Wellcome BW-502, Wellcome BW-773, calcium carbonate, Calcet, Calci-Chew, Calci-Mix, Roxane calcium carbonate 15 tablets, caracemide, carmethizole hydrochloride, Ajinomoto CDAF, chlorsulfaquinoxalone, Chemes CHX-2053, Chemex CHX-100, Warner-Lambert CI-921, Warner-Lambert CI-937, Warner-Lambert CI-941, Warner-Lambert CI-958, clanfenur, claviridenone, ICN compound 1259, ICN 20 compound 4711, Contracan, Cell Pathways CP-461, Yakult Honsha CPT-11, crisnatol, curaderm, cytochalasin B, cytarabine, cytocytin, Merz D-609, DABIS maleate,

dacarbazine, datelliptinium, DFMO, didemnin-B,  
dihaematoporphyrin ether, dihydrolenperone, dinaline,  
distamycin, Toyo Pharmar DM-341, Toyo Pharmar DM-75,  
Daiichi Seiyaku DN-9693, docetaxel, Encore  
5 Pharmaceuticals E7869, elliprabin, elliptinium acetate,  
Tsumura EPMTC, ergotamine, etoposide, etretinate,  
Eulexin®, Cell Pathways Exisulind® (sulindac sulphone or  
CP-246), fenretinide, Merck Research Labs Finasteride,  
Florical, Fujisawa FR-57704, gallium nitrate,  
10 gemcitabine, genkwadaphnin, Gerimed, Chugai GLA-43,  
Glaxo GR-63178, grifolan NMF-5N,  
hexadecylphosphocholine, Green Cross HO-221,  
homoharringtonine, hydroxyurea, BTG ICRF-187,  
ilmofosine, irinotecan, isoglutamine, isotretinoin,  
15 Otsuka JI-36, Ramot K-477, ketoconazole, Otsuak K-  
76COONa, Kureha Chemical K-AM, MECT Corp KI-8110,  
American Cyanamid L-623, leucovorin, levamisole,  
leukoregulin, lonidamine, Lundbeck LU-23-112, Lilly LY-  
186641, Materna, NCI (US) MAP, marycin, Merrel Dow MDL-  
20 27048, Medco MEDR-340, megestrol, merbarone, merocyanine  
derivatives, methylanilinoacridine, Molecular Genetics  
MGI-136, minactivin, mitonafide, mitoquidone, Monocal,  
mopidamol, motretinide, Zenyaku Kogyo MST-16, Mylanta,  
N-(retinoyl)amino acids, Nilandron; Nisshin Flour  
25 Milling N-021, N-acylated-dehydroalanines, nafazatrom,  
Taisho NCU-190, Nephro-Calci tablets, nocodazole  
derivative, Normosang, NCI NSC-145813, NCI NSC-361456,  
NCI NSC-604782, NCI NSC-95580, octreotide, Ono ONO-112,  
oquizanocene, Akzo Org-10172, paclitaxel,  
30 pancratistatin, pazelliptine, Warner-Lambert PD-111707,  
Warner-Lambert PD-115934, Warner-Lambert PD-131141,

- Pierre Fabre PE-1001, ICRT peptide D, piroxantrone,  
 polyhaematoporphyrin, polypreic acid, Efamol porphyrin,  
 probimane, procarbazine, proglumide, Invitron protease  
 nexin I, Tobishi RA-700, razoxane, retinoids, Encore  
 5 Pharmaceuticals R-flurbiprofen, Sandostatin; Sapporo  
 Breweries RBS, restrictin-P, retelliptine, retinoic  
 acid, Rhone-Poulenc RP-49532, Rhone-Poulenc RP-56976,  
 Scherring-Plough SC-57050, Scherring-Plough SC-57068,  
 selenium(selenite and selenomethionine), SmithKline  
 10 SK&F-104864, Sumitomo SM-108, Kuraray SMANCS, SeaPharm  
 SP-10094, spatol, spirocyclopropane derivatives,  
 spirogermanium, Unimed, SS Pharmaceutical SS-554,  
 strypoldinone, Stypoldione, Suntory SUN 0237, Suntory  
 SUN 2071, Sugen SU-101, Sugen SU-5416, Sugen SU-6668,  
 15 sulindac, sulindac sulfone; superoxide dismutase, Toyama  
 T-506, Toyama T-680, taxol, Teijin TEI-0303, teniposide,  
 thaliblastine, Eastman Kodak TJB-29, tocotrienol,  
 Topostin, Teijin TT-82, Kyowa Hakko UCN-01, Kyowa Hakko  
 UCN-1028, ukrain, Eastman Kodak USB-006, vinblastine  
 20 sulfate, vincristine, vindesine, vinestramide,  
 vinorelbine, vinriptol, vinzolidine, withanolides,  
 Yamanouchi YM-534, Zileuton, ursodeoxycholic acid, and  
 Zanosar.

Preferred miscellaneous agents that may be used in  
 25 the present invention include, but are not limited to,  
 those identified in Table No. 6, below.

Table No. 6. Miscellaneous agents

Compound	Common Name/ Trade Name	Company	Reference	Dosage
Flutamide; 2-methyl- N-(4-nitro-3-	EULEXIN®	Schering Corp		750 mg/d in 3 8-hr doses.

Compound	Common Name/ Trade Name	Company	Reference	Dosage
(trifluoro-methyl)phenyl propanamide				
	Ketoconazole		US 4144346	
	leucovorin		US 4148999	
	irinotecan		US 4604463	
	levamisole		GB 11/20406	
	megestrol		US 4696949	
	paclitaxel		US 5641803	
Nilutamide 5,5-dimethyl 3-(4-nitro 3-(trifluoromethyl) phenyl) 2,4-imidazolidinedione	Nilandron	Hoechst Marion Roussel		A total daily dose of 300 mg for 30 days followed thereafter by three tablets (50 mg each) once a day for a total daily dosage of 150 mg.
	Vinorelbine		EP 0010458	
	vinblastine			
	vincristine			
Octreotide acetate L-cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-	Sandostatin	Sandoz Pharmaceuticals		s.c. or i.v. administration Acromegaly: 50 - 300 mcgm tid. Carcinoid tumors: 100

Compound	Common Name/ Trade Name	Company	Reference	Dosage
threonyl- NSAIDs-(2- hydroxy-1- (hydroxymethyl )propyl)-, cyclic- disulfide; (R- (R*,R*) acetate salt				- 600 mcgm/d (mean = 300 mcgm/d) Vipomas: 200-300 mcgm in first two weeks of therapy
Streptozocin Streptozocin 2-deoxy-2- ((methylnitro sarnino)carbony l)amino)- alpha (and beta) -D- glucopyranose)	Zanosar	Pharmacia & Upjohn		i.v. 1000 mg/M2 of body surface per week for two weeks.
	topotecan		US 5004758	
Selenium			EP 804927	
L- selenomethioni ne	ACES®	J.R. Carlson Laborat- ories		
calcium carbonate				
sulindac sulfone	Exisuland®		US 5858694	
ursodeoxycho lic acid			US 5843929	
	Cell Pathways CP-461			

Some additional preferred antineoplastic agents include those described in the individual patents listed in Table No. 7 below, and are hereby individually incorporated by reference.

5 Table No. 7. Antineoplastic agents

EP 0296749	EP 0882734	EP 00253738	GB 02/135425
------------	------------	-------------	--------------

-96-

WO 09/832762	EP 0236940	US 5338732	US 4418068
US 4692434	US 5464826	US 5061793	EP 0702961
EP 0702961	EP 0702962	EP 0095875	EP 0010458
EP 0321122	US 5041424	JP 60019790	WO 09/512606
US 4,808614	US 4526988	CA 2128644	US 5455270
WO 99/25344	WO 96/27014	US 5695966	DE 19547958
WO 95/16693	WO 82/03395	US 5789000	US 5902610
EP 189990	US 4500711	FR 24/74032	US 5925699
WO 99/25344	US 4537883	US 4808614	US 5464826
US 5366734	US 4767628	US 4100274	US 4584305
US 4336381	JP 5050383	JP 5050384	JP 5064281
JP 51146482	JP 5384981	US 5472949	US 5455270
US 4140704	US 4537883	US 4814470	US 3590028
US 4564675	US 4526988	US 4100274	US 4604463
US 4144346	US 4749713	US 4148999	GB 11/20406
US 4696949	US 4310666	US 5641803	US 4418068
US 5,004758	EP 0095875	EP 0010458	US 4935437
US 4,278689	US 4820738	US 4413141	US 5843917
US 5,858694	US 4330559	US 5851537	US 4499072
US 5,217886	WO 98/25603	WO 98/14188	

Table No. 8 provides illustrative examples of median dosages for selected cancer agents that may be used in combination with an antiangiogenic agent. It should be noted that specific dose regimen for the chemotherapeutic agents below depends upon dosing considerations based upon a variety of factors including the type of neoplasia; the stage of the neoplasm; the age, weight, sex, and medical condition of the patient; the route of administration; the renal and hepatic

function of the patient; and the particular combination employed.

Table No. 8. Median dosages for selected cancer  
5 agents.

	NAME OF CHEMOTHERAPEUTIC <u>AGENT</u>	<u>MEDIAN DOSAGE</u>
10	Asparaginase	10,000 units
	Bleomycin Sulfate	15 units
	Carboplatin	50-450 mg.
	Carmustine	100 mg.
	Cisplatin	10-50 mg.
	Cladribine	10 mg.
15	Cyclophosphamide (lyophilized)	100 mg.-2 gm.
	Cyclophosphamide (non- lyophilized)	100 mg.-2 gm.
	Cytarabine (lyophilized powder)	100 mg.-2 gm.
	Dacarbazine	100 mg.-200 mg.
20	Dactinomycin	0.5 mg.
	Daunorubicin	20 mg.
	Diethylstilbestrol	250 mg.
	Doxorubicin	10-150 mg.
	Etidronate	300 mg.
	Etoposide	100 mg.
25	Floxuridine	500 mg.
	Fludarabine Phosphate	50 mg.
	Fluorouracil	500 mg.-5 gm.
	Goserelin	3.6 mg.

-98-

	Granisetron Hydrochloride	1 mg.
	Idarubicin	5-10 mg.
	Ifosfamide	1-3 gm.
	Leucovorin Calcium	50-350 mg.
5	Leuprolide	3.75-7.5 rng.
	Mechlorethamine	10 mg.
	Medroxyprogesterone	1 gm.
	Melphalan	50 gm.
	Methotrexate	20 mg.-1 gm.
10	Mitomycin	5-40 mg.
	Mitoxantrone	20-30 mg.
	Ondansetron Hydrochloride	40 mg.
	Paclitaxel	30 mg.
	Pamidronate Disodium	30-90 mg.
15	Pegaspargase	750 units
	Plicamycin	2,500 mcgm.
	Streptozocin	1 gm.
	Thiotepa	15 mg.
	Teniposide	50 mg.
20	Vinblastine	10 mg.
	Vincristine	1-5 mg.
	Aldesleukin	22 million units
	Epoetin Alfa	2,000-10,000 units
	Filgrastim	300-480 mcgm.
25	Immune Globulin	500 mg.-10 gm.
	Interferon Alpha-2a	3-36 million units
	Interferon Alpha-2b	3-50 million units
	Levamisole	50 mg.
	Octreotide	1,000-5,000 mcgm.
30	<u>Sargramostim</u>	<u>250-500 mcgm.</u>

The anastrozole used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,935,437. The capecitabine used in the therapeutic combinations of the 5 present invention can be prepared in the manner set forth in U.S. Patent No. 5,472,949. The carboplatin used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 5,455,270. The Cisplatin used in the 10 therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,140,704. The cyclophosphamide used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,537,883. The 15 eflornithine (DFMO) used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,413,141. The docetaxel used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,814,470. The doxorubicin used in the 20 therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 3,590,028. The etoposide used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,564,675. The 25 fluorouracil used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,336,381. The gemcitabine used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,526,988. The goserelin used in the 30

-100-

therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,100,274. The irinotecan used in the therapeutic combinations of the present invention can be prepared in 5 the manner set forth in U.S. Patent No. 4,604,463. The ketoconazole used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,144,346. The letrozole used in the therapeutic combinations of the present invention 10 can be prepared in the manner set forth in U.S. Patent No. 4,749,713. The leucovorin used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,148,999. The levamisole used in the therapeutic combinations of the 15 present invention can be prepared in the manner set forth in GB 11/20,406. The megestrol used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,696,949. The mitoxantrone used in the therapeutic 20 combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,310,666. The paclitaxel used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 5,641,803. The Retinoic acid 25 used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 4,843,096. The tamoxifen used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 30 4,418,068. The topotecan used in the therapeutic combinations of the present invention can be prepared in

-101-

the manner set forth in U.S. Patent No. 5,004,758. The toremifene used in the therapeutic combinations of the present invention can be prepared in the manner set forth in EP 00/095,875. The vinorelbine used in the 5 therapeutic combinations of the present invention can be prepared in the manner set forth in EP 00/010,458. The sulindac sulfone used in the therapeutic combinations of the present invention can be prepared in the manner set forth in U.S. Patent No. 5,858,694. The selenium 10 (selenomethionine) used in the therapeutic combinations of the present invention can be prepared in the manner set forth in EP 08/04,927. The ursodeoxycholic acid used in the therapeutic combinations of the present invention can be prepared in the manner set forth in WO 15 97/34,608. Ursodeoxycholic acid can also be prepared according to the manner set forth in EP 05/99,282. Finally, ursodeoxycholic acid can be prepared according to the manner set forth in U.S. Patent No. 5,843,929.

Still more preferred antineoplastic agents include:  
20 anastrozole, calcium carbonate, capecitabine, carboplatin, cisplatin, Cell Pathways CP-461, cyclophosphamide, docetaxel, doxorubicin, etoposide, Exisulind®, fluorouracil (5-FU), fluoxymestrine, gemcitabine, goserelin, irinotecan, ketoconazole,  
25 letrozol, leucovorin, levamisole, megestrol, mitoxantrone, paclitaxel, raloxifene, retinoic acid, tamoxifen, thiotepa, topotecan, toremifene, vinorelbine, vinblastine, vincristine, selenium (selenomethionine), ursodeoxycholic acid, sulindac sulfone and eflornithine  
30 (DFMO).

The phrase "taxane" includes a family of diterpene alkaloids all of which contain a particular eight (8) member "taxane" ring structure. Taxanes such as paclitaxel prevent the normal post division breakdown of 5 microtubules which form to pull and separate the newly duplicated chromosome pairs to opposite poles of the cell prior to cell division. In cancer cells which are rapidly dividing, taxane therapy causes the microtubules to accumulate which ultimately prevents further division 10 of the cancer cell. Taxane therapy also affects other cell processes dependant on microtubules such as cell motility, cell shape and intracellular transport. The major adverse side-effects associated with taxane therapy can be classified into cardiac effects, 15 neurotoxicity, haematological toxicity, and hypersensitivity reactions. (See Exp. Opin. Thera. Patents (1998) 8(5), hereby incorporated by reference). Specific adverse side-effects include neutropenia, alopecia, bradycardia, cardiac conduction defects, acute 20 hypersensitivity reactions, neuropathy, mucositis, dermatitis, extravascular fluid accumulation, arthralgias, and myalgias. Various treatment regimens have been developed in an effort to minimize the side effects of taxane therapy, but adverse side-effects 25 remain the limiting factor in taxane therapy.

Taxane derivatives have been found to be useful in treating refractory ovarian carcinoma, urothelial cancer, breast carcinoma, melanoma, non-small-cell lung carcinoma, gastric, and colon carcinomas, squamous 30 carcinoma of the head and neck, lymphoblastic, myeloblastic leukemia, and carcinoma of the esophagus.

Paclitaxel is typically administered in a 15-420 mg/m<sup>2</sup> dose over a 6 to 24 hour infusion. For renal cell carcinoma, squamous carcinoma of head and neck, carcinoma of esophagus, small and non-small cell lung cancer, and breast cancer, paclitaxel is typically administered as a 250 mg/m<sup>2</sup> 24 hour infusion every 3 weeks. For refractory ovarian cancer paclitaxel is typically dose escalated starting at 110 mg/m<sup>2</sup>.

Docetaxel is typically administered in a 60 - 100 mg/M<sup>2</sup> i.v. over 1 hour, every three weeks. It should be noted, however, that specific dose regimen depends upon dosing considerations based upon a variety of factors including the type of neoplasia; the stage of the neoplasm; the age, weight, sex, and medical condition of the patient; the route of administration; the renal and hepatic function of the patient; and the particular agents and combination employed.

In one embodiment, paclitaxel is used in the present invention in combination with an integrin antagonist and with cisplatin, cyclophosphamide, or doxorubicin for the treatment of breast cancer. In another embodiment paclitaxel is used in combination with an integrin antagonist, cisplatin or carboplatin, and ifosfamide for the treatment of ovarian cancer.

In another embodiment docetaxal is used in the present invention in combination with an integrin antagonist and in combination with cisplatin, cyclophosphamide, or doxorubicin for the treatment of ovary and breast cancer and for patients with locally

advanced or metastatic breast cancer who have progressed during anthracycline based therapy.

The following references listed in Table No. 9 below, hereby individually incorporated by reference herein, describe various taxanes and taxane derivatives suitable for use in the present invention, and processes for their manufacture.

Table No. 9. Taxanes and taxane derivatives

EP 694539	EP 683232	EP 639577	EP 627418
EP 604910	EP 797988	EP 727492	EP 767786
EP 767376	US 5886026	US 5880131	US 5879929
US 5871979	US 5869680	US 5871979	US 5854278
US 5840930	US 5840748	US 5827831	US 5824701
US 5821363	US 5821263	US 5811292	US 5808113
US 5808102	US 5807888	US 5780653	US 5773461
US 5770745	US 5767282	US 5763628	US 5760252
US 5760251	US 5756776	US 5750737	US 5744592
US 5739362	US 5728850	US 5728725	US 5723634
US 5721268	US 5717115	US 5716981	US 5714513
US 5710287	US 5705508	US 5703247	US 5703117
US 5700669	US 5693666	US 5688977	US 5684175
US 5683715	US 5679807	US 5677462	US 5675025
US 5670673	US 5654448	US 5654447	US 5646176
US 5637732	US 5637484	US 5635531	US 5631278
US 5629433	US 5622986	US 5618952	US 5616740
US 5616739	US 5614645	US 5614549	US 5608102
US 5599820	US 5594157	US 5587489	US 5580899
US 5574156	US 5567614	US 5565478	US 5560872
US 5556878	US 5547981	US 5539103	US 5532363

US 5530020	US 5508447	US 5489601	US 5484809
US 5475011	US 5473055	US 5470866	US 5466834
US 5449790	US 5442065	US 5440056	US 5430160
US 5412116	US 5412092	US 5411984	US 5407816
US 5407674	US 5405972	US 5399726	US 5395850
US 5384399	US 5380916	US 5380751	US 5367086
US 5356928	US 5356927	US 5352806	US 5350866
US 5344775	US 5338872	US 5336785	US 5319112
US 5296506	US 5294737	US 5294637	US 5284865
US 5284864	US 5283253	US 5279949	US 5274137
US 5274124	US 5272171	US 5254703	US 5254580
US 5250683	US 5243045	US 5229526	US 5227400
US 5200534	US 5194635	US 5175,315	US 5136060
US 5015744	WO 98/38862	WO 95/24402	WO 93/21173
EP 681574	EP 681575	EP 568203	EP 642503
EP 667772	EP 668762	EP 679082	EP 681573
EP 688212	EP 690712	EP 690853	EP 710223
EP 534708	EP 534709	EP 605638	EP 669918
EP 855909	EP 605638	EP 428376	EP 428376
EP 534707	EP 605637	EP 679156	EP 689436
EP 690867	EP 605637	EP 690867	EP 687260
EP 690711	EP 400971	EP 690711	EP 400971
EP 690711	EP 884314	EP 568203	EP 534706
EP 428376	EP 534707	EP 400971	EP 669918
EP 605637	US 5015744	US 5175315	US 5243045
US 5283253	US 5250683	US 5254703	US 5274124
US 5284864	US 5284865	US 5350866	US 5227400
US 5229526	US 4876399	US 5136060	US 5336785
US 5710287	US 5714513	US 5717115	US 5721268
US 5723634	US 5728725	US 5728850	US 5739362

US 5760219	US 5760252	US 5384399	US 5399726
US 5405972	US 5430160	US 5466834	US 5489601
US 5532363	US 5539103	US 5574156	US 5587489
US 5618952	US 5637732	US 5654447	US 4942184
US 5059699	US 5157149	US 5202488	US 5750736
US 5202488	US 5549830	US 5281727	US 5019504
US 4857653	US 4924011	US 5733388	US 5696153
WO 93/06093	WO 93/06094	WO 94/10996	WO 9/10997
WO 94/11362	WO 94/15599	WO 94/15929	WO 94/17050
WO 94/17051	WO 94/17052	WO 94/20088	WO 94/20485
WO 94/21250	WO 94/21251	WO 94/21252	WO 94/21623
WO 94/21651	WO 95/03265	WO 97/09979	WO 97/42181
WO 99/08986	WO 99/09021	WO 93/06079	US 5202448
US 5019504	US 4857653	US 4924011	WO 97/15571
WO 96/38138	US 5489589	EP 781778	WO 96/11683
EP 639577	EP 747385	US 5422364	WO 95/11020
EP 747372	WO 96/36622	US 5599820	WO 97/10234
WO 96/21658	WO 97/23472	US 5550261	WO 95/20582
WO 97/28156	WO 96/14309	WO 97/32587	WO 96/28435
WO 96/03394	WO 95/25728	WO 94/29288	WO 96/00724
WO 95/02400	EP 694539	WO 95/24402	WO 93/10121
WO 97/19086	WO 97/20835	WO 96/14745	WO 96/36335

U.S. Patent No. 5,019,504 describes the isolation of paclitaxel and related alkaloids from culture grown *Taxus brevifolia* cells.

- 5 U.S. Patent No. 5,675,025 describes methods for synthesis of Taxol®, Taxol® analogues and intermediates from baccatin III.

-107-

U.S. Patent No. 5,688,977 describes the synthesis of Docetaxel from 10-deacetyl baccatin III.

U.S. Patent No. 5,202,488 describes the conversion of partially purified taxane mixture to baccatin III.

5 U.S. Patent No. 5,869,680 describes the process of preparing taxane derivatives.

U.S. Patent No. 5,856,532 describes the process of the production of Taxol®.

10 U.S. Patent No. 5,750,737 describes the method for paclitaxel synthesis.

U.S. Patent No. 6,688,977 describes methods for docetaxel synthesis.

U.S. Patent No. 5,677,462 describes the process of preparing taxane derivatives.

15 U.S. Patent No. 5,594,157 describes the process of making Taxol® derivatives.

Some preferred taxanes and taxane derivatives are described in the patents listed in Table No. 10 below, and are hereby individually incorporated by reference  
20 herein.

Table No. 10. Some preferred taxanes and taxane derivatives

US 5015744	US 5136060	US 5175315	US 5200534
US 5194635	US 5227400	US 4924012	US 5641803
US 5059699	US 5157049	US 4942184	US 4960790
US 5202488	US 5675025	US 5688977	US 5750736
US 5684175	US 5019504	US 4814470	WO 95/01969

The phrase "retinoid" includes compounds which are natural and synthetic analogues of retinol (Vitamin A). The retinoids bind to one or more retinoic acid receptors to initiate diverse processes such as reproduction, development, bone formation, cellular proliferation and differentiation, apoptosis, hematopoiesis, immune function and vision. Retinoids are required to maintain normal differentiation and proliferation of almost all cells and have been shown to reverse/suppress carcinogenesis in a variety of in vitro and in vivo experimental models of cancer, see (Moon et al., Ch. 14 Retinoids and cancer. *In The Retinoids*, Vol. 2. Academic Press, Inc. 1984). Also see Roberts et al. 15 Cellular biology and biochemistry of the retinoids. *In The Retinoids*, Vol. 2. Academic Press, Inc. 1984, hereby incorporated by reference), which also shows that vesanoid (tretinoid trans retinoic acid) is indicated for induction of remission in patients with acute 20 promyelocytic leukemia (APL).

A synthetic description of retinoid compounds, hereby incorporated by reference, is described in: Dawson MI and Hobbs PD. The synthetic chemistry of retinoids: in *The retinoids*, 2<sup>nd</sup> edition. MB Sporn, AB 25 Roberts, and DS Goodman(eds). New York: Raven Press, 1994, pp 5-178.

Lingen et al. describe the use of retinoic acid and interferon alpha against head and neck squamous cell carcinoma (Lingen, MW et al., *Retinoic acid and 30 interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck*

-109-

squamous cell carcinoma. Cancer Research 58 (23) 5551-5558 (1998), hereby incorporated by reference).

Iurlaro et al. describe the use of beta interferon and 13-cis retinoic acid to inhibit angiogenesis.

5 (Iurlaro, M et al., Beta interferon inhibits HIV-1 Tat-induced angiogenesis: synergism with 13-cis retinoic acid. European Journal of Cancer 34 (4) 570-576 (1998), hereby incorporated by reference).

Majewski et al. describe Vitamin D3 and retinoids 10 in the inhibition of tumor cell-induced angiogenesis. (Majewski, S et al., Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J. Invest. Dermatology. Symposium Proceedings, 1 (1), 97-101 (1996), hereby incorporated by reference.

15 Majewski et al. describe the role of retinoids and other factors in tumor angiogenesis. Majewski, S et al.. Role of cytokines, retinoids and other factors in tumor angiogenesis. Central-European journal of Immunology 21 (4) 281-289 (1996), hereby incorporated by reference).

20 Bollag describes retinoids and alpha-interferon in the prevention and treatment of neoplastic disease. (Bollag W. Retinoids and alpha-interferon in the prevention and treatment of preneoplastic and neoplastic diseases. Chemotherapie Journal, (Suppl) 5 (10) 55-64 25 (1996), hereby incorporated by reference.

Bigg, HF et al. describe all-trans retinoic acid with basic fibroblast growth factor and epidermal growth factor to stimulate tissue inhibitor of metalloproteinases from fibroblasts. (Bigg, HF et al., 30 All-trans-retinoic acid interacts synergistically with basic fibroblast growth factor and epidermal growth

factor to stimulate the production of tissue inhibitor of metalloproteinases from fibroblasts. Arch. Biochem. Biophys. 319 (1) 74-83 (1995), hereby incorporated by reference).

- 5 Nonlimiting examples of retinoids that may be used in the present invention are identified in Table No. 11 below.

Table No. 11. Retinoids

Compound	Common Name/ Trade Name	Company	Reference	Dosage
CD-271	Adapaline		EP 199636	
Tretinoïn trans retinoic acid	Vesanoid	Roche Holdings		45 mg/M <sup>2</sup> /day as two evenly divided doses until complete remission
2,4,6,8- Nonatetraen oic acid, 9-(4- methoxy- 2,3,6- trimethylph enyl)-3,7- dimethyl- ethyl	etretinate isoetretin; Ro-10- 9359; Ro- 13-7652; Tegison; Tigason	Roche Holdings	US 4215215	.25 - 1.5 mg/kg/day

ester, (all-E)-				
Retinoic acid, 13- cis-	isotret- inoin  Accutane; Isotrex; Ro-4-3780; Roaccutan; Roaccutane	Roche Holdings	US 4843096	.5 to 2 mg/kg/day
	Roche Ro- 40-0655	Roche Holdings		
	Roche Ro- 25-6760	Roche Holdings		
	Roche Ro- 25-9022	Roche Holdings		
	Roche Ro- 25-9716	Roche Holdings		
Benzoic acid, 4- [[3,5- bis(trimeth- ylsilyl)ben- zoyl]amino] -	TAC-101	Taiho Pharmace- utical		
Retinamide, N-(4-	fenretinid e 4-HPR;			50 - 400 mg/kg/day

hydroxyphenyl)-	HPR; McN-R-1967			
(2E, 4E, 6E)-7-(3,5-Di-tert-butylphenyl)-3-methylocta-2,4,6-trienoic acid	LGD-1550 ALRT-1550; ALRT-550; LG-1550	Ligand Pharmaeuticas ; Allergan USA		20 microg/m <sup>2</sup> /day to 400 microg/m <sup>2</sup> /day administered as a single daily oral dose
	Molecular Design MDI-101		US 4885311	
	Molecular Design MDI-403		US 4677120	
Benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)-	bexarotene LG-1064; LG-1069; LGD-1069; Targretin; Targretin Oral; Targretin Topical Gel		WO 94/15901	
Benzoic	bexarotene	R P		

acid, 4-(1-(5,6,7,8-tetrahydro-3,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)-	, soft gel bexarotene, Ligand; bexaroten	Scherer		
(2E,4E)-3-methyl-5-[3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-thiopen-2-yl]-penta-2,4-dienoic acid			WO 96/05165	
	SR-11262 F	Hoffmann -La Roche Ltd		
	BMS-181162	Bristol Myers Squibb	EP 476682	
N-(4-	IIT		Cancer	

-114-

hydroxyphenyl)retinamide	Research Institute		Research 39, 1339-1346 (1979)	
	AGN-193174	Allergan USA	WO 96/33716	

The following individual patent references listed in Table No. 12 below, hereby individually incorporated by reference, describe various retinoid and retinoid derivatives suitable for use in the present invention described herein, and processes for their manufacture.

Table No. 12. Retinoids

US 4215215	US 4885311	US 4677120	US 4105681
US 5260059	US 4503035	US 5827836	US 3878202
US 4843096	WO 96/05165	WO 97/34869	WO 97/49704
EP 19/9636	WO 96/33716	WO 97/24116	WO 97/09297
WO 98/36742	WO 97/25969	WO 96/11686	WO 94/15901
WO 97/24116	CH 61/6134	DE 2854354	EP 579915
US 5547947	EP 552624	EP 728742	EP 331983
EP 476682			

10 Some preferred retinoids include Accutane; Adapalene; Allergan AGN-193174; Allergan AGN-193676;

Allergan AGN-193836; Allergan AGN-193109; Aronex AR-623; BMS-181162; Galderma CD-437; Eisai ER-34617; Etrinate; Fenretinide; Ligand LGD-1550; lexacalcitol; Maxia Pharmaceuticals MX-781; mofarotene; Molecular Design 5 MDI-101; Molecular Design MDI-301; Molecular Design MDI-403; Motretinide; Eisai 4-(2-[5-(4-methyl-7-ethylbenzofuran-2-yl)pyrrolyl]) benzoic acid; Johnson & Johnson N-[4-[2-thyl-1-(1H-imidazol-1-yl)butyl]phenyl]-2-benzothiazolamine; Soriatane; Roche SR- 11262; 10 Tocoretinate; Advanced Polymer Systems trans-retinoic acid; UAB Research Foundation UAB-8; Tazorac; TopiCare; Taiho TAC-101; and Vesanoid.

CGMP phosphodiesterase inhibitors, including Sulindac sulfone (Exisuland®) and CP-461 for example, 15 are apoptosis inducers and do not inhibit the cyclooxygenase pathways. cGMP phosphodiesterase inhibitors increase apoptosis in tumor cells without arresting the normal cycle of cell division or altering the cell's expression of the p53 gene.

Ornithine decarboxylase is a key enzyme in the polyamine synthesis pathway that is elevated in most tumors and premalignant lesions. Induction of cell growth and proliferation is associated with dramatic increases in ornithine decarboxylase activity and 20 subsequent polyamine synthesis. Further, blocking the formation of polyamines slows or arrests growth in transformed cells. Consequently, polyamines are thought to play a role in tumor growth. Difluoromethylornithine (DFMO) is a potent inhibitor of ornithine decarboxylase 25 that has been shown to inhibit carcinogen-induced cancer development in a variety of rodent models (Meyskens et 30

al. Development of Difluoromethylornithine (DFMO) as a chemoprevention agent. Clin. Cancer Res. 1999 May, 5(%):945-951, hereby incorporated by reference, herein). DFMO is also known as 2-difluoromethyl-2,5-  
5 diaminopentanoic acid, or 2-difluoromethyl-2,5-diaminovaleic acid, or α-(difluoromethyl) ornithine; DFMO is marketed under the tradename Elfornithine®. Therefore, the use of DFMO in combination with COX-2 inhibitors is contemplated to treat or prevent cancer,  
10 including but not limited to colon cancer or colonic polyps.

Populations with high levels of dietary calcium have been reported to be protected from colon cancer. In vivo, calcium carbonate has been shown to inhibit colon cancer via a mechanism of action independent from COX-2 inhibition. Further, calcium carbonate is well tolerated. A combination therapy including an integrin antagonist, calcium carbonate and a selective COX-2 inhibitor is contemplated to treat or prevent cancer,  
15 including but not limited to colon cancer or colonic polyps.

Several studies have focused attention on bile acids as a potential mediator of the dietary influence on colorectal cancer risk. Bile acids are important detergents for fat solubilization and digestion in the proximal intestine. Specific transprot processes in the apical domain of the terminal ileal enterocyte and basolateral domain of the hepatocyte account for the efficient conservation in the enterohepatic circulation.  
25  
30 Only a small fraction of bile acids enter the colon; however, perturbations of the cycling rate of bile acids

by diet (e.g. fat) or surgery may increase the fecal bile load and perhaps account for the associated increased risk of colon cancer. (Hill MJ, Bile flow and colon cancer. 238 Mutation Review, 313 (1990)).

5 Ursodeoxycholate (URSO), the hydrophilic 7-beta epimer of chenodeoxycholate, is non cytotoxic in a variety of cell model systems including colonic epithelia. URSO is also virtually free of side effects. URSO, at doses of 15mg/kg/day used primarily in biliary cirrhosis trials

10 were extremely well tolerated and without toxicity. (Pourpon et al., A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. 324 New Engl. J. Med. 1548 (1991)). While the precise mechanism of URSO action is unknown, beneficial effects

15 of URSO therapy are related to the enrichment of the hepatic bile acid pool with this hydrophilic bile acid. It has thus been hypothesized that bile acids more hydrophilic than URSO will have even greater beneficial effects than URSO. For example, tauroursodeoxycholate

20 (TURSO) the taurine conjugate of URSO. Non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit the neoplastic transformation of colorectal epithelium. The likely mechanism to explain this chemopreventive effect is inhibition of prostaglandin synthesis. NSAIDs inhibit

25 cyclooxygenase, the enzyme that converts arachidonic acid to prostaglandins and thromboxanes. However, the potential chemopreventive benefits of NSAIDs such as sulindac or mesalamine are tempered by their well known toxicities and moderately high risk of intolerance.

30 Abdominal pain, dispepsia, nausea, diarrhea, constipation, rash, dizziness, or headaches have been

reported in up to 9% of patients. The elderly appear to be particularly vulnerable as the incidence of NSAID-induced gastroduodenal ulcer disease, including gastrointestinal bleeding, is higher in those over the 5 age of 60; this is also the age group most likely to develop colon cancer, and therefore most likely to benefit from chemoprevention. The gastrointestinal side effects associated with NSAID use result from the inhibition of cyclooxygenase-1, an enzyme responsible 10 for maintenance of the gastric mucosa. Therefore, the use of COX-2 inhibitors in combination with URSO is contemplated to treat or prevent cancer, including but not limited to colon cancer or colonic polyps; it is contemplated that this treatment will result in lower 15 gastrointestinal side effects than the combination of standard NSAIDs and URSO.

An additional class of antineoplastic agents that may be used in the present invention include nonsteroidal antiinflammatory drugs (NSAIDs). NSAIDs 20 have been found to prevent the production of prostaglandins by inhibiting enzymes in the human arachidonic acid/prostaglandin pathway, including the enzyme cyclooxygenase (COX). However, for the purposes of the present invention the definition of an NSAID does 25 not include the "cyclooxygenase-2 inhibitors" described herein. Thus the phrase "nonsteroidal antiinflammatory drug" or "NSAID" includes agents that specifically inhibit cyclooxygenase-1, without significant inhibition of cyclooxygenase-2; or inhibit cyclooxygenase-1 and 30 cyclooxygenase-2 at substantially the same potency; or inhibit neither cyclooxygenase-1 or cyclooxygenase-2.

The potency and selectivity for the enzyme cyclooxygenase-1 and cyclooxygenase-2 can be determined by assays well known in the art, see for example, Cromlish and Kennedy, Biochemical Pharmacology, Vol. 52, 5 pp 1777-1785, 1996.

Examples of NSAIDs that can be used in the combinations of the present invention include sulindac, indomethacin, naproxen, diclofenac, tolectin, fenoprofen, phenylbutazone, piroxicam, ibuprofen, 10 ketophen, mefenamic acid, tolmetin, flufenamic acid, nimesulide, niflumic acid, piroxicam, tenoxicam, phenylbutazone, fenclofenac, flurbiprofen, ketoprofen, fenoprofen, acetaminophen, salicylate and aspirin.

The term "clinical tumor" includes neoplasms that 15 are identifiable through clinical screening or diagnostic procedures including, but not limited to, palpation, biopsy, cell proliferation index, endoscopy, mammography, digital mammography, ultrasonography, computed tomography (CT), magnetic resonance imaging 20 (MRI), positron emmission tomaagraphy (PET), radiography, radionuclide evaluation, CT- or MRI-guided aspiration cytology, and imaging-guided needle biopsy, among others. Such diagnostic techniques are well known to those skilled in the art and are described in Cancer 25 Medicine 4<sup>th</sup> Edition, Volume One. J.F. Holland, R.C. Bast, D.L. Morton, E. Frei III, D.W. Kufe, and R.R. Weichselbaum (Editors). Williams & Wilkins, Baltimore (1997).

The term "tumor marker" or "tumor biomarker" 30 encompasses a wide variety of molecules with divergent characteristics that appear in body fluids or tissue in

association with a clinical tumor and also includes tumor-associated chromosomal changes. Tumor markers fall primarily into three categories: molecular or cellular markers, chromosomal markers, and serological or serum markers. Molecular and chromosomal markers complement standard parameters used to describe a tumor (i.e. histopathology, grade, tumor size) and are used primarily in refining disease diagnosis and prognosis after clinical manifestation. Serum markers can often be measured many months before clinical tumor detection and are thus useful as an early diagnostic test, in patient monitoring, and in therapy evaluation.

Molecular Tumor Markers

Molecular markers of cancer are products of cancer cells or molecular changes that take place in cells because of activation of cell division or inhibition of apoptosis. Expression of these markers can predict a cell's malignant potential. Because cellular markers are not secreted, tumor tissue samples are generally required for their detection. Non-limiting examples of molecular tumor markers that can be used in the present invention are listed in Table No. 1, below.

Table No. 1. Non-limiting Examples of Molecular Tumor Markers

Tumor	Marker
Breast	p53
Breast, Ovarian	ErbB-2/Her-2
Breast	S phase and ploidy

Breast	pS2
Breast	MDR2
Breast	urokinase plasminogen activator
Breast, Colon, Lung	myc family

Chromosomal Tumor Markers

Somatic mutations and chromosomal aberrations have been associated with a variety of tumors. Since the 5 identification of the Philadelphia Chromosome by Nowell and Hungerford, a wide effort to identify tumor-specific chromosomal alterations has ensued. Chromosomal cancer markers, like cellular markers, are can be used in the diagnosis and prognosis of cancer. In addition to the 10 diagnostic and prognostic implications of chromosomal alterations, it is hypothesized that germ-line mutations can be used to predict the likelihood that a particular person will develop a given type of tumor. Non-limiting examples of chromosomal tumor markers that can be used 15 in the present invention are listed in Table No. 2, below.

Table No. 2. Non-limiting Examples of Chromosomal  
Tumor Markers

Tumor	Marker
Breast	1p36 loss
Breast	6q24-27 loss
Breast	11q22-23 loss
Breast	11q13 amplification
Breast	TP53 mutation

Colon	Gain of chromosome 13
Colon	Deletion of short arm of chromosome 1
Lung	Loss of 3p
Lung	Loss of 13q
Lung	Loss of 17p
Lung	Loss of 9p

Serological Tumor Markers

Serum markers including soluble antigens, enzymes and hormones comprise a third category of tumor markers.

- 5 Monitoring serum tumor marker concentrations during therapy provides an early indication of tumor recurrence and of therapy efficacy. Serum markers are advantageous for patient surveillance compared to chromosomal and cellular markers because serum samples are more easily obtainable than tissue samples, and because serum assays can be performed serially and more rapidly. Serum tumor markers can be used to determine appropriate therapeutic doses within individual patients. For example, the efficacy of a combination regimen consisting of
- 10 15 chemotherapeutic and antiangiogenic agents can be measured by monitoring the relevant serum cancer marker levels. Moreover, an efficacious therapy dose can be achieved by modulating the therapeutic dose so as to keep the particular serum tumor marker concentration stable or within the reference range, which may vary depending upon the indication. The amount of therapy can then be modulated specifically for each patient so as to minimize side effects while still maintaining stable, reference range tumor marker levels. Table No.
- 20

-123-

3 provides non-limiting examples of serological tumor markers that can be used in the present invention.

Table No. 3. Non-limiting Examples of Serum Tumor  
5 Markers

Cancer Type	Marker
Germ Cell Tumors	a-fetoprotein (AFP)
Germ Cell Tumors	human chorionic gonadotrophin (hCG)
Germ Cell Tumors	placental alkaline phosphatase (PLAP)
Germ Cell Tumors	lactate dehydrogenase (LDH)
Prostate	prostate specific antigen (PSA)
Breast	carcinoembryonic antigen (CEA)
Breast	MUC-1 antigen (CA15-3)
Breast	tissue polypeptide antigen (TPA)
Breast	tissue polypeptide specific antigen (TPS)
Breast	CYFRA 21.1
Breast	soluble erb-B-2
Ovarian	CA125
Ovarian	OVX1
Ovarian	cancer antigen CA72-4
Ovarian	TPA
Ovarian	TPS
Gastrointestinal	CD44v6

Gastrointestinal	CEA
Gastrointestinal	cancer antigen CA19-9
Gastrointestinal	NCC-ST-439 antigen (Dukes C)
Gastrointestinal	cancer antigen CA242
Gastrointestinal	soluble erb-B-2
Gastrointestinal	cancer antigen CA195
Gastrointestinal	TPA
Gastrointestinal	YKL-40
Gastrointestinal	TPS
Esophageal	CYFRA 21-1
Esophageal	TPA
Esophageal	TPS
Esophageal	cancer antigen CA19-9
Gastric Cancer	CEA
Gastric Cancer	cancer antigen CA19-9
Gastric Cancer	cancer antigen CA72-4
Lung	neruon specific enolase (NSE)
Lung	CEA
\Lung	CYFRA 21-1
Lung	cancer antigen CA 125
Lung	TPA
Lung	squamous cell carcinoma antigen (SCC)
Pancreatic cancer	ca19-9
Pancreatic cancer	ca50
Pancreatic cancer	ca119
Pancreatic cancer	ca125
Pancreatic cancer	CEA
Pancreatic cancer	
Renal Cancer	CD44v6

Renal Cancer	E-cadherin
Renal Cancer	PCNA (proliferating cell nuclear antigen)

ExamplesGerm Cell Cancers

5       Non-limiting examples of tumor markers useful in the present invention for the detection of germ cell cancers include, but are not limited to, a-fetoprotein (AFP), human chorionic gonadotrophin (hCG) and its beta subunit (hCGB), lactate dehydrogenase (LDH), and  
10      placental alkaline phosphatase (PLAP).

      AFP has an upper reference limit of approximately -10 kU/L after the first year of life and may be elevated in germ cell tumors, hepatocellular carcinoma and also in gastric, colon, biliary, pancreatic and lung cancers. AFP serum half life is approximately five days after orchidectomy. According to EGT recommendations, AFP serum levels less than 1,000 kU/L correlate with a good prognosis, AFP levels between 1,000 and 10,000 kU/L, inclusive, correlate with intermediate prognosis, 15 and AFP levels greater than 10,000 U/L correlate with a poor prognosis.

      HCG is synthesized in the placenta and is also produced by malignant cells. Serum hCG concentrations may be increased in pancreatic adenocarcinomas, islet cell tumors, tumors of the small and large bowel, hepatoma, stomach, lung, ovaries, breast and kidney. Because some tumors only hCGB, measurement of both hCG and hCGB is recommended. Normally, serum hCG in men and  
25

pre-menopausal women is as high as -5 U/L while post-menopausal women have levels up to -10 U/L. Serum half life of hCG ranges from 16-24 hours. According to the EGTM, hCG serum levels under 5000 U/L correlate with a good prognosis, levels between 5000 and 50000 U/L, inclusively correlate with an intermediate prognosis, and hCG serum levels greater than 50000 U/L correlate with a poor prognosis. Further, normal hCG half lives correlate with good prognosis while prolonged half lives correlate with poor prognosis.

LDH is an enzyme expressed in cardiac and skeletal muscle as well as in other organs. The LDH-1 isoenzyme is most commonly found in testicular germ cell tumors but can also occur in a variety of benign conditions such as skeletal muscle disease and myocardial infarction. Total LDH is used to measure independent prognostic value in patients with advanced germ cell tumors. LDH levels less than 1.5 x the reference range are associated with a good prognosis, levels between 1.5 and 10 x the reference range, inclusive, are associated with an intermediate prognosis, and levels more than 10 x the reference range are associated with a poor prognosis.

PLAP is a enzyme of alkaline phosphatase normally expressed by placental syncytiotrophoblasts. Elevated serum concentrations of PLAP are found in seminomas, non-seminomatous tumors, and ovarian tumors, and may also provide a marker for testicular tumors. PLAP has a normal half life after surgical resection of between 0.6 and 2.8 days.

Prostate Cancer

A nonlimiting example of a tumor marker useful in the present invention for the detection of prostate cancer is prostate specific antigen (PSA). PSA is a 5 glycoprotein that is almost exclusively produced in the prostate. In human serum, uncomplexed f-PSA and a complex of f-PSA with α<sub>1</sub>-antichymotrypsin make up total PSA (t-PSA). T-PSA is useful in determining prognosis in patients that are not currently undergoing anti-androgen 10 treatment. Rising t-PSA levels via serial measurement indicate the presence of residual disease.

Breast Cancer

Non-limiting examples of serum tumor markers useful in the present invention for the detection of breast cancer include, but is not limited to carcinoembryonic antigen (CEA) and MUC-1 (CA 15.3). Serum CEA and CA15.3 15 levels are elevated in patients with node involvement compared to patients without node involvement, and in patients with larger tumors compared to smaller tumors. 20 Normal range cutoff points (upper limit) are 5-10 mg/L for CEA and 35-60 u/ml for CA15.3. Additional specificity (99.3%) is gained by confirming serum levels with two serial increases of more than 15%.

Ovarian Cancer

25 A non-limiting example of a tumor marker useful in the present invention for the detection of ovarian cancer is CA125. Normally, women have serum CA125 levels between 0-35 kU/L; 99% of post-menopausal women have levels below 20 kU/L. Serum concentration of CA125 30 after chemotherapy is a strong predictor of outcome as elevated CA125 levels are found in roughly 80% of all

patients with epithelial ovarian cancer. Further, prolonged CA125 half-life or a less than 7-fold decrease during early treatment is also a predictor of poor disease prognosis.

5

#### Gastrointestinal Cancers

A non-limiting example of a tumor marker useful in the present invention for the detection of colon cancer is carcinoembryonic antigen (CEA). CEA is a glycoprotein produced during embryonal and fetal development and has a high sensitivity for advanced carcinomas including those of the colon, breast, stomach and lung. High pre- or postoperative concentrations (>2.5 ng/ml) of CEA are associated with worse prognosis than are low concentrations. Further, some studies in the literature report that slow rising CEA levels indicates local recurrence while rapidly increasing levels suggests hepatic metastasis.

#### Lung Cancer

Examples of serum markers useful in the present invention to monitor lung cancer therapy include, but are not limited to, CEA, cytokeratin 19 fragments (CYFRA 21-1), and Neuron Specific Enolase (NSE).

NSE is a glycolytic isoenzyme of enolase produced in central and peripheral neurons and malignant tumors of neuroectodermal origin. At diagnosis, NSE concentrations greater than 25 ng/mL are suggestive of malignancy and lung cancer while concentrations greater than 100 ng/mL are suggestive of small cell lung cancer.

CYFRA 21-1 is a tumor marker test which uses two specific monoclonal antibodies against a cytokeratin 19

fragment. At diagnosis, CYFRA 21-1 concentrations greater than 10 ng/mL are suggestive of malignancy while concentrations greater than 30 ng/mL are suggestive of lung cancer.

5 Accordingly, dosing of the integrin antagonist and antineoplastic agent may be determined and adjusted based on measurement of tumor markers in body fluids or tissues, particularly based on tumor markers in serum. For example, a decrease in serum marker level relative  
10 to baseline serum marker prior to administration of the integrin antagonist and antineoplastic agent indicates a decrease in cancer-associated changes and provides a correlation with inhibition of the cancer. In one embodiment, therefore, the method of the present  
15 invention comprises administering the integrin antagonist and antineoplastic agent at doses that in combination result in a decrease in one or more tumor markers, particularly a decrease in one or more serum tumor markers, in the mammal relative to baseline tumor  
20 marker levels.

Similarly, decreasing tumor marker concentrations or serum half lives after administration of the combination indicates a good prognosis, while tumor marker concentrations which decline slowly and do not  
25 reach the normal reference range predict residual tumor and poor prognosis. Further, during follow-up therapy, increases in tumor marker concentration predicts recurrent disease many months before clinical manifestation.

30 In addition to the above examples, Table No. 4, below, lists several references, hereby individually

-130-

incorporated by reference herein, that describe tumor markers and their use in detecting and monitoring tumor growth and progression.

5 Table No. 4. Tumor marker references.

European Group on Tumor Markers Publications Committee. Consensus Recommendations. Anticancer Research 19: 2785-2820 (1999)

Human Cytogenetic Cancer Markers. Sandra R. Wolman and Stewart Sell (eds.). Totowa, New Jersey: Humana Press. 1997

Cellular Markers of Cancer. Carleton Garrett and Stewart Sell (eds.). Totowa, New Jersey: Human Press. 1995

Also included in the combination of the invention are the isomeric forms, prodrugs and tautomers of the described compounds and the pharmaceutically-acceptable salts thereof. Illustrative pharmaceutically acceptable salts are prepared from formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic,

-131-

glutamic, benzoic, anthranilic, mesylic, stearic,  
salicylic, p-hydroxybenzoic, phenylacetic, mandelic,  
embonic (pamoic), methanesulfonic, ethanesulfonic,  
benzenesulfonic, pantothenic, toluenesulfonic, 2-  
5 hydroxyethanesulfonic, sulfanilic,  
cyclohexylaminosulfonic, algenic,  $\beta$ -hydroxybutyric,  
galactaric and galacturonic acids.

Suitable pharmaceutically-acceptable base addition salts of compounds of the present invention include  
10 metallic ion salts and organic ion salts. More preferred metallic ion salts include, but are not limited to appropriate alkali metal (group Ia) salts, alkaline earth metal (group IIa) salts and other physiological acceptable metal ions. Such salts can be  
15 made from the ions of aluminum, calcium, lithium, magnesium, potassium, sodium and zinc. Preferred organic salts can be made from tertiary amines and quaternary ammonium salts, including in part, trimethylamine, diethylamine, N,N'-dibenzylethylenediamine,  
20 chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of the above salts can be prepared by those skilled in the art by conventional means from the corresponding compound of the present invention.  
25

#### Administration Regimen

Any effective treatment regimen can be utilized and readily determined and repeated as necessary to effect treatment. In clinical practice, the compositions  
30 containing an integrin antagonist alone or in combination with other therapeutic agents are

administered in specific cycles until a response is obtained.

For patients who initially present without advanced or metastatic cancer, an integrin antagonist in combination with another integrin antagonist or one or more anticancer agents as an immediate initial therapy prior to surgery, chemotherapy, or radiation therapy, and as a continuous post-treatment therapy in patients at risk for recurrence or metastasis (for example, in adenocarcinoma of the prostate, risk for metastasis is based upon high PSA, high Gleason's score, locally extensive disease, and/or pathological evidence of tumor invasion in the surgical specimen). The goal in these patients is to inhibit the growth of potentially metastatic cells from the primary tumor during surgery or radiotherapy and inhibit the growth of tumor cells from undetectable residual primary tumor.

For patients who initially present with advanced or metastatic cancer, an integrin antagonist in combination with another integrin antagonist or one or more anticancer agents of the present invention is used as a continuous supplement to, or possible replacement for hormonal ablation. The goal in these patients is to slow or prevent tumor cell growth from both the untreated primary tumor and from the existing metastatic lesions.

In addition, the invention may be particularly efficacious during post-surgical recovery, where the present compositions and methods may be particularly effective in lessening the chances of recurrence of a tumor engendered by shed cells that cannot be removed by surgical intervention.

Combinations with Other Treatments

Integrin antagonists may be used in conjunction with other treatment modalities, including, but not limited to surgery and radiation, hormonal therapy, chemotherapy, immunotherapy, antiangiogenic therapy and cryotherapy. The present invention may be used in conjunction with any current or future therapy.

The following discussion highlights some agents in this respect, which are illustrative, not limitative. A wide variety of other effective agents also may be used.

Surgery and Radiation

In general, surgery and radiation therapy are employed as potentially curative therapies for patients under 70 years of age who present with clinically localized disease and are expected to live at least 10 years.

For example, approximately 70% of newly diagnosed prostate cancer patients fall into this category. Approximately 90% of these patients (65% of total patients) undergo surgery, while approximately 10% of these patients (7% of total patients) undergo radiation therapy. Histopathological examination of surgical specimens reveals that approximately 63% of patients undergoing surgery (40% of total patients) have locally extensive tumors or regional (lymph node) metastasis that was undetected at initial diagnosis. These patients are at a significantly greater risk of recurrence. Approximately 40% of these patients will actually develop recurrence within five years after surgery.

Results after radiation are even less encouraging. Approximately 80% of patients who have undergone radiation as their primary therapy have disease persistence or develop recurrence or metastasis within 5 five years after treatment. Currently, most of these surgical and radiotherapy patients generally do not receive any immediate follow-up therapy. Rather, for example, they are monitored frequently for elevated Prostate Specific Antigen ("PSA"), which is the primary 10 indicator of recurrence or metastasis prostate cancer.

Thus, there is considerable opportunity to use the present invention in conjunction with surgical intervention.

15        Hormonal Therapy

Hormonal ablation is the most effective palliative treatment for the 10% of patients presenting with metastatic prostate cancer at initial diagnosis. Hormonal ablation by medication and/or orchietomy is 20 used to block hormones that support the further growth and metastasis of prostate cancer. With time, both the primary and metastatic tumors of virtually all of these patients become hormone-independent and resistant to therapy. Approximately 50% of patients presenting with 25 metastatic disease die within three years after initial diagnosis, and 75% of such patients die within five years after diagnosis. Continuous supplementation with NAALADase inhibitor based drugs are used to prevent or reverse this potentially metastasis-permissive state.

30        Among hormones which may be used in combination with the present inventive compounds, diethylstilbestrol

(DES), leuprolide, flutamide, cyproterone acetate, ketoconazole and amino glutethimide are preferred.

Immunotherapy

5       The integrin antagonists may also be used in combination with monoclonal antibodies in treating cancer. For example monoclonal antibodies may be used in treating prostate cancer. A specific example of such an antibody includes cell membrane-specific anti-  
10      prostate antibody.

The present invention may also be used with immunotherapies based on polyclonal or monoclonal antibody-derived reagents, for instance. Monoclonal antibody-based reagents are most preferred in this  
15      regard. Such reagents are well known to persons of ordinary skill in the art. Radiolabelled monoclonal antibodies for cancer therapy, such as the recently approved use of monoclonal antibody conjugated with strontium-89, also are well known to persons of ordinary  
20      skill in the art.

Antiangiogenic Therapy

The MMP inhibitors may also be used in combination with other antiangiogenic agents in treating cancer.  
25      Antiangiogenic agents include but are not limited to Cox-2 inhibitors, integrin antagonists, angiostatin, endostatin, thrombospondin-1, and interferon alpha. Examples of preferred antiangiogenic agents include, but  
30      are not limited to vitaxin, celecoxib, rofecoxib, JTE-522, EMD-121974, and D-2163 (BMS-275291).

Cryotherapy

Cryotherapy recently has been applied to the treatment of some cancers. Methods and compositions of the present invention also could be used in conjunction 5 with an effective therapy of this type.

All of the various cell types of the body can be transformed into benign or malignant neoplasia or tumor cells and are contemplated as objects of the invention. A "benign" tumor cell denotes the non-invasive and non-10 metastasized state of a neoplasm. In man the most frequent neoplasia site is lung, followed by colorectal, breast, prostate, bladder, pancreas, and then ovary. Other prevalent types of cancer include leukemia, central nervous system cancers, including brain cancer, 15 melanoma, lymphoma, erythroleukemia, uterine cancer, and head and neck cancer. Examples 1 through 9 are provided to illustrate contemplated therapeutic combinations, and are not intended to limit the scope of the invention.

20

**Illustrations**

The following non-limiting illustrative examples describe various cancer diseases and therapeutic approaches that may be used in the present invention, and are for illustrative purposes only.

25

Example 1Lung Cancer

In many countries including Japan, Europe and 30 America, the number of patients with lung cancer is fairly large and continues to increase year after year

and is the most frequent cause of cancer death in both men and women. Although there are many potential causes for lung cancer, tobacco use, and particularly cigarette smoking, is the most important. Additionally, etiologic factors such as exposure to asbestos, especially in smokers, or radon are contributory factors. Also occupational hazards such as exposure to uranium have been identified as an important factor. Finally, genetic factors have also been identified as another factor that increase the risk of cancer.

Lung cancers can be histologically classified into non-small cell lung cancers (e.g. squamous cell carcinoma (epidermoid), adenocarcinoma, large cell carcinoma (large cell anaplastic), etc.) and small cell lung cancer (oat cell). Non-small cell lung cancer (NSCLC) has different biological properties and responses to chemotherapeutics from those of small cell lung cancer (SCLC). Thus, chemotherapeutic formulas and radiation therapy are different between these two types of lung cancer.

#### Non-Small Cell Lung Cancer

Where the location of the non-small cell lung cancer tumor can be easily excised (stage I and II disease) surgery is the first line of therapy and offers a relatively good chance for a cure. However, in more advanced disease (stage IIIa and greater), where the tumor has extended to tissue beyond the bronchopulmonary lymph nodes, surgery may not lead to complete excision of the tumor. In such cases, the patient's chance for a cure by surgery alone is greatly diminished. Where

-138-

surgery will not provide complete removal of the NSCLC tumor, other types of therapies must be utilized.

Today radiation therapy is the standard treatment to control unresectable or inoperable NSCLC. Improved results have been seen when radiation therapy has been combined with chemotherapy, but gains have been modest and the search continues for improved methods of combining modalities.

Radiation therapy is based on the principle that high-dose radiation delivered to a target area will result in the death of reproductive cells in both tumor and normal tissues. The radiation dosage regimen is generally defined in terms of radiation absorbed dose (rad), time and fractionation, and must be carefully defined by the oncologist. The amount of radiation a patient receives will depend on various consideration but the two most important considerations are the location of the tumor in relation to other critical structures or organs of the body, and the extent to which the tumor has spread. A preferred course of treatment for a patient undergoing radiation therapy for NSCLC will be a treatment schedule over a 5 to 6 week period, with a total dose of 50 to 60 Gy administered to the patient in a single daily fraction of 1.8 to 2.0 Gy, 5 days a week. A Gy is an abbreviation for Gray and refers to 100 rad of dose.

However, as NSCLC is a systemic disease, and radiation therapy is a local modality, radiation therapy as a single line of therapy is unlikely to provide a cure for NSCLC, at least for those tumors that have metastasized distantly outside the zone of treatment.

Thus, the use of radiation therapy with other modality regimens have important beneficial effects for the treatment of NSCLC.

- Generally, radiation therapy has been combined
- 5 temporally with chemotherapy to improve the outcome of treatment. There are various terms to describe the temporal relationship of administering radiation therapy in combination with integrin antagonists and chemotherapy, and the following examples are the
- 10 preferred treatment regimens and are provided for illustration only and are not intended to limit the use of other combinations. "Sequential" therapy refers to the administration of chemotherapy and/or integrin antagonists and/or radiation therapy separately in time
- 15 in order to allow the separate administration of either chemotherapy and/or integrin antagonists, and/or radiation therapy. "Concomitant" therapy refers to the administration of chemotherapy and/or integrin antagonists, and/or radiation therapy on the same day.
- 20 Finally, "alternating" therapy refers to the administration of radiation therapy on the days in which chemotherapy and/or integrin antagonist therapy would not have been administered if it was given alone.

It is reported that advanced non-small cell lung

25 cancers do not respond favorably to single-agent chemotherapy and useful therapies for advanced inoperable cancers have been limited. (Journal of Clinical Oncology, vol. 10, pp. 829-838 (1992)).

Japanese Patent Kokai 5-163293 refers to some

30 specified antibiotics of 16-membered-ring macrolides as a drug delivery carrier capable of transporting

-140-

anthoracycline-type anticancer drugs into the lungs for the treatment of lung cancers. However, the macrolide antibiotics specified herein are disclosed to be only a drug carrier, and there is no reference to the  
5 therapeutic use of macrolides against non-small cell lung cancers.

WO 93/18,652 refers to the effectiveness of the specified 16-membered-ring macrolides such as baflomycin, etc. in treating non-small cell lung  
10 cancers, but they have not yet been clinically practicable.

Pharmacology, vol. 41, pp. 177-183 (1990) describes that a long-term use of erythromycin increases productions of interleukins 1, 2 and 4, all of which  
15 contribute to host immune responses, but there is no reference to the effect of this drug on non-small cell lung cancers.

Teratogenesis, Carcinogenesis, and Mutagenesis, vol. 10, pp. 477-501 (1990) describes that some of  
20 antimicrobial drugs can be used as an anticancer agent, but does not refer to their application to non-small cell lung cancers.

In addition, interleukins are known to have an antitumor effect, but have not been reported to be  
25 effective against non-small cell lung cancers.

Any 14 - or 15-membered-ring macrolides have not been reported to be effective against non-small cell lung cancers.

However, several chemotherapeutic agents have been  
30 shown to be efficacious against NSCLC. Preferred chemotherapeutic agents that can be used in the present

invention against NSCLC include etoposide, carboplatin, methotrexate, 5-Fluorouracil, epirubicin, doxorubicin, taxol, inhibitor of normal mitotic activity; and cyclophosphamide. Even more preferred chemotherapeutic  
5 agents active against NSCLC include cisplatin, ifosfamide, mitomycin C, epirubicin, vinblastine, and vindesine.

Other agents that are under investigation for use against NSCLC include: camptothecins, a topoisomerase 1  
10 inhibitor; navelbine (vinorelbine), a microtubule assembly inhibitor; gemcitabine, a deoxycytidine analogue; fotemustine, a nitrosourea compound; and edatrexate, a antifol.

The overall and complete response rates for NSCLC  
15 has been shown to increase with use of combination chemotherapy as compared to single-agent treatment.  
Haskel CM: Chest. 99: 1325, 1991; Bakowski MT: Cancer Treat Rev 10:159, 1983; Joss RA: Cancer Treat Rev 11:205, 1984.

20 A preferred therapy for the treatment of NSCLC is a combination of therapeutically effective amounts of an integrin antagonist in combination with the following combinations of antineoplastic agents: 1) ifosfamide, cisplatin, etoposide; 2) cyclophosphamide, doxorubicin,  
25 cisplatin; 3) ifosfamide, carboplatin, etoposide; 4) bleomycin, etoposide, cisplatin; 5) ifosfamide, mitomycin, cisplatin; 6) cisplatin, vinblastine; 7) cisplatin, vindesine; 8) mitomycin C, vinblastine, cisplatin; 9) mitomycin C, vindesine, cisplatin; 10)  
30 ifosfamide, etoposide; 11) etoposide, cisplatin; 12) ifosfamide, mitomycin C; 13) flurouracil, cisplatin,

-142-

vinblastine; 14) carboplatin, etoposide; or radiation therapy.

Accordingly, apart from the conventional concept of anticancer therapy, there is a strong need for the  
5 development of therapies practicably effective for the treatment of non-small cell lung cancers.

Small Cell Lung Cancer

Approximately 15 to 20 percent of all cases of lung  
10 cancer reported worldwide is small cell lung cancer (SCLC). Ihde DC: Cancer 54:2722, 1984. Currently, treatment of SCLC incorporates multi-modal therapy, including chemotherapy, radiation therapy and surgery. Response rates of localized or disseminated SCLC remain  
15 high to systemic chemotherapy, however, persistence of the primary tumor and persistence of the tumor in the associated lymph nodes has led to the integration of several therapeutic modalities in the treatment of SCLC.

A preferred therapy for the treatment of lung  
20 cancer is a combination of therapeutically effective amounts of an integrin antagonist in combination with the following antineoplastic agents: vincristine, cisplatin, carboplatin, cyclophosphamide, epirubicin (high dose), etoposide (VP-16) I.V., etoposide (VP-16)  
25 oral, ifosfamide, teniposide (VM-26), and doxorubicin. Other preferred single-agents chemotherapeutic agents that may be used in the present invention include BCNU (carmustine), vindesine, hexamethylmelamine (altretamine), methotrexate, nitrogen mustard, and CCNU (lomustine). Other chemotherapeutic agents under investigation that have shown activity against SCLC

-143-

include iroplatin, gemcitabine, lonidamine, and taxol. Single-agent chemotherapeutic agents that have not shown activity against SCLC include mitoguazone, mitomycin C, aclarubicin, diaziquone, bisantrene, cytarabine, 5 idarubicin, mitomxantrone, vinblastine, PCNU and esorubicin.

The poor results reported from single-agent chemotherapy has led to use of combination chemotherapy.

A preferred therapy for the treatment of NSCLC is a 10 combination of therapeutically effective amounts of an integrin antagonist in combination with the following combinations of antineoplastic agents: 1) etoposide (VP-16), cisplatin; 2) cyclophosphamide, adriamycin [(doxorubicin), vincristine, etoposide (VP-16)]; 3) 15 Cyclophosphamide, adriamycin(doxorubicin), vincristine; 4) Etoposide (VP-16), ifosfamide, cisplatin; 5) etoposide (VP-16), carboplatin; 6) cisplatin, vincristine (Oncovin), doxorubicin, etoposide.

Additionally, radiation therapy in conjunction with 20 the preferred combinations of integrin antagonists and systemic chemotherapy is contemplated to be effective at increasing the response rate for SCLC patients. The typical dosage regimen for radiation therapy ranges from 40 to 55 Gy, in 15 to 30 fractions, 3 to 7 times week.

25 The tissue volume to be irradiated is determined by several factors and generally the hilum and subcarnial nodes, and bilateral mediastinal nodes up to the thoracic inlet are treated, as well as the primary tumor up to 1.5 to 2.0 cm of the margins.

30

Example 2

Colorectal Cancer

Survival from colorectal cancer depends on the stage and grade of the tumor, for example precursor adenomas to metastatic adenocarcinoma. Generally, colorectal cancer can be treated by surgically removing the tumor, but overall survival rates remain between 45 and 60 percent. Colonic excision morbidity rates are fairly low and is generally associated with the anastomosis and not the extent of the removal of the tumor and local tissue. In patients with a high risk of reoccurrence, however, chemotherapy has been incorporated into the treatment regimen in order to improve survival rates.

Tumor metastasis prior to surgery is generally believed to be the cause of surgical intervention failure and up to one year of chemotherapy is required to kill the non-excised tumor cells. As severe toxicity is associated with the chemotherapeutic agents, only patients at high risk of recurrence are placed on chemotherapy following surgery. Thus, the incorporation of an antiangiogenesis inhibitor into the management of colorectal cancer will play an important role in the treatment of colorectal cancer and lead to overall improved survival rates for patients diagnosed with colorectal cancer.

A preferred combination therapy for the treatment of colorectal cancer is surgery, followed by a regimen of one or more chemotherapeutic agents and an integrin antagonist, cycled over a one year time period. A more preferred combination therapy for the treatment of

colorectal cancer is a regimen of one or more integrin antagonists, followed by surgical removal of the tumor from the colon or rectum and then followed be a regimen of one or more chemotherapeutic agents and one or more 5 integrin antagonists, cycled over a one year time period. An even more preferred therapy for the treatment of colon cancer is a combination of therapeutically effective amounts of one or more antiangiogenesis agents including a matrix metalloproteinase inhibitor, a 10 cyclooxygenase-II inhibitor, or an integrin antagonist.

A more preferred therapy for the treatment of colon cancer is a combination of therapeutically effective amounts of an integrin antagonist in combination with the following antineoplastic agents: fluorouracil, and 15 Levamisole. Preferably, fluorouracil and Levamisole are used in combination.

Example 3

20           Breast Cancer

Today, among women in the United States, breast cancer remains the most frequent diagnosed cancer. One in 8 women in the United States are at risk of developing breast cancer in their lifetime. Age, family 25 history, diet, and genetic factors have been identified as risk factors for breast cancer. Breast cancer is the second leading cause of death among women.

Different chemotherapeutic agents are known in art for treating breast cancer. Cytoxic agents used for 30 treating breast cancer include doxorubicin,

-146-

cyclophosphamide, methotrexate, 5-fluorouracil, mitomycin C, mitoxantrone, taxol, and epirubicin. CANCER SURVEYS, Breast Cancer volume 18, Cold Spring Harbor Laboratory Press, 1993.

- 5        In the treatment of locally advanced noninflammatory breast cancer, integrin antagonists can be used to treat the disease in combination with other integrin antagonists, or in combination with surgery, radiation therapy, antiangiogenic agents or with  
10      chemotherapeutic agents. Preferred combinations of chemotherapeutic agents, radiation therapy and surgery that can be used in combination with the present invention include, but are not limited to the following combinations: 1) doxorubicin, vincristine, radical mastectomy; 2) doxorubicin, vincristine, radiation therapy; 3) cyclophosphamide, doxorubicin, 5-flourouracil, vincristine, prednisone, mastectomy; 4) cyclophosphamide, doxorubicin, 5-flourouracil, vincristine, prednisone, radiation therapy; 5)  
15      cyclophosphamide, doxorubicin, 5-flourouracil, premarin, tamoxifen, radiation therapy for pathologic complete response; 6) cyclophosphamide, doxorubicin, 5-flourouracil, premarin, tamoxifen, mastectomy, radiation therapy for pathologic partial response; 7) mastectomy,  
20      radiation therapy, levamisole; 8) mastectomy, radiation therapy; 9) mastectomy, vincristine, doxorubicin, cyclophosphamide, levamisole; 10) mastectomy, vincristine, doxorubicin, cyclophosphamide; 11)  
25      mastectomy, cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen, halotestin, radiation therapy;  
30

12) mastectomy, cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen, halotestin.

In the treatment of locally advanced inflammatory breast cancer, integrin antagonists can be used to treat  
5 the disease in combination with other antiangiogenic agents, or in combination with surgery, radiation therapy or with chemotherapeutic agents. Preferred combinations of chemotherapeutic agents, radiation therapy and surgery that can be used in combination with  
10 the present invention include, but or not limited to the following combinations: 1) cyclophosphamide, doxorubicin, 5-fluorouracil, radiation therapy; 2) cyclophosphamide, doxorubicin, 5-fluorouracil, mastectomy, radiation therapy; 3) 5-flurouracil,  
15 doxorubicin, cyclophosphamide, vincristine, prednisone, mastectomy, radiation therapy; 4) 5-flurouracil, doxorubicin, cyclophosphamide, vincristine, mastectomy, radiation therapy; 5) cyclophosphamide, doxorubicin, 5-fluorouracil, vincristine, radiation therapy;  
20 6) cyclophosphamide, doxorubicin, 5-fluorouracil, vincristine, mastectomy, radiation therapy;  
7) doxorubicin, vincristine, methotrexate, radiation therapy, followed by vincristine, cyclophosphamide, 5-florouracil; 8) doxorubicin, vincristine,  
25 cyclophosphamide, methotrexate, 5-florouracil, radiation therapy, followed by vincristine, cyclophosphamide, 5-florouracil; 9) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, predinsone, tamoxifen, followed by radiation therapy, followed by  
30 cyclophosphamide, methotrexate, 5-fluorouracil, predinsone, tamoxifen, doxorubicin, vincristine,

tamoxifen; 10) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, followed by radiation therapy, followed by cyclophosphamide, methotrexate, 5-fluorouracil, predinsone, tamoxifen, doxorubicin,  
5 vincristine, tamoxifen; 11) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, predinsone, tamoxifen, followed by radiation therapy, followed by cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin, vincristine, tamoxifen;  
10 12) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, followed by radiation therapy, followed by cyclophosphamide, methotrexate, 5-fluorouracil, predinsone, tamoxifen, doxorubicin, vincristine;  
15 13) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, predinsone, tamoxifen, followed by radiation therapy, followed by cyclophosphamide, methotrexate, 5-fluorouracil, predinsone, tamoxifen, doxorubicin, vincristine, tamoxifen; 14) surgery,  
followed by cyclophosphamide, methotrexate, 5-  
20 fluorouracil, followed by radiation therapy, followed by cyclophosphamide, methotrexate, 5-fluorouracil, predinsone, tamoxifen, doxorubicin, vincristine; 15)  
surgery, followed by cyclophosphamide, methotrexate, 5-  
fluorouracil, predinsone, tamoxifen, followed by  
25 radiation therapy, followed by cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin, vincristine;  
16) 5-florouracil, doxorubicin, cyclophosphamide  
followed by mastectomy, followed by 5-florouracil,  
doxorubicin, cyclophosphamide, followed by radiation  
30 therapy.

In the treatment of metastatic breast cancer, integrin antagonists can be used to treat the disease in combination with other antiangiogenic agents, or in combination with surgery, radiation therapy or with 5 chemotherapeutic agents. Preferred combinations of chemotherapeutic agents that can be used in combination with the integrin antagonists of the present invention include, but are not limited to the following combinations: 1) cyclophosphamide, methotrexate, 5- 10 fluorouracil; 2) cyclophosphamide, adriamycin, 5- fluorouracil; 3) cyclophosphamide, methotrexate, 5- fluorouracil, vincristine, prednisone; 4) adriamycin, vincristine; 5) thiotepa, adriamycin, vinblastine; 6) mitomycin, vinblastine; 7) cisplatin, etoposide.

15

Example 4

Prostate Cancer

20 Prostate cancer is now the leading form of cancer among men and the second most frequent cause of death from cancer in men. It is estimated that more than 165,000 new cases of prostate cancer were diagnosed in 1993, and more than 35,000 men died from prostate cancer 25 in that year. Additionally, the incidence of prostate cancer has increased by 50% since 1981, and mortality from this disease has continued to increase. Previously, most men died of other illnesses or diseases before dying from their prostate cancer. We now face increasing 30 morbidity from prostate cancer as men live longer and the disease has the opportunity to progress.

Current therapies for prostate cancer focus exclusively upon reducing levels of dihydrotestosterone to decrease or prevent growth of prostate cancer. In addition to the use of digital rectal examination and 5 transrectal ultrasonography, prostate-specific antigen (PSA) concentration is frequently used in the diagnosis of prostate cancer.

A preferred therapy for the treatment of prostate cancer is a combination of therapeutically effective 10 amounts of an integrin antagonist in combination with one or more additional antiangiogenic agents.

U.S. Pat. No. 4,472,382 discloses treatment of benign prostatic hyperplasia (BPH) with an antiandrogen and certain peptides which act as LH-RH agonists.

15 U.S. Pat. No. 4,596,797 discloses aromatase inhibitors as a method of prophylaxis and/or treatment of prostatic hyperplasia.

U.S. Pat. No. 4,760,053 describes a treatment of certain cancers which combines an LHRH agonist with an 20 antiandrogen and/or an antiestrogen and/or at least one inhibitor of sex steroid biosynthesis.

U.S. Pat. No. 4,775,660 discloses a method of treating breast cancer with a combination therapy which may include surgical or chemical prevention of 25 ovarian secretions and administering an antiandrogen and an antiestrogen.

U.S. Pat. No. 4,659,695 discloses a method of treatment of prostate cancer in susceptible male animals including humans whose testicular hormonal secretions 30 are blocked by surgical or chemical means, e.g. by use of an LHRH agonist, which comprises administering an

antiandrogen, e.g. flutamide, in association with at least one inhibitor of sex steroid biosynthesis, e.g. aminoglutethimide and/or ketoconazole.

5           Prostate Specific Antigen

One well known prostate cancer marker is Prostate Specific Antigen (PSA). PSA is a protein produced by prostate cells and is frequently present at elevated levels in the blood of men who have prostate cancer. PSA  
10 has been shown to correlate with tumor burden, serve as an indicator of metastatic involvement, and provide a parameter for following the response to surgery, irradiation, and androgen replacement therapy in prostate cancer patients. It should be noted that  
15 Prostate Specific Antigen (PSA) is a completely different protein from Prostate Specific Membrane Antigen (PSMA). The two proteins have different structures and functions and should not be confused because of their similar nomenclature.

20

Prostate Specific Membrane Antigen (PSMA)

In 1993, the molecular cloning of a prostate-specific membrane antigen (PSMA) was reported as a potential prostate carcinoma marker and hypothesized to  
25 serve as a target for imaging and cytotoxic treatment modalities for prostate cancer. Antibodies against PSMA have been described and examined clinically for diagnosis and treatment of prostate cancer. In particular, Indium-111 labelled PSMA antibodies have  
30 been described and examined for diagnosis of prostate cancer and Itrium-labelled PSMA antibodies have been

described and examined for the treatment of prostate cancer.

Example 5

5

Bladder Cancer

The classification of bladder cancer is divided into three main classes: 1) superficial disease, 2) muscle-invasive disease, and 3) metastatic disease.

10 Currently, transurethral resection (TUR), or segmental resection, account for first line therapy of superficial bladder cancer, i.e., disease confined to the mucosa or the lamina propria. However, intravesical therapies are necessary, for example, for the treatment 15 of high-grade tumors, carcinoma in situ, incomplete resections, recurrences, and multifocal papillary. Recurrence rates range from up to 30 to 80 percent, depending on stage of cancer.

Therapies that are currently used as intravesical 20 therapies include chemotherapy, immunootherapy, bacille Calmette-Guerin (BCG) and photodynamic therapy. The main objective of intravesical therapy is twofold: to prevent recurrence in high-risk patients and to treat disease that cannot be resected. The use of 25 intravesical therapies must be balanced with its potentially toxic side effects. Additionally, BCG requires an unimpaired immune system to induce an antitumor effect. Chemotherapeutic agents that are known to be inactive against superficial bladder cancer 30 include Cisplatin, actinomycin D, 5-fluorouracil, bleomycin, and cyclophosphamide methotrexate.

In the treatment of superficial bladder cancer, integrin antagonists can be used to treat the disease in combination with other integrin antagonists, or in combination with surgery (TUR), chemotherapy,  
5 antiangiogenic therapy and intravesical therapies.

A preferred therapy for the treatment of superficial bladder cancer is a combination of therapeutically effective amounts of an integrin antagonist in combination with: thiotepa (30 to 60  
10 mg/day), mitomycin C (20 to 60 mg/day), and doxorubicin (20 to 80 mg/day).

A preferred intravesicle immunotherapeutic agent that may be used in the present invention is BCG. A preferred daily dose ranges from 60 to 120 mg, depending  
15 on the strain of the live attenuated tuberculosis organism used.

A preferred photodynamic therapeutic agent that may be used with the present invention is Photofrin I, a photosensitizing agent, administered intravenously. It  
20 is taken up by the low-density lipoprotein receptors of the tumor cells and is activated by exposure to visible light. Additionally, neodymium YAG laser activation generates large amounts of cytotoxic free radicals and singlet oxygen.

25 In the treatment of muscle-invasive bladder cancer, integrin antagonists can be used to treat the disease in combination with other integrin antagonists, antiangiogenic agents, or in combination with surgery (TUR), intravesical chemotherapy, radiation therapy, and  
30 radical cystectomy with pelvic lymph node dissection.

A preferred radiation dose for the treatment of bladder cancer is between 5,000 to 7,000 cGY in fractions of 180 to 200 cGY to the tumor. Additionally, 3,500 to 4,700 cGY total dose is administered to the 5 normal bladder and pelvic contents in a four-field technique. Radiation therapy should be considered only if the patient is not a surgical candidate, but may be considered as preoperative therapy.

A preferred combination of surgery and 10 chemotherapeutic agents that can be used in combination with the integrin antagonists of the present invention is cystectomy in conjunction with five cycles of cisplatin (70 to 100 mg/m<sup>2</sup>); doxorubicin (50 to 60 mg/m<sup>2</sup>); and cyclophosphamide (500 to 600 15 mg/m<sup>2</sup>).

A more preferred therapy for the treatment of superficial bladder cancer is a combination of therapeutically effective amounts of an integrin antagonist plus one or more additional antiangiogenesis 20 agents including a matrix metalloproteinase inhibitor (MMP), or a cyclooxygenase-II inhibitor (COX-II).

An even more preferred combination for the treatment of superficial bladder cancer is a combination of therapeutically effective amounts of an integrin 25 antagonist in combination with the following combinations of antineoplastic agents: 1) cisplatin, doxorubicin, cyclophosphamide; and 2) cisplatin, 5-fluorouracil. An even more preferred combination of 30 chemotherapeutic agents that can be used in combination with radiation therapy and the integrin antagonists is a combination of cisplatin, methotrexate, vinblastine.

-155-

Currently no curative therapy exists for metastatic bladder cancer. The present invention contemplates an effective treatment of bladder cancer leading to improved tumor inhibition or regression, as compared to  
5 current therapies.

In the treatment of metastatic bladder cancer, integrin antagonists can be used to treat the disease in combination with other antiangiogenic agents, or in combination with surgery, radiation therapy or with  
10 chemotherapeutic agents.

A preferred therapy for the treatment of metastatic bladder cancer is a combination of therapeutically effective amounts of an integrin antagonist plus one or more additional antiangiogenesis agents including a  
15 matrix metalloproteinase inhibitor (MMP) or a cyclooxygenase-II inhibitor (COX-II).

A more preferred combination for the treatment of metastatic bladder cancer is a combination of therapeutically effective amounts of one or more  
20 integrin antagonists in combination with the following combinations of antineoplastic agents: 1) cisplatin and methotrexate; 2) doxorubicin, vinblastine, cyclophosphamide, and 5-fluorouracil; 3) vinblastine, doxorubicin, cisplatin, methotrexate; 4) vinblastine,  
25 cisplatin, methotrexate; 5) cyclophosphamide, doxorubicin, cisplatin; 6) 5-fluorouracil, cisplatin.

Example 6

Approximately 2% of new cancer cases diagnoses in the United States are pancreatic cancer. Pancreatic cancer is generally classified into two clinical types: 1) adenocarcinoma (metastatic and non-metastatic), and 5 2) cystic neoplasms (serous cystadenomas, mucinous cystic neoplasms, papillary cystic neoplasms, acinar cell systadenocarcinoma, cystic choriocarcinoma, cystic teratomas, angiomatous neoplasms).

Preferred combinations of therapy for the treatment 10 of non-metastatic adenocarcinoma that may be used in the present invention include the use of an integrin antagonist along with preoperative biliary tract decompression (patients presenting with obstructive jaundice); surgical resection, including standard 15 resection, extended or radial resection and distal pancreatectomy (tumors of body and tail); antiangiogenic therapy, adjuvant radiation; and chemotherapy.

For the treatment of metastatic adenocarcinoma, a preferred combination therapy consists of an integrin 20 antagonist of the present invention in combination with continuous treatment of 5- fluorouracil, followed by weekly cisplatin therapy.

A more preferred combination therapy for the treatment of cystic neoplasms is the use of an integrin 25 antagonist along with resection.

#### Example 7

##### Ovary Cancer

30 Celomic epithelial carcinoma accounts for approximately 90% of ovarian cancer cases. A preferred

therapy for the treatment of ovary cancer is a combination of therapeutically effective amounts of an integrin antagonist plus one or more antiangiogenesis agents including a matrix metalloproteinase inhibitor 5 (MMP) and/or a cyclooxygenase-II inhibitor.

Preferred single agents that can be used in combination with an integrin antagonist include, but are not limited to: alkylating agents, ifosfamide, cisplatin, carboplatin, taxol, doxorubicin, 5-10 fluorouracil, methotrexate, mitomycin, hexamethylmelamine, progestins, antiestrogens, prednimustine, dihydroxybusulfan, galactitol, interferon alpha, and interferon gama.

Preferred combinations for the treatment of celomic epithelial carcinoma is a combination of therapeutically effective amounts of an integrin antagonist in combination with the following combinations of antineoplastic agents: 1) cisplatin, doxorubicin, cyclophosphamide; 2) hexamethylmelamine, cyclophosphamide, doxorubicin, cisplatin; 3) cyclophosphamide, hexamethylmelamine, 5-flurouracil, cisplatin; 4) melphalan, hexamethylmelamine, cyclophosphamide; 5) melphalan, doxorubicin, cyclophosphamide; 6) cyclophosphamide, cisplatin, carboplatin; 7) cyclophosphamide, doxorubicin, hexamethylmelamine, cisplatin; 8) cyclophosphamide, doxorubicin, hexamethylmelamine, carboplatin; 9) cyclophosphamide, cisplatin; 10) hexamethylmelamine, doxorubicin, carboplatin; 11) cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin; 12) carboplatin, cyclophosphamide; 13) cisplatin, cyclophosphamide.

Germ cell ovarian cancer accounts for approximately 5% of ovarian cancer cases. Germ cell ovarian carcinomas are classified into two main groups: 1) dysgerminoma, and nondysgerminoma. Nondysgerminoma is further classified into teratoma, endodermal sinus tumor, embryonal carcinoma, chlorigerminoma, polyembryoma, and mixed cell tumors.

A preferred therapy for the treatment of germ cell carcinoma is a combination of therapeutically effective amounts of an integrin antagonist plus one or more antiangiogenesis agents including a matrix metalloproteinase inhibitor (MMP) and/or a cyclooxygenase-II inhibitor.

A more preferred therapy for the treatment of germ cell carcinoma is a combination of therapeutically effective amounts of an integrin antagonist in combination with the following combinations of antineoplastic agents: 1) vincristine, actinomycin D, cyclophosphamide; 2) bleomycin, etoposide, cisplatin; 3) vinblastine, bleomycin, cisplatin.

Cancer of the fallopian tube is the least common type of ovarian cancer, accounting for approximately 400 new cancer cases per year in the United States. Papillary serous adenocarcinoma accounts for approximately 90% of all malignancies of the ovarian tube.

A preferred therapy for the treatment of fallopian tube cancer is a combination of therapeutically effective amounts of an integrin antagonist plus one or more antiangiogenesis agents including a matrix

metalloproteinase inhibitor (MMP) and/or a cyclooxygenase-II inhibitor.

A more preferred therapy for the treatment of fallopian tube cancer is a combination of 5 therapeutically effective amounts of an integrin antagonist in combination with the following of antineoplastic agents: alkylating agents, ifosfamide, cisplatin, carboplatin, taxol, doxorubicin, 5-fluorouracil, methotrexate, mitomycin, 10 hexamethylmelamine, progestins, antiestrogens, prednimustine, dihydroxybusulfan, galactitol, interferon alpha, and interferon gama.

An even more preferred therapy for the treatment of fallopian tube cancer is a combination of 15 therapeutically effective amounts of an integrin antagonist in combination with the following combinations of antineoplastic agents: 1) cisplatin, doxorubicin, cyclophosphamide; 2) hexamethylmelamine, cyclophosphamide, doxorubicin, cisplatin; 3) 20 cyclophosphamide, hexamehtylmelamine, 5-flurouracil, cisplatin; 4) melphalan, hexamethylmelamine, cyclophosphamide; 5) melphalan, doxorubicin, cyclophosphamide; 6) cyclophosphamide, cisplatin, carboplatin; 7) cyclophosphamide, doxorubicin, 25 hexamethylmelamine, cisplatin; 8) cyclophosphamide, doxorubicin, hexamethylmelamine, carboplatin; 9) cyclophosphamide, cisplatin; 10) hexamethylmelamine, doxorubicin, carboplatin; 11) cyclophosphamide, hexamethlmelamine, doxorubicin, cisplatin; 12) 30 carboplatin, cyclophosphamide; 13) cisplatin, cyclophosphamide.

Example 8Central Nervous System Cancers

5       Central nervous system cancer accounts for approximately 2% of new cancer cases in the United States. Common intracranial neoplasms include glioma, meninigioma, neurinoma, and adenoma.

10      A preferred therapy for the treatment of central nervous system cancers is a combination of therapeutically effective amounts of an integrin antagonist plus one or more antiangiogenesis agents including a matrix metalloproteinase inhibitor (MMP) and/or a cyclooxygenase-II inhibitor.

15      A preferred therapy for the treatment of malignant glioma is a combination of therapeutically effective amounts of an integrin antagonist in combination with the following combinations of therapies and antineoplastic agents:: 1) radiation therapy, BCNU (carmustine); 2) radiation therapy, methyl CCNU (lomustine); 3) radiation therapy, medol; 4) radiation therapy, procarbazine; 5) radiation therapy, BCNU, medrol; 6) hyperfraction radiation therapy, BCNU; 7) radiation therapy, misonidazole, BCNU; 8) radiation therapy, streptozotocin; 9) radiation therapy, BCNU, procarbazine; 10) radiation therapy, BCNU, hydroxyurea, procarbazine, VM-26; 11) radiation therapy, BNCU, 5-flourouacil; 12) radiation therapy, Methyl CCNU, dacarbazine; 13) radiation therapy, misonidazole, BCNU; 14) diaziquone; 15) radiation therapy, PCNU; 16) procarbazine (matulane), CCNU, vincristine. A preferred

-161-

dose of radiation therapy is about 5,500 to about 6,000 cGY. Preferred radiosensitizers include misonidazole, intra-arterial Budr and intravenous iododeoxyuridine (IUDR). It is also contemplated that radiosurgery may  
5 be used in combinations with integrin antagonists.

### **Biological Evaluation**

#### Integrin Antagonists

10 1.

Cancer cells were implanted subcutaneously in genetically engineered mice and grew large-volume tumors ( $>1,500 \text{ mm}^3$ ). Subsequent administration of compound I7 reduced tumor growth by as much as 85 percent in a dose  
15 dependent manner. (Nickols A, et al. Inhibition of tumor growth and metastasis by an  $\alpha\beta 3$  integrin antagonist. Presented at the 89<sup>th</sup> Annual Meeting of the American Association for Cancer Research, March, 1998.)

20 2.

In an additional experiment, tumor cells were implanted into mice; lung tumors of volumes greater than 2,000  $\text{mm}^3$  were developed. The mice were then separated into four groups, including a control group and three  
25 treatment groups: compound I7 alone; compound I7 with cisplatin (a cytotoxic drug); or cisplatin alone. Compared to the control groups, the mice treated with combination compound I7/cisplatin therapy experienced more than an 80 percent reduction in tumor size. In  
30 comparison, the group receiving cisplatin alone experienced 50 percent reductions in tumor size and

the compound I7 group experienced 20-30 percent reductions. These studies indicate that compound I7 has prominent anti-tumor activity.

5    3. M21 human melanoma, rat Leydig testicular carcinoma, Lewis Lung and human xenograft models:

To test the utility of a,b, antagonists as single agents and in combination chemotherapy, the M21 human 10 melanoma, rat Leydig testicular carcinoma, and the Lewis Lung carcinoma (LLC) model as well as other human tumor xenograft models were utilized. Tumor cells for implantation were taken from cells either grown in tissue culture (Leydig, M21) or serially passaged as 15 tumors in mice and prepared as tumor brei (LLC). Mice were injected subcutaneously in the proximal dorsal midline with  $5 \times 10^6$  tumor cells and administration of test compound or vehicle was initiated the evening of the same day. Tumor volumes were measured at intervals 20 over the course of the experiments. Tumors were measured with a vernier caliper and volumes were determined using the formula for the volume of a cylinder: tumor volume = width<sup>2</sup> x length x 0.52. Blood was routinely drawn for plasma drug concentration 25 hours post-dosing on day 4 or 5 and again 12 hours post-dosing on the day of sacrifice. On the final day of the experiment, tumors were dissected free and weighed. The data are expressed as the mean +/- SEM. Student's and Mann-Whitney tests were used to assess differences 30 between means or medians using the InStat software package.

In the LLC model, compound I7 was administered continuously beginning on day 1 after implantation of the tumor cells, and the chemotherapeutic, cisplatin, was administered as a single intraperitoneal dose of 10 mg/kg on day 5. In this study, cisplatin alone significantly retarded the growth of the LLC tumor ( $p<0.05$ ). Compound I7 (1 and 10 mg/kg, BID, PO) did not affect the growth of the primary tumor mass. However, the combination of compound I7 together with cisplatin resulted in an additive effect and a significant tumor growth delay (time to develop a tumor  $> 500 \text{ mm}^3$  was: vehicle = 18.1 days; cisplatin = 22.4 days; cisplatin + compound I7 (10 mg/kg) = 27.3 days). The final tumor volume was also significantly reduced with the combination of cisplatin and compound I7 producing a reduction of final tumor volume of 68% in combination ( $p<0.05$ ). Moreover, the combination of cisplatin and compound I7 resulted in a 39% improvement in median survival time over vehicle controls and an enhancement over either agent alone (28 days for the vehicle group; 33 days for the cisplatin group; 33 days for the compound I7 at 10 mg/kg group; 38 days for the combination group). Similarly, compound I7 reduced tumor volume when given with cisplatin in a dose-sequencing protocol. The combination of a,b, antagonist and chemotherapeutic agent was more efficacious than cisplatin alone, particularly when therapy with compound I7 (po, BID) was begun at the same time as cisplatin (once, IP on day 5) or 5 days later ( $p<0.05$  or less for all).

In the M21 model, M21 human melanoma cells implanted subcutaneously into SCID mice developed tumors which grew to approximately 400 mm<sup>3</sup> within 30 days. Oral administration of compound compound I7 (BID) dose-dependently retarded the growth of these tumors when administered at the time of tumor implantation or beginning up to 21 days after implantation. Time to develop a tumor mass > 200mm<sup>3</sup> was significantly lengthened in the group treated with the a,b,<sub>3</sub> antagonist (time to tumor volume > 200 mm<sup>3</sup> was: vehicle = 15 days; compound I7, 10 mg/kg = 27 days). These data clearly demonstrate the utility of compound compound I7 to inhibit the growth of pre-existing and established tumors. Moreover, compound compound I7 increased the antitumor efficacy of cisplatin when treatment with the a,b,<sub>3</sub> antagonist was begun on day 1, prophylactically, or therapeutically, on day 14 or 17 (all combinations significantly less than cisplatin alone, p<0.05). Cisplatin was administered once by ip injection (10 mg/kg) on day 14. Final tumor weights were nearly identical in the combination treated groups, with clear enhancement of the effect of cisplatin treatment alone. The results of this dose sequencing experiment establish the efficacy of compound I7 in combination therapy with cisplatin when administered before, concurrent with, or after cisplatin dosing.

The Rice 500 rat Leydig testicular tumor grows very quickly when implanted into the flank of SCID mice. Compound I7 inhibited tumor growth dose-dependently when given in the drinking water at concentrations of 0.02 to

2 mg/ml. Tumor growth was reduced by about 50% at the 2 mg/ml dose in this aggressive model. Since the tumor does not express the  $\alpha_v\beta_3$  integrin, the antitumor effects were likely to be produced by the inhibition of  
5 angiogenesis. Similar to the results seen in the M21 tumor model, compound I7 increased the effects of cisplatin in the Leydig tumor model. Indeed, the combination of cisplatin and compound I7 was almost 100% effective in preventing tumor growth over the 11 day  
10 course of the study. Dose-related inhibition of tumor growth by compound I7 (10 or 100 mg/kg, BID, PO) was also seen when the compound was given as monotherapy or in combination with cisplatin (10 mg/kg, ip once on day 5) ( $p<0.01$  vs control). Therapeutic treatment with the  
15  $\alpha_v\beta_3$  antagonist was begun at the same time as cisplatin on day 5, with tumor volumes of about 200 mm<sup>3</sup> at the initiation of therapy. In a similar experiment, the effects of compound I7, cisplatin and the combination were evaluated for potentiation of overall survival in  
20 the Leydig tumor mice. Survival was increased by either compound I7 or cisplatin alone when compared to vehicle treated controls ( $p<0.05$ ). More importantly, the combination of the two agents almost doubled overall survival (from 17 to 29 days) ( $p<0.01$  combination vs.  
25 cisplatin,  $p<0.001$  combination vs. control). Thus, the ability of compound I7 to work alone or in combination therapy to prevent tumor growth clearly correlates with enhanced survival.

4. U251 Glioblastoma Model:

compound I7 was evaluated in the human U251 glioblastoma model. The tumors were implanted onto the flanks of SCID mice and the mean tumor volume with time was calculated. In this model, at the dose tested (10 mg/kg, BID, PO), compound I7 produced little inhibition of tumor growth by itself when administered from day 14 through 44. The chemotherapeutic agent, BCNU (12 mg/kg) administered once a day on days 14, 18 and 22, induced a regression of the tumors to the limit of detectability, but the tumors grew back. Combination treatment with BCNU and compound I7 regressed tumors to the limit of detectability throughout the period of treatment (compound I7 administered from day 14-44) and almost through the rest of the study. When the data are examined as time to tumor progression (days to 2 tumor doublings), there is clear enhancement by the drug combination over the antitumor effects of either agent alone ( $p<0.01$ ). Moreover, the response rate (responders to BCNU) is markedly enhanced and the duration of the response is increased 5-fold from 5 days to 25 days ( $p<0.01$ ). These clinically relevant measurements of antitumor efficacy establish the antitumor efficacy of compound I7, especially when combined with standard of care chemotherapeutic agents.

5. A2780 Mouse Model:

compound I7 prevents the growth of human ovarian carcinoma in SCID mice. The A2780 tumor line is another aggressive tumor model characterized by rapid growth.

-167-

compound I7 treatment (10 mg/kg, BID, PO) was equally effective as cisplatin (10 mg/kg, ip once on day 20) in decreasing tumor growth. However, as seen in the other tumor models, compound I7 potentiated the effects of 5 cisplatin, resulting in an 80% reduction vs control on day 30. Survival studies are now underway to characterize the survival benefit of combination therapy in this model.

10 6. Corneal Micropocket Assay:

In this model, an intrastromal pocket is surgically created in the normally avascular cornea of female C57BL6 mice 1mm distance from the corneal-scleral junction. A slow release hydron polymer pellet containing an angiogenic growth factor (bFGF or VEGF) is inserted into the corneal pocket. The pocket is self sealing and antibiotic ointment is placed in the eye. Five days later the eyes are examined under a slit lamp and the neovascular response is quantitated by measuring 20 the average vessel length (VL) and the contiguous circumferential zone (CH=clock hours where 1 CH = 30 degrees) and plugged into the formula of half an ellipse; Area (mm<sup>2</sup>) = 0.5 x 3.1416 x VL x CH x 0.4. compound I7 administered BID is a potent inhibitor of 25 angiogenesis in the mouse corneal micropocket model. compound I7 dose-dependently inhibited the angiogenic response up to 42% with maximal inhibitory activity observed at doses of 10mg/kg, BID orally. Moreover, compound I7 inhibited angiogenesis induced by either 30 bFGF or VEGF, the two predominant growth factors known to be produced by tumor cells in vivo. These data

confirm the mechanism of action of compound I7 as direct inhibition of angiogenesis in vivo.

#### 7. Metastasis

5        Accurate quantitation of early-stage metastasis in animal models is typically hampered by the lack of sensitive and convenient assays to detect low numbers of tumor cells in a background of normal tissue.

10      Quantitation of late-stage metastasis by counting of visible foci or comparison of organ weights requires substantial tumor burden which can take 3-4 months to develop in conventional models of breast cancer, and generally cannot detect subtle differences. To develop a more quantitative metastasis model in which the effect

15      of inhibitors on multiple stages of the metastatic process could be dissected, we have produced stable MDA-MB-435 breast carcinoma cell lines expressing a synthetic variant of green fluorescent protein (GFP). The GFP-transfected cells are easily detected by flow

20      cytometry, and fixation of the cells or the addition of antibodies or exogenous substrates is not required. A highly aggressive clone was isolated from the lung of a SCID mouse implanted in the mammary fat pad with several GFP-expressing clones. This line, designated 435/GFP

25      HAL-1, consistently generates substantial tumor burden in the lungs by 8-9 weeks compared with 12-16 weeks for the parent line. As few as 1 tumor cell in 200,000 host cells can be detected by flow cytometry, and fluorescent cells are detected in the lungs and blood as early as

30      one week post-orthotopic implantation. compound I7 was administered at doses of 1, 10, and 30 mg/kg, BID,

orally following orthotopic surgical implantation of 435/GFP HAL-1 cells into the mammary fat pad of SCID mice. Eight weeks later, lungs were removed and weighed. Metastasis was quantitated using a semi-  
5 quantitative visible scoring method of gross metastases under a dissecting scope or, following dissection and disaggregation of lung tissue, by flow cytometry of GFP expressing cells. compound I7 administration dose-dependently reduced the spontaneous metastasis of 435  
10 breast carcinoma cells to the lungs as determined either by direct visual counting or quantitation by flow cytometry. Doses of 10 and 30 mg/kg resulted in a 55% and 69% reduction in lung metastatic burden, respectively. However, compound I7 did not delay the  
15 growth of the primary tumor mass in this model. Histological examination of lung sections from these studies revealed a dramatic reduction in the number of large macroscopic metastases and an increase in the presence of microscopic foci of metastases in the  
20 compound I7 treated animals.

What is claimed is:

1. A method for treating or preventing a neoplasia disorder in a mammal in need of such treatment or prevention, which method comprises administering to said mammal a therapeutically-effective amount of a combination of an integrin antagonist and one or more antineoplastic agents, wherein said antineoplastic agents are selected from the group consisting of  
5 anastrozole, calcium carbonate, capecitabine, carboplatin, cisplatin, Cell Pathways CP-461, cyclophosphamide, docetaxel, doxorubicin, etoposide, fluorouracil (5-FU), fluoxymestrine, gemcitabine, goserelin, irinotecan, ketoconazole, letrozol,  
10 leucovorin, levamisole, megestrol, mitoxantrone, paclitaxel, raloxifene, retinoic acid, tamoxifen, thiotepa, topotecan, toremifene, vinorelbine, vinblastine, vincristine, selenium (selenomethionine), 15 ursodeoxycholic acid, sulindac sulfone and eflornithine  
20 (DFMO) .

2. The method of Claim 1 wherein the combination is administered in a sequential manner.

3. The method of Claim 1 wherein the combination is administered in a substantially simultaneous manner.

25 4. The method of Claim 1 wherein the antineoplastic agent is capecitabine.

5. The method of Claim 1 wherein the antineoplastic agent is carboplatin.

6. The method of Claim 1 wherein the  
30 antineoplastic agent is cisplatin.

7. The method of Claim 1 wherein the antineoplastic agent is Cell Pathways CP-461.

8. The method of Claim 1 wherein the antineoplastic agent is docetaxel.

5 9. The method of Claim 1 wherein the antineoplastic agent is doxorubicin.

10. The method of Claim 1 wherein the antineoplastic agent is etoposide.

11. The method of Claim 1 wherein the 10 antineoplastic agent is fluorouracil (5-FU).

12. The method of Claim 1 wherein the antineoplastic agent is fluoxymestrone.

13. The method of Claim 1 wherein the antineoplastic agent is gemcitabine.

15 14. The method of Claim 1 wherein the antineoplastic agent is goserelin.

15. The method of Claim 1 wherein the antineoplastic agent is irinotecan.

16. The method of Claim 1 wherein the 20 antineoplastic agent is ketoconazole.

17. The method of Claim 1 wherein the antineoplastic agent is letrozol.

18. The method of Claim 1 wherein the antineoplastic agent is leucovorin.

25 19. The method of Claim 1 wherein the antineoplastic agent is levamisole.


20. The method of Claim 1 wherein the antineoplastic agent is megestrol.

21. The method of Claim 1 wherein the 30 antineoplastic agent is mitoxantrone.

- PCT/US99/30670
22. The method of Claim 1 wherein the antineoplastic agent is paclitaxel.
23. The method of Claim 1 wherein the antineoplastic agent is raloxifene.
- 5 24. The method of Claim 1 wherein the antineoplastic agent is retinoic acid.
25. The method of Claim 1 wherein the antineoplastic agent is tamoxifen.
- 10 26. The method of Claim 1 wherein the antineoplastic agent is thiotepa.
27. The method of Claim 1 wherein the antineoplastic agent is topotecan.
28. The method of Claim 1 wherein the antineoplastic agent is toremifene.
- 15 29. The method of Claim 1 wherein the antineoplastic agent is vinorelbine.
30. The method of Claim 1 wherein the antineoplastic agent is vinblastine.
- 20 31. The method of Claim 1 wherein the antineoplastic agent is vincristine.
32. The method of Claim 1 wherein the antineoplastic agent is selenium (selenomethionine).
33. The method of Claim 1 wherein the antineoplastic agent is sulindac sulfone.
- 25 34. The method of Claim 1 wherein the antineoplastic agent is ursodeoxycholic acid.
35. The method of Claim 1 wherein the antineoplastic agent is eflornithine (DFMO).
- 30 36. The method of Claim 1 wherein the integrin antagonist is selected from compounds, and their


pharmaceutically acceptable salts thereof, of the group consisting of:

1)



5 (3R)-N-[{5-[{(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl}carbonyl]glycyl}-3-(3-bromo-5-chloro-2-hydroxyphenyl)-β-alanine,


2)



10 (3R)-N-[{1,6-dihydro-6-oxo-5-[{(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl}carbonyl]glycyl}-3-(3-bromo-5-chloro-2-hydroxyphenyl)-β-alanine,


15

3)



(3R)-N-[3-amino-5-{(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino}benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-β-alanine,

4)




(3R)-N-[3-[(hydroxyamino)carbonyl]-5-

[(1,4,5,6-tetrahydro-5-hydroxy)-2-

5 pyrimidinyl]amino]benzoyl]glycyl-3-(3-bromo-5-  
chloro-2-hydroxyphenyl)-D-alanine,


5)



(3R)-N-[3-[(4-,5-dihydro-1H-imidazol-2-

10 yl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-  
hydroxyphenyl)-D-alanine,

6)




(3R)-N-[3-

15 [(aminoiminomethyl)amino]benzoyl]glycyl-3-(3-  
bromo-5-chloro-2-hydroxyphenyl)-D-alanine,

-175-


7)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)- $\beta$ -alanine,

5


8)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)- $\beta$ -alanine,

10

9)




(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(5-bromo-3-chloro-2-hydroxyphenyl)- $\beta$ -alanine,

15

-176-


10)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine,

5


11)



b-[3-[[3-[4,5-dihydro-1H-imidazol-2-yl]amino]phenyl]sulfonyl]amino]phenyl]-3,5-difluorobenzenepropanoic acid,

10

12)




3,5-difluoro-D-[3-[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]amino]methyl]phenyl]benzenepropanoic acid,


15

-177-

13)




14)



5

(2E)-3-[3-ethyl-4-[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]amino]phenyl]-2-propenoic acid,


15)



10

(2E)-3-[3-[2-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]-2-oxoethoxy]phenyl]-2-propenoic acid,

16)




15

(10S)-10,11-dihydro-3-[3-(2-pyridinylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid,

-178-


17)



(2S)-7-[[(1H-benzimidazol-2-  
ylmethyl)methylamino]carbonyl]-2,3,4,5-  
tetrahydro-4-methyl-3-oxo-1H-1,4-  
benzodiazepine-2-acetic acid,

5


18)



10

(2S)-2,3,4,5-tetrahydro-4-methyl-7-[[(5-  
methyl-1H-imidazo[4,5-b]pyridin-2-  
yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-  
benzodiazepine-2-acetic acid,

19)




15


(bR)-b-[[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-  
1,8-naphthyridin-2-yl)ethyl]-1-  
pyrrolidinyl]acetyl]amino]-1H-indole-3-  
pentanoic acid,

-179-

20)




21)




5

22)



23)




10

24) Vitaxin antibody (Ixsys),


25) Merck KGaA EMD-121974, cyclo[RGDF-N(Me)V-],

26)




-180-

27)




28)




5


29)



30)




31)




10

-181-

32)




33)




5

34)




35)




10

36)




-182-

37)




38)




5

39)




40)




41)

10




-183-

42)




, and

43)




5 37. The method of Claim 1 wherein the integrin antagonist is



10 (10S)-10,11-dihydro-3-[3-(2-pyridylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid.

38. The method of Claim 1 wherein the integrin antagonist is




15

(2S)-7-[[[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid.

-184-


39. The method of Claim 1 wherein the integrin antagonist is



5 (2S)-2,3,4,5-tetrahydro-4-methyl-7-[[(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-benzodiazepine-2-acetic acid.

40. The method of Claim 1 wherein the integrin antagonist is

10




15

(bR)-b-[[[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]pyrrolidinyl]acetyl]amino]-1H-indole-3-pentanoic acid.

-185-


41. The method of Claim 1 wherein the integrin antagonist is



5 42. The method of Claim 1 wherein the integrin antagonist is Vitaxin antibody(Ixsys).


43. The method of Claim 1 wherein the integrin antagonist is Merck KGaA EMD-121974, cyclo[RGDF-N(Me)V-]

10 44. The method of Claim 1 wherein the integrin antagonist is




45. The method of Claim 1 wherein the integrin antagonist is

15




46. The method of Claim 1 wherein the integrin antagonist is



5

47. The method of Claim 1 wherein the integrin antagonist is



10

48. The method of Claim 1 wherein the neoplasia is selected from the group consisting of lung cancer, breast cancer, gastrointestinal cancer, bladder cancer, head and neck cancer and cervical cancer.

15

15        49. The method of Claim 1 wherein the neoplasia is  
selected from the group consisting of acral lentiginous  
melanoma, actinic keratoses, adenocarcinoma, adenoid  
cystic carcinoma, adenomas, adenosarcoma, adenosquamous  
carcinoma, astrocytic tumors, bartholin gland carcinoma,  
20 basal cell carcinoma, bronchial gland carcinomas,  
capillary, carcinoids, carcinoma, carcinosarcoma,  
cavernous, cholangiocarcinoma, chondrosarcoma, choriod  
plexus papilloma/carcinoma, clear cell carcinoma,  
cystadenoma, endodermal sinus tumor, endometrial

hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ependymal, epitheloid, Ewing's sarcoma, fibrolamellar, focal nodular hyperplasia, gastrinoma, germ cell tumors, glioblastoma, glucagonoma,

5       hemangiblastomas, hemangiopericytoma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatocellular carcinoma, insulinoma, intraepithelial neoplasia, interepithelial squamous cell neoplasia, invasive squamous cell carcinoma, large cell carcinoma,

10      leiomyosarcoma, lentigo maligna melanomas, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, melanoma, meningeal, mesothelial, metastatic carcinoma, mucoepidermoid carcinoma, neuroblastoma, neuroepithelial adenocarcinoma nodular

15      melanoma, oat cell carcinoma, oligodendroglial, osteosarcoma, pancreatic polypeptide, papillary serous adenocarcinoma, pineal cell, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma,

20      sarcoma, serous carcinoma, small cell carcinoma, soft tissue carcinomas, somatostatin-secreting tumor, squamous carcinoma, squamous cell carcinoma, submesothelial, superficial spreading melanoma, undifferentiated carcinoma, uveal melanoma, verrucous

25      carcinoma, vipoma, well differentiated carcinoma, and Wilm's tumor.

50. A method for treating or preventing a neoplasia disorder in a mammal in need of such treatment or prevention, which method comprises administering to  
30      said mammal a therapeutically-effective amount of a combination of radiation therapy, an integrin

antagonist, and one or more antineoplastic agents, wherein said antineoplastic agents are selected from the group consisting of anastrozole, calcium carbonate, capecitabine, carboplatin, cisplatin, Cell Pathways CP-  
5 461, cyclophosphamide, docetaxel, doxorubicin, etoposide, fluorouracil (5-FU), fluoxymestrone, gemcitabine, goserelin, irinotecan, ketoconazole, letrozol, leucovorin, levamisole, megestrol, mitoxantrone, paclitaxel, raloxifene, retinoic acid,  
10 tamoxifen, thiotepa, topotecan, toremifene, vinorelbine, vinblastine, vincristine, selenium (selenomethionine), ursodeoxycholic acid, sulindac sulfone and eflornithine (DFMO).

51. The method of Claim 50 wherein the combination  
15 is administered in a sequential manner.

52. The method of Claim 50 wherein the combination  
is administered in a substantially simultaneous manner.

53. The method of Claim 50 wherein the  
antineoplastic agent is capecitabine.

20 54. The method of Claim 50 wherein the  
antineoplastic agent is carboplatin.

55. The method of Claim 50 wherein the  
antineoplastic agent is cisplatin.

25 56. The method of Claim 50 wherein the  
antineoplastic agent is Cell Pathways CP-461.

57. The method of Claim 50 wherein the  
antineoplastic agent is docetaxel.

58. The method of Claim 50 wherein the  
antineoplastic agent is doxorubicin.

30 59. The method of Claim 50 wherein the  
antineoplastic agent is etoposide.

60. The method of Claim 50 wherein the antineoplastic agent is fluorouracil (5-FU).

61. The method of Claim 50 wherein the antineoplastic agent is fluoxymestrine.

5 62. The method of Claim 50 wherein the antineoplastic agent is gemcitabine.

63. The method of Claim 50 wherein the antineoplastic agent is goserelin.

10 64. The method of Claim 50 wherein the antineoplastic agent is irinotecan.

65. The method of Claim 50 wherein the antineoplastic agent is ketoconazole.

66. The method of Claim 50 wherein the antineoplastic agent is letrozol.

15 67. The method of Claim 50 wherein the antineoplastic agent is leucovorin.

68. The method of Claim 50 wherein the antineoplastic agent is levamisole.

20 69. The method of Claim 50 wherein the antineoplastic agent is megestrol.

70. The method of Claim 50 wherein the antineoplastic agent is mitoxantrone.

71. The method of Claim 50 wherein the antineoplastic agent is paclitaxel.

25 72. The method of Claim 50 wherein the antineoplastic agent is raloxifene.

73. The method of Claim 50 wherein the antineoplastic agent is retinoic acid.

30 74. The method of Claim 50 wherein the antineoplastic agent is tamoxifen.

-190-

75. The method of Claim 50 wherein the antineoplastic agent is thiotepa.

76. The method of Claim 50 wherein the antineoplastic agent is topotecan.

5 77. The method of Claim 50 wherein the antineoplastic agent is toremifene.

78. The method of Claim 50 wherein the antineoplastic agent is vinorelbine.

10 79. The method of Claim 50 wherein the antineoplastic agent is vinblastine.

80. The method of Claim 50 wherein the antineoplastic agent is vincristine.

81. The method of Claim 50 wherein the antineoplastic agent is selenium (selenomethionine).

15 82. The method of Claim 50 wherein the antineoplastic agent is sulindac sulfone.


83. The method of Claim 50 wherein the antineoplastic agent is ursodeoxycholic acid.

20 84. The method of Claim 50 wherein the antineoplastic agent is eflornithine (DFMO).

85. The method of Claim 50 wherein the integrin antagonist is selected from compounds, and their pharmaceutically acceptable salts thereof, of the group consisting of:


-191-

1)




(3R)-N-[5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-  
5  
3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-  
chloro-2-hydroxyphenyl)-β-alanine,

2)



10  
(3R)-N-[1,6-dihydro-6-oxo-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-  
pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-  
2-hydroxyphenyl)-β-alanine,


3)



15  
(3R)-N-[3-amino-5-[(1,4,5,6-tetrahydro-5-  
hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-  
(3-bromo-5-chloro-2-hydroxyphenyl)-β-alanine,

-192-


4)



(3R)-N-[3-[(hydroxyamino)carbonyl]-5-[(1,4,5,6-tetrahydro-5-hydroxy)-2-pyrimidinyl]amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine,

5


5)



10

(3R)-N-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine,


6)



15

(3R)-N-[3-[(aminoiminomethyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine,


7)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine,

5


8)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-D-alanine,

10


9)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(5-bromo-3-chloro-2-hydroxyphenyl)-D-alanine,

15

10)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine,

5


11)



b-[3-[[3-[[4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]sulfonyl]amino]phenyl]-3,5-difluorobenzene propanoic acid,

10

12)




3,5-difluoro-b-[3-[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]amino]methyl]phenyl]benzenepropanoic acid,


15

-195-

13)




14)



5

(2E)-3-[3-ethyl-4-[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]amino]phenyl]-2-propenoic acid,


15)



10

(2E)-3-[3-[2-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]-2-oxoethoxy]phenyl]-2-propenoic acid,


16)



15

(10S)-10,11-dihydro-3-[3-(2-pyridinylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid,


17)



(2S)-7-[[(1H-benzimidazol-2-  
yl)methylamino]carbonyl]-2,3,4,5-  
tetrahydro-4-methyl-3-oxo-1H-1,4-  
benzodiazepine-2-acetic acid,

5


18)



(2S)-2,3,4,5-tetrahydro-4-methyl-7-[[[(5-  
methyl-1H-imidazo[4,5-b]pyridin-2-  
yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-  
benzodiazepine-2-acetic acid,

10


19)




15

(bR)-b-[[[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-  
1,8-naphthyridin-2-yl)ethyl]-1-  
pyrrolidinyl]acetyl]amino]-1H-indole-3-  
pentanoic acid,

20)




21)




5

22)



23)




10

24) Vitaxin antibody(Ixsys),


25) Merck KGaA EMD-121974, cyclo[RGDF-N(Me)V-],

26)




-198-

27)




28)




5


29)



30)




31)




10

32)




33)




5


34)



35)




36)




-200-

37)




38)




5


39)



40)




41)



10


-201-

42)




, and

43)




5 86. The method of Claim 50 wherein the integrin  
antagonist is



10 (10S)-10,11-dihydro-3-[3-(2-  
pyridylamino)propoxy]-5H-  
dibenzo[a,d]cycloheptene-10-acetic acid.


87. The method of Claim 50 wherein the integrin  
antagonist is



15 (2S)-7-[(1H-benzimidazol-2-  
ylmethyl)methylamino]carbonyl]-2,3,4,5-  
tetrahydro-4-methyl-3-oxo-1H-1,4-  
benzodiazepine-2-acetic acid.


-202-

88. The method of Claim 50 wherein the integrin antagonist is




5 (2S)-2,3,4,5-tetrahydro-4-methyl-7-[[(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-benzodiazepine-2-acetic acid.

89. The method of Claim 50 wherein the integrin antagonist is



10 (bR)-b-[[[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl]acetyl]amino]-1H-indole-3-pentanoic acid.

15 90. The method of Claim 50 wherein the integrin antagonist is




91. The method of Claim 50 wherein the integrin antagonist is Vitaxin antibody(Ixsys).


-203-

92. The method of Claim 50 wherein the integrin antagonist is Merck KGaA EMD-121974, cyclo[RGDf-N(Me)V-].


93. The method of Claim 50 wherein the integrin antagonist is




94. The method of Claim 50 wherein the integrin antagonist is



95. The method of Claim 50 wherein the integrin antagonist is



96. The method of Claim 50 wherein the integrin antagonist is



15

97. The method of Claim 50 wherein the neoplasia is selected from the group consisting of lung cancer,

breast cancer, gastrointestinal cancer, bladder cancer, head and neck cancer and cervical cancer.

98. The method of Claim 50 wherein the neoplasia is selected from the group consisting of acral lentiginous melanoma, actinic keratoses, adenocarcinoma, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, astrocytic tumors, bartholin gland carcinoma, basal cell carcinoma, bronchial gland carcinomas, capillary, carcinoids, carcinoma, 10 carcinosarcoma, cavernous, cholangiocarcinoma, chondrosarcoma, choriod plexus papilloma/carcinoma, clear cell carcinoma, cystadenoma, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ependymal, epitheloid, 15 Ewing's sarcoma, fibrolamellar, focal nodular hyperplasia, gastrinoma, germ cell tumors, glioblastoma, glucagonoma, hemangiblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatocellular carcinoma, insulinoma, intraepithelial 20 neoplasia, interepithelial squamous cell neoplasia, invasive squamous cell carcinoma, large cell carcinoma, leiomyosarcoma, lentigo maligna melanomas, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, melanoma, meningeal, mesothelial, 25 metastatic carcinoma, mucoepidermoid carcinoma, neuroblastoma, neuroepithelial adenocarcinoma nodular melanoma, oat cell carcinoma, oligodendroglial, osteosarcoma, pancreatic polypeptide, papillary serous adenocarcinoma, pineal cell, pituitary tumors, 30 plasmacytoma, pseudosarcoma, pulmonary blastoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma,


-205-

sarcoma, serous carcinoma, small cell carcinoma, soft tissue carcinomas, somatostatin-secreting tumor, squamous carcinoma, squamous cell carcinoma, submesothelial, superficial spreading melanoma,  
5 undifferentiated carcinoma, uveal melanoma, verrucous carcinoma, vipoma, well differentiated carcinoma, and Wilm's tumor.

99. A combination comprising an integrin antagonist and one or more antineoplastic agents,  
10 wherein said antineoplastic agents are selected from the group consisting of anastrozole, calcium carbonate, capecitabine, carboplatin, cisplatin, Cell Pathways CP-461, cyclophosphamide, docetaxel, doxorubicin, etoposide, fluorouracil (5-FU), fluoxymestrine,  
15 gemcitabine, goserelin, irinotecan, ketoconazole, letrozol, leucovorin, levamisole, megestrol, mitoxantrone, paclitaxel, raloxifene, retinoic acid, tamoxifen, thiotepa, topotecan, toremifene, vinorelbine, vinblastine, vincristine, selenium (selenomethionine),  
20 ursodeoxycholic acid, sulindac sulfone and eflornithine (DFMO).


100. The combination of Claim 99 wherein the integrin antagonist is selected from compounds, and their pharmaceutically acceptable salts thereof, of the  
25 group consisting of:

1)




(3R)-N-[5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-  
5  
3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-  
chloro-2-hydroxyphenyl)-β-alanine,

2)



10  
(3R)-N-[1,6-dihydro-6-oxo-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-  
pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-  
2-hydroxyphenyl)-β-alanine,


3)



15  
(3R)-N-[3-amino-5-[(1,4,5,6-tetrahydro-5-  
hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-  
(3-bromo-5-chloro-2-hydroxyphenyl)-β-alanine,


-207-

4)




(3R)-N-[3-[(hydroxyamino)carbonyl]-5-  
[(1,4,5,6-tetrahydro-5-hydroxy)-2-  
5 pyrimidinyl]amino]benzoyl]glycyl-3-(3-bromo-5-  
chloro-2-hydroxyphenyl)-D-alanine,

5)



(3R)-N-[3-[(4,5-dihydro-1H-imidazol-2-  
y1)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-  
hydroxyphenyl)-D-alanine,

6)



15 (3R)-N-[3-  
[(aminoiminomethyl)amino]benzoyl]glycyl-3-(3-  
bromo-5-chloro-2-hydroxyphenyl)-D-alanine,


7)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine,

5


8)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-D-alanine,

10


9)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(5-bromo-3-chloro-2-hydroxyphenyl)-D-alanine,

15


10)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine,

5


11)



D-[3-[[3-[[4,5-dihydro-1H-imidazol-2-yl]amino]phenyl]sulfonyl]amino]phenyl]-3,5-difluorobenzene propanoic acid,

10


12)



3,5-difluoro-D-[3-[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]amino]methyl]phenyl]benzenepropanoic acid,


15

13)




14)

-210-




(2E)-3-[3-ethyl-4-[(3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl)amino]phenyl]-2-propenoic acid,

5 15)




(2E)-3-[3-[2-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]-2-oxoethoxy]phenyl]-2-propenoic acid,

10 16)



(10S)-10,11-dihydro-3-[3-(2-pyridinylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid,


15 17)



(2S)-7-[[[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid,

20 18)


-211-



(2S)-2,3,4,5-tetrahydro-4-methyl-7-[[(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-benzodiazepine-2-acetic acid,

5


19)




10

(3R)-3-[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]acetyl]amino]-1H-indole-3-pentanoic acid,

20)




21)




15

-212-

22)



23)




5


24) Vitaxin antibody (Ixsys),

25) Merck KGaA EMD-121974, cyclo[RGDF-N(Me)V-],

26)




27)




10

28)




-213-

29)




30)




5

31)




32)




33)

10




-214-

34)




35)




5

36)




37)




10

38)




-215-

39)




40)




5


41)



42)




43)



10


-216-

101. The combination of Claim 99 wherein the integrin antagonist is




5 (10S)-10,11-dihydro-3-[3-(2-pyridinylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid.

102. The combination of Claim 99 wherein the integrin antagonist is



10 (2S)-7-[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid.


15 103. The combination of Claim 99 wherein the integrin antagonist is



20 (2S)-2,3,4,5-tetrahydro-4-methyl-7-[[[(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-benzodiazepine-2-acetic acid.


-217-

104. The combination of Claim 99 wherein the integrin antagonist is



5 (bR)-b-[ [(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl]acetyl]amino]-1H-indole-3-pentanoic acid.


105. The combination of Claim 99 wherein the integrin antagonist is



10 106. The combination of Claim 99 wherein the integrin antagonist is Vitaxin antibody(Ixsys).


107. The combination of Claim 99 wherein the integrin antagonist is Merck KGaA EMD-121974,  
15 cyclo[RGDF-N(Me)V-].

108. The combination of Claim 99 wherein the integrin antagonist is




-218-


109. The combination of Claim 99 wherein the integrin antagonist is



110. The combination of Claim 99 wherein the  
5 integrin antagonist is



111. The combination of Claim 99 wherein the integrin antagonist is



10 112. The combination of Claim 1 wherein the antineoplastic agent is anastrozole.

113. The combination of Claim 1 wherein the antineoplastic agent is calcium carbonate.

15 114. The combination of Claim 50 wherein the antineoplastic agent is anastrozole.

115. The combination of Claim 50 wherein the antineoplastic agent is calcium carbonate.

**PATENT**

Docket: CU-2561

**COMBINED DECLARATION AND POWER OF ATTORNEY***(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,  
CONTINUATION OR CIP)*

As a below named inventor, I hereby declare that:

**TYPE OF DECLARATION**

This declaration is of the following type: *(check one applicable item below)*

- original
- design
- supplemental

*Note: If the Declaration is for an International Application being filed as a divisional, continuation or continuation-in-part application, do not check next item; check appropriate one of last three items.*

- national stage of PCT

*Note: If one of the following 3 items apply, then complete and also attach ADDED PAGES FOR DIVISIONAL, CONTINUATION OR CIP.*

- divisional
- continuation
- continuation-in-part (CIP)

**INVENTORSHIP IDENTIFICATION**

*WARNING: If the inventors are each not the inventors of all the claims, an explanation of the facts, including the ownership of all the claims at the time the last claimed invention was made, should be submitted.*

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

**TITLE OF INVENTION**

METHOD OF USING AN INTEGRIN ANTAGONIST AND ONE OR MORE  
ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN  
THE TREATMENT OF NEOPLASIA

## SPECIFICATION IDENTIFICATION

the specification of which: (*complete (a), (b) or (c)*)

- (a) is attached hereto.
- (b) was filed on \_\_\_\_\_ as  Serial No. \_\_\_\_\_ or   
Express Mail No. (*as Serial No. not yet known*) \_\_\_\_\_ and was amended  
on \_\_\_\_\_ (*if applicable*).

*Note:* Amendments filed after the original papers are deposited with the PTO that contain new matter are not accorded a filing date by being referred to in the Declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental Declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 CFR 1.67.

- (c) was described and claimed in PCT International Application No. PCT/US99/30670 filed on 22 December 1999.

## ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, § 1.56,

*(also check the following items, if desired)*

- and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and
- in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 CFR 1.98.

## PRIORITY CLAIM (35 U.S.C. § 119(a)-(d))

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

(complete (d) or (e))

- (d) no such applications have been filed.  
 (e) such applications have been filed as follows.

Note: Where item (c) is entered above and the international application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

**PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION  
AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119(a)-(d)**

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day/month/year)	PRIORITY CLAIMED UNDER 35 USC 119
			<input type="checkbox"/> YES      NO <input type="checkbox"/>
			<input type="checkbox"/> YES      NO <input type="checkbox"/>

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)  
(35 U.S.C. § 119(e))**

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER	FILING DATE
60/113,786	23 December 1998

**ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS  
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION**

---



---

Note: If the application filed more than 12 months from the filing date of this application is a PCT filing forming the basis for this application entering the United States as (1) the national stage or (2) a continuation, divisional, or continuation-in-part, then also complete ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR CIP APPLICATION for benefit of the prior U.S. or PCT application(s) under 35 U.S.C. § 120.

## POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (*list name and registration number*).

(B) Thomas F. Peterson, 24790; Richard J. Streit, 25765; Donald P. Reynolds, 26220; W. Dennis Drehkoff, 27193; Vangelis Economou, 32341; Brian W. Hameder, 45613; Valerie Neymeyer-Tynkov, Reg. 46956; Paul B. West, 18947; Joseph H. Handelman, 26179; Peter D. Galloway 27885; John Richards, 31503; Iain C. Baillie, 24090; Richard P. Berg, 28145

- Attached, as part of this declaration and power of attorney, is the authorization of the above-named practitioner(s) to accept and follow instructions from my representative(s).

**SEND CORRESPONDENCE TO:****DIRECT TELEPHONE CALLS TO:***(Name and telephone number)*

Richard J. Streit  
c/o Ladas & Parry  
224 South Michigan Avenue  
Suite 1200  
Chicago, Illinois 60604

(312) 427-1300

### DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

### SIGNATURE(S)

*Note: Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other documents.*

**Full name of first inventor**

John  
(Given Name)

P.  
(Middle Initial or Name)

McKEARN  
(Family (or Last) Name)

**Inventor's signature**

Date

Country of Citizenship

United States

Residence


Glencoe, Missouri

Post Office Address

18612 Babler Meadows Drive, Glencoe, Missouri 63038, USA


**Full name of second joint inventor**2-00  
Gary

(Given Name)



GORDON

(Family (or Last) Name)

**Inventor's signature**Date Sept 5 2001 Country of Citizenship United States

Residence

Highland, IllinoisIL

Post Office Address

3282 University Avenue, Highland, Illinois 60035, USA**Full name of third joint inventor**

James

(Given Name)

J.

(Middle Initial or Name)

CUNNINGHAM

(Family (or Last) Name)

**Inventor's signature**Country of Citizenship Canada

Date

Residence Chicago, IllinoisPost Office Address 3733 North Bell Avenue, Chicago, Illinois 60618, USA**Full name of fourth joint inventor**

Stephen

(Given Name)

T.

(Middle Initial or Name)

GATELY

(Family (or Last) Name)

**Inventor's signature**Country of Citizenship Canada

Date

Residence Palatine, IllinoisPost Office Address 357 E. Shady Pines Court, Palatine, Illinois 60067-8800, USA**Full name of fifth joint inventor**

Alane

(Given Name)

T.

(Middle Initial or Name)

KOKI

(Family (or Last) Name)

**Inventor's signature**Country of Citizenship United States

Date

Residence Beaufort, MissouriPost Office Address 6689 Highway 185, Beaufort, Missouri 63013, USA

**Full name of second joint inventor**

Gary \_\_\_\_\_ (Given Name) \_\_\_\_\_ (Middle Initial or Name) \_\_\_\_\_ (Family (or Last) Name) **GORDON**

**Inventor's signature** \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship \_\_\_\_\_ United States

Residence \_\_\_\_\_ Highland, Illinois

Post Office Address \_\_\_\_\_ 3282 University Avenue, Highland, Illinois 60035, USA

**Full name of third joint inventor**

3-00 James \_\_\_\_\_ J. \_\_\_\_\_ (Given Name) \_\_\_\_\_ (Middle Initial or Name) \_\_\_\_\_ (Family (or Last) Name) **CUNNINGHAM**

**Inventor's signature** \_\_\_\_\_

Date Aug 17 2001 Country of Citizenship \_\_\_\_\_ Canada

Residence \_\_\_\_\_ Chicago, Illinois

Post Office Address \_\_\_\_\_ 3733 North Bell Avenue, Chicago, Illinois 60618, USA

**Full name of fourth joint inventor**

Stephen \_\_\_\_\_ T. \_\_\_\_\_ (Given Name) \_\_\_\_\_ (Middle Initial or Name) \_\_\_\_\_ (Family (or Last) Name) **GATELY**

**Inventor's signature** \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship \_\_\_\_\_ Canada

Residence \_\_\_\_\_ Palatine, Illinois

Post Office Address \_\_\_\_\_ 357 E. Shady Pines Court, Palatine, Illinois 60067-8800, USA

**Full name of fifth joint inventor**

5-00 Alane \_\_\_\_\_ T. \_\_\_\_\_ (Given Name) \_\_\_\_\_ (Middle Initial or Name) \_\_\_\_\_ (Family (or Last) Name) **KOKI**

**Inventor's signature** \_\_\_\_\_

Date Aug 29th, 2001 Country of Citizenship \_\_\_\_\_ United States

Residence \_\_\_\_\_ Beaufort, Missouri

Post Office Address \_\_\_\_\_ 6689 Highway 185, Beaufort, Missouri 63013, USA

**Full name of second joint inventor**

Gary \_\_\_\_\_ (Given Name) \_\_\_\_\_ (Middle Initial or Name) \_\_\_\_\_ GORDON \_\_\_\_\_ (Family (or Last) Name)

**Inventor's signature** \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship \_\_\_\_\_ United States

Residence \_\_\_\_\_ Highland, Illinois

Post Office Address \_\_\_\_\_ 3282 University Avenue, Highland, Illinois 60035, USA

**Full name of third joint inventor**

James \_\_\_\_\_ J. \_\_\_\_\_ (Middle Initial or Name) \_\_\_\_\_ CUNNINGHAM \_\_\_\_\_ (Family (or Last) Name)

**Inventor's signature** \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship \_\_\_\_\_ Canada

Residence \_\_\_\_\_ Chicago, Illinois

Post Office Address \_\_\_\_\_ 3733 North Bell Avenue, Chicago, Illinois 60618, USA

**Full name of fourth joint inventor**

H-00 Stephen \_\_\_\_\_ T. \_\_\_\_\_ (Middle Initial or Name) \_\_\_\_\_ GATELY \_\_\_\_\_ (Family (or Last) Name)

**Inventor's signature** \_\_\_\_\_

Date \_\_\_\_\_ 01/64/01 Country of Citizenship \_\_\_\_\_ Canada

Residence \_\_\_\_\_ Palatine, Illinois IL

Post Office Address \_\_\_\_\_ 357 E. Shady Pines Court, Palatine, Illinois 60067-8800, USA

**Full name of fifth joint inventor**

Alane \_\_\_\_\_ T. \_\_\_\_\_ (Middle Initial or Name) \_\_\_\_\_ KOKI \_\_\_\_\_ (Family (or Last) Name)

**Inventor's signature** \_\_\_\_\_

Date \_\_\_\_\_ Country of Citizenship \_\_\_\_\_ United States

Residence \_\_\_\_\_ Beaufort, Missouri


Post Office Address \_\_\_\_\_ 6689 Highway 185, Beaufort, Missouri 63013, USA

**Full name of sixth joint inventor**

6-00 Jaime  
(Given Name)

L.  
(Middle Initial or Name)

MASFERRER  
(Family (or Last) Name)

**Inventor's signature**  

Date 8/29/01 Country of Citizenship Chile USA 7/02

**Residence** Ballwin, Missouri **M8**

---

**Post Office Address** 1213 Blairshire, Ballwin, Missouri 63011, USA